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Summary 
 
Huntington’s disease (HD) is a primary example of a basal ganglia disorder, from 
which, medium spiny neurons in the striatum degenerate. As this causes a breakdown in 
basal ganglia cortico-thalamic circuitry, this leads to a range of symptoms including motor, 
cognitive and behavioural deficits. One therapeutic option is to replace medium spiny 
neurons with precursor striatal cells and reconnect the lost circuitry. However, the lack of 
performance based functional outcome measures for people with HD have made it 
difficult to assess how the graft affects standards of daily living.  Although neuroimaging 
techniques can be used to quantify the morphological and molecular effects that the 
intervention has on that brain region, and associated circuitry, an important question still 
remains, namely whether there has been any effect on functional ability. Using 
assessments that have high ecological validity, such as dual tasks could be a valuable 
measure, especially as previous studies suggest that the striatum is required for optimal 
performance in such tasks. Therefore the focus of this thesis was to design, develop and 
assess performance based functional tasks that involve the neurocircuity affected in HD; 
namely the basal ganglia.  
 
The aim of the study in Chapter 2 was to select, develop and evaluate motor-
cognitive dual task paradigms for use in people with HD. The findings revealed that the 
Step and Stroop which targeted lower limb function, best distinguished disease stage in 
HD compared to the other lower limb assessments tested. During this experiment, it 
became apparent that upper limb assessments for people with HD were particularly 
limited. Therefore, in Part 2, a new upper limb dual task assessment was developed and 
called the Clinch token transfer test (C3t). The findings revealed that this was sensitive to 
disease stage and could provide a useful outcome measure for people with HD in the 
future.  
 
To take the findings from Chapter 2 further, a new, standardised C3t was 
developed. This version was evaluated, optimised, and then validated in a large group of 
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people gene positive for HD, and in heathy controls. The findings revealed that the C3t 
significantly correlated with all the Unified Huntington Disease Rating Scale measures, 
successfully distinguished between all disease stages, and revealed that the performance 
in this task was also sensitive to the subtle disease symptoms in the early stages of HD.   
 
As the Stroop task is commonly used in people with HD, the aim of Chapter 3 was 
to use immediate early gene expression to identify if the striatum was activated during a 
rodent analogue of the Stroop task. The findings revealed what could be the first in a 
series of experiments in that, striatal activation significantly correlated with performance 
in the congruent and the incongruent versions of this test when compared to cage 
controls. 
 
 The findings presented in this thesis support that dual task assessments could 
have an important role in assessing function in HD, which could translate to performance 
in tasks that affect the standards of daily living. Importantly, as different dual tasks can 
result in different levels of dual task interference, this suggests that practice effects could 
affect how sensitive some dual task paradigms are over others. In addition, selecting 
outcome measures that are specific to the regions affected in HD, in both clinic and in pre-
clinical models, will permit sensitive tracking of neurodegeneration, and could also be 
used to assess the outcomes of therapies that target this specific neural region.   
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Chapter 1 
General Introduction 
 
Introduction Summary 
 
The basal ganglia consists of a group of nuclei in the midbrain. The striatum is the 
largest nucleus of the basal ganglia and receives input from virtually all areas of the cortex 
(Braunlich and Seger, 2013). This forms a highly organised cortico-basal ganglia circuitry, 
which is responsible for motor, cognitive and emotionally based behaviours. In 
Huntington’s disease (HD), degeneration of medium spiny neurons (MSNs), the most 
abundant cell in the striatum, are primarily affected, meaning that the striatum takes a 
major part of the pathological burden. This leads to a break in basal ganglia circuitry and 
results in a triad of motor, cognitive and psychiatric symptoms. There is currently no cure 
for HD. However, there are a number of therapeutic strategies in pre-clinical assessment 
and very early clinical trials that have the potential to alter the course of the disease. For 
example, the relatively focal neuronal loss makes cell replacement therapy a promising 
therapeutic option.  
 
Cell transplantation is used to replace the MSNs lost in HD with another healthy 
source, typically striatal precursor neurons from foetal tissue. Proof of concept trials in 
animal models and in people with HD have shown that transplantation using foetal striatal 
cells can alleviate and/or stabilise some motor and cognitive symptoms associated with 
HD (Bachoud-Lévi et al., 2000, 2006; Brasted et al., 2000). Importantly, pre-clinical studies 
have revealed rehabilitative training post transplantation is necessary for optimal graft 
functionality (Mayer et al., 1992; Brasted et al., 2000; Döbrössy and Dunnett, 2005; 
Döbrössy et al., 2010). However, such training has not yet been implemented in patients 
with HD, following cell transplantation (Cisbani and Cicchetti, 2014), and may contribute 
to the limited clinical improvements. 
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A further challenge is the lack of translational and functional outcome measures 
that specifically target the neurocircuitry affected in this population. Such outcome 
measures are necessary to ensure an optimal cohort is selected for cell transplantation 
trials, and to detect change over time, whilst also aiding the development of rehabilitative 
strategies to implement post transplantation.  
 
Current performance based functional outcome measures for HD are limited. 
Many of these are rated on an ordinal scale, which can result in observer bias. This also 
limits the sensitivity when measuring change in disease symptoms over time. Performance 
based functional outcome measures provide a fundamental link for the 
researcher/clinician between performance in assessments at clinic and how these relate 
to tasks at home. Dual tasks are a primary example of an activity performed on a daily 
basis, which involves performing two tasks simultaneously. This is a reported deficit in 
people with HD. An explanation for this is that this population have limited attentional 
capacity, meaning they have limited resources that can be allocated to more than one 
task. Previous studies suggest that the striatum might be implicated in dual task 
performance, by prioritising certain behaviours and automating others (Yogev-Seligmann, 
Hausdorff and Giladi, 2008; Ashby, Turner and Horvitz, 2010; Kim and Hikosaka, 2015).  
This suggests that dual tasks could provide a useful performance based functional 
outcome measure for people with HD. The possibilities for such tacks includes, tracking 
disease progression in HD, a functional outcome measure following interventions such as 
neural transplantation, and for moulding the development of rehabilitative strategies to 
help reconstruct basal ganglia circuitry post transplantation.  
 
There are numerous avenues for exploration in the development of therapeutics 
for HD; the focus in this thesis is cell transplantation, and so this introduction is divided 
into four parts: 
 
 Part 1: The Basal ganglia and Huntington’s disease  
 Part 2: Cell transplantation 
 Part 3: Outcome measures used in Huntington’s disease 
 Part 4: Outcome measures used to assess cell transplantation in Huntington’s 
disease 
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1.1 Part 1: The Basal Ganglia and Huntington’s disease 
1.1.1 The Basal ganglia 
 
The basal ganglia consists of a group of nuclei embedded in the midbrain, which 
includes the striatum (caudate and putamen in primates), globus pallidus (externa and 
interna), the subthalamic nucleus and the substantia nigra (pars reticula and pars 
compacta (Figure 1). The function of the basal ganglia was originally based on clinical 
observations that showed lesions to the putamen, globus pallidus and subthalamic 
nucleus resulted in Parkinsonian motor disturbances and dystonia (Motility, 1925). Thus, 
many early researchers proposed the function of the cortico-basal ganglia relationship 
was primarily for motor control (reviewed in: Braunlich and Seger, 2013).  However, 
additional studies revealed that lesions to regions of the basal ganglia resulted in many of 
the same cognitive deficits as those with damage to the frontal regions of the brain 
(Leisman, Braun-Benjamin and Melillo, 2014). It is now known that the basal ganglia forms 
both closed loop and open loop circuitry that involves several brain regions, including the 
cerebral cortex, the thalamus and the cerebellum (Hélie, Ell and Ashby, 2015).  
 
Figure 1: The basal ganglia nuclei in primates. In the rodent brain, the caudate and putamen are 
contiguous and referred to as the striatum. This figure was reproduced from: (Leisman, Braun-
Benjamin and Melillo, 2014). 
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One of the primary roles of the basal ganglia  is to facilitate and inhibit patterns 
of cortical activity (Braunlich and Seger, 2013; Hélie, Ell and Ashby, 2015), which is done 
through a cortico-basal ganglia-thalamo cortical loop. Within this circuitry, five segregated 
but partially overlapping parallel loops have been identified, where the basal ganglia 
receives inputs from separate cortical regions including the prefrontal, cingulate cortices, 
orbitofrontal, the supplementary motor area and the frontal eye fields  (Leisman, Braun-
Benjamin and Melillo, 2014). The loops involving these regions have been supported by 
studies using retrogradely transported virus particles (Kelly and Strick, 2004) and 
behaviourally are associated with motor, associative (cognitive), and limbic (emotional) 
domains (Alexander, DeLong and Strick, 1986). As a result, a break in the basal ganglia 
circuitry can cause widespread symptoms, including dysregulation of mood, cognition and 
motor function. 
 
The basal ganglia has evolved over time and consists of the paleostriatum (globus 
pallidus), and the neostriatum (known as the caudate and the putamen in primates). In 
rodents the caudate and putamen are contiguous and instead referred to as the 
dorsomedial and the dorsolateral striatum (Braunlich and Seger, 2013). In primates, the 
ventral striatum consists of the ventral portions of the caudate and putamen, whereas in 
rodents, this consists largely of the nucleus accumbens. For the entirety of this thesis, the 
caudate and putamen will be collectively referred to and specified as the dorso 
medial/lateral or ventral striatum.  
 
The striatum is the largest nucleus of the basal ganglia and receives 
topographically organized fibres from almost the entire neocortex (Alexander, DeLong 
and Strick, 1986). The organisation of the striatum can be divided into distinct 
compartments; the matrisomes and the striosomes, also known as the patch and matrix 
(Reinius et al., 2015). These can be defined by the neurochemical make-up and 
connections (Huot and Parent, 2007), where the matrisome receives input primarily from 
associate and sensorimotor cortex, whereas the striosome receives input from the limbic 
regions (Reinius et al., 2015).   
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The striatum consists of predominantly one neuronal type, named medium spiny 
neurons (MSNs). MSNs are inhibitory and use γ-aminobutyric acid (GABA) as their 
neurotransmitters, and in rodents, consist of approximately 95-98% of the neuronal 
population (Dubé, Smith and Bolam, 1988; Reiner et al., 1988; Kravitz, 2009). The 
remaining striatal makeup are interneurons, which can be classified based on their 
morphology, behaviour and histological properties. These receive both glutamatergic and 
dopaminergic inputs and consist of cholinergic interneurons and three different types of 
aspiny GABAergic interneurons (Huot and Parent, 2007).  
 
 The direct and indirect pathways of the basal ganglia 
 
The direct, indirect and hyperdirect pathways form three cortical routes which 
are primarily responsible for forming the motor circuit, of which the striatum is integral.  
These pathways exert opposing influences on the excitation of the thalamus to convert 
information to control movement into a highly organised motor program (Figure 2). 
Striatal MSNs form two populations which define the direct and indirect pathways, which 
are dependent on the dopaminergic receptors they possess (Galvan et al., 2012), and their 
efferent projections to either the globus pallidus interna or externa (Albin, Young and 
Penney, 1989; Delong, 1990). Output projections from the striatum to the globus pallidus 
interna/substantia nigra reticula represent the direct, monosynaptic pathway and express 
D1 dopamine receptors, substance P and dynorphin (Galvan et al., 2012). Activation of 
this pathway is inhibitory which lowers the threshold required to excite the thalamus, 
which leads to hyperstimulation and movement activation. MSNs that form the indirect 
pathway possess D2 receptors and encephalin. In this pathway, the globus pallidus 
externa and the subthalamic nucleus inhibits striatal output to the globus pallidus interna 
and substantia nigra pars reticula, which increases the threshold required to excite the 
thalamus, leading to movement inhibition. The third pathway is the hyperdirect pathway. 
These projections are excitatory and bypass the striatum, projecting straight to the 
subthalamic nucleus, and then the globus pallidus interna and substantia nigra pars 
reticula. This lowers the excitatory outputs from the thalamus and leads to movement 
activation. As the hyperdirect pathway has a greater inhibitory effect on the cortex than 
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both the direct and indirect pathways, this route may play a role movement initiation 
(Nambu, Tokuno and Takada, 2002).  
 
 
The parallel structure of the direct and indirect pathways were recently debated 
since it was revealed that a subpopulation of MSNs (~6%) distributed throughout the 
striatum, coexpressed both D1 and D2 receptors (Perreault et al., 2012; Calabresi et al., 
2014; Gagnon et al., 2017). Although the function of these neurons remains elusive, it was 
suggested that the direct and indirect pathways might communicate information 
bidirectionally (Perreault et al., 2012), proposing that the pathways may not be as 
segregated as the original model suggests.  
 
Figure 2: The direct, indirect and hyperdirect pathways are the three major pathways that involve 
the basal ganglia circuitry (basal ganglia nuclei inside the grey box). The cortex projects afferents 
to the striatum which are excitatory (indicated in the diagram by the bold yellow line). The SNpc 
releases dopamine which either binds to the D1 receptors and excite the neurons of the direct 
pathway (purple), or the D2 receptors which inhibit the neurons of the indirect pathway (green). 
Afferents from the striatum are inhibitory (GABAergic) as indicated by the dotted arrows. The 
hyperdirect pathway (blue) is excitatory (glutamatergic) and bypassess the striatum from the cortex 
to the STN, to the Gpi/SNr and the thalamus. Where GPe, globus pallidum externa; GPi, globus 
pallidum interna; STN, subthalamic nucleus; SNpr, substantia nigra pars reticula; substantia nigra 
pars compacta, SNpc. 
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1.1.2 General overview of Huntington’s disease 
 
Huntington’s disease (HD) is a prime example of a basal ganglia disorder, as 
degeneration of MSNs in the striatum take the major pathological burden, leading to a 
breakdown of cortico-basal ganglia circuitry. HD was originally described by George 
Huntington in 1872 and later termed Huntington’s chorea (Huntington, 1872). Although 
he denoted emphasis on the motor aspects of the disease, he also recognised sufferers 
having a “tendency for insanity and suicide” (Huntington, 1872). It is now accepted that 
these form some of the behavioural abnormalities that manifest as part of HD, with 
cognitive deficits also being a prominent feature (reviewed in: Paulsen, 2011). As a result, 
people with HD present with a triad of motor, cognitive and behavioural symptoms.  
 
People positive for the HD gene have a 50% chance of passing the disease to their 
children. In 1983, it was revealed that the genetic locus of HD is localised to Chromosome 
4 (Gusella et al., 1983). This was followed by a large collaborative effort that in 1993, 
revealed IT15 as the autosomal dominant gene that causes the disease, which is now 
known as the Huntingtin gene (MacDonald et al., 1993). This is explained in more detail 
in Section 1.1.3 (page 8). 
 
The discovery of the Huntingtin gene has meant that an accurate diagnosis for HD 
is now available. This has led to improved accuracy in epidemiology studies and inevitably 
an increased prevalence. Over the last 25 years records of people living with HD in the UK 
rose from an average of 5.3 people per 100,000 in 1990, to 12.3 in 2010 (Evans et al., 
2013). Prevalence rates in Caucasian populations such as Western Europe, North America 
and Australia, have risen from 15-20% per decade, compared to Asia where reported rates 
have not increased (Rawlins et al., 2016) and were previously reported as low as 0.4 per 
100,000 (Pringsheim et al., 2012).  
 
People who carry the HD gene (termed gene positive) can begin showing 
symptoms at any age, although this is most commonly between 30 and 55 years of age 
(Figure 3). As symptoms worsen, so does function and quality of life (Helder et al., 2001; 
Ready et al., 2008; Ho et al., 2009) and loss of independence is the primary predictor of 
General Introduction  Chapter 1: Part 1 
8 
 
nursing home admission (Wheelock et al., 2003). Death occurs approximately 20 years 
after motor onset (Bates et al., 2015) and, although the cause of death is not fully 
understood, it is usually a result of symptom complications, such as falling, 
malnourishment and pneumonia (Walker, 2007). A small number of gene carriers develop 
juvenile HD, in cases where symptom onset occurs before the age of 20 years (Walker, 
2007). The phenotypic profile of juvenile HD differs from adult onset HD as the movement 
disorder is predominantly  bradykinetic and rigid in nature rather than choreic (Douglas 
et al., 2013). Current treatments for HD are symptomatic only and are limited to treating 
symptoms such as chorea and depression (Mestre and Ferreira, 2012).  
 
 
 
 
 
1.1.3 HD Genetics 
 
HD is caused by a mutation in the Huntingtin gene, which is located on the short 
arm of chromosome 4 (MacDonald et al., 1993). This results in an expanded cytosine, 
adenine, guanine (CAG) polyglutamine repeat, which encodes the protein mutant 
huntingtin (mHtt). The average person carries between carry 10-29 CAG repeats (Kumar, 
Kalonia and Kumar, 2010), whereas people with HD carry CAG repeats of more than 35 
and have full penetrance with repeats of 40 or more (Walker, 2007). Wild type huntingtin 
is ubiquitously expressed throughout the body and is essential for embryonic 
development and in adulthood (Nasir et al., 1995; Schulte and Littleton, 2011; Martin et 
Figure 3: The age of onset in Huntington’s disease. This typically peaks mid-life but can span from 
2 to 85 years of age. This image was reproduced from (Myers, 2004). 
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al., 2015). Although the exact function of the huntingtin protein is not completely 
understood, previous studies suggest that it is involved in intracellular trafficking, 
membrane recycling and interacts with transcriptional regulatory proteins (see reviews: 
Sari, 2011; Schulte and Littleton, 2011; Martin et al., 2015). In HD there is an abundance 
of evidence to suggest that pathology is caused by a toxic gain of mHtt (Han et al., 2010; 
Schulte and Littleton, 2011). At the same time it is also recognised that loss of wildtype 
huntingtin in HD could also lead to cellular dysfunction, exacerbating the neuropathology 
in HD (Martin et al., 2015).  
 
In HD, the age of disease onset cannot be accurately predicted. However, it is 
thought that both environmental and genetic factors are involved in determining this. The 
main driving factor is understood to be the CAG repeat length, which influences as much 
as 70% variance in age of disease onset  (Tabrizi et al., 2012). Previous studies revealed 
that CAG repeat length inversely correlated with age of onset (Langbehn et al., 2010), and 
positively correlated with a more aggressive rate of disease progression (Rosenblatt et al., 
2012).  Therefore, as a way of estimating disease onset, the CAG disease burden score 
was developed (Penney et al., 1997). This is calculated using the equation: CAG repeat 
length minus 35.5, multiplied by the subject’s age. In this equation, 35.5 is used as a 
constant where this is the maximal number of CAG repeats that no HD symptoms are 
likely to develop. This measure was strongly associated with the amount of striatal 
pathology in the brains of people with HD at autopsy (Penney et al., 1997). As a result, 
this is widely used as an effective, non-invasive method to estimate disease progression 
in HD.  
 
1.1.4  Basal ganglia pathology in HD 
 
HD is a multisystem degenerative disease (Ruocco et al., 2006). One of the 
primary outcomes of mHtt is neuron degeneration, and particularly the MSNs located in 
the striatum, whereas large cholinergic striatal interneurons are spared (Raymond et al., 
2011).  It is unclear the exact role of mHtt and why MSNs are particularly susceptible, 
especially as mHtt is ubiquitously expressed and distributed throughout the cell, including 
the cytoplasm, axon and synapse (Sari, 2011; Rüb et al., 2016). One explanation for the 
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striatal susceptibility in HD is the presence of RASD2/Rhes, a protein specifically located 
in the striatum and selectively binds to mHtt (Subramaniam and Snyder, 2011). This 
interaction enhances sumoylation of mHtt, causing disaggregation and enhanced mHtt 
toxicity, which could lead to dysfunction and cell death (Cepeda et al., 2007; Subramaniam 
et al., 2009). Another explanation for striatal sensitivity is post-mitotic CAG-expansion 
(Swami et al., 2009). As the CAG repeats in the striatum are particularly unstable (Kennedy 
and Shelbourne, 2000), this means that the  number of repeats get progressively longer 
with increasing cell cycles, leading to increased transcription and translation of mHtt 
(Swami et al., 2009). This could lead to increased microglia activation, excitotoxity and a 
decrease in important neurotrophins such as brain derived neurotrophic factor (BDNF) 
(Ehrlich, 2012; Andre, Carty and Tabrizi, 2016). As the mechanisms whereby mHtt 
produces dysfunction are not yet completely clear, this means that the development of 
treatments to address the underlying neuropathology in HD has been slow, and in many 
cases unsuccessful (Ross et al., 2014; Kumar et al., 2015).  
 
Advances in neuroimaging have extended understanding of the neuropathology 
underlying HD and how it leads to such widespread symptoms (Dogan et al., 2015). The 
most prominent changes are evident in the striatum, where people with early to mid-
stage HD have reduced putamen and caudate volume by up to 50% and 27% (Niccolini, 
2014). Changes in other regions of the HD brain include the pre-frontal cortex, parietal 
cortex, motor and premotor cortex, amygdala, thalamus and hippocampus (Sari, 2011; 
Dogan et al., 2015; Novak et al., 2015). Previous studies revealed that people with pre-
manifest HD had widespread white matter atrophy 15 years before symptom onset, and 
reduced blood oxygen level dependent signals between the caudate and the premotor 
cortex (Unschuld et al., 2012; Niccolini, 2014). Furthermore, it has been reported that 
people with early manifest HD had an overall loss and a gain in cortico-basal ganglia 
connectivity compared to controls (Novak et al., 2015). As structural and functional 
changes in the HD brain are evident before any clinical symptoms have developed (Tabrizi 
et al., 2013), this suggests that compensatory mechanisms may delay the onset of HD 
symptoms and increased synaptogenesis and angiogenesis may be a potential coping 
mechanism early in the disease process (Niccolini, 2014; Drouin-Ouellet et al., 2015).  
 
General Introduction  Chapter 1: Part 1 
11 
 
Neuroimaging studies have also been extremely valuable in understanding and 
tracking disease progression in HD. Positron electron topography (PET) has been useful in 
identifying specific targets such as glucose and cerebral blood flow changes in HD, as well 
as changes in neurotransmitter signalling as a result of altered neuroreceptors (Niccolini, 
2014; Pagano, Niccolini and Politis, 2016). For instance, a previous study revealed an 
increase in GABA receptors in the globus pallidus externa (Glass, Dragunow and Faull, 
2000). An explanation for this could be to intensify GABA sensitivity due to degenerating 
striatal projections. Clinically, this may explain why involuntary movements are one of the 
first noticeable motor symptoms in HD, as loss of striatal projections could lead to 
intensified GABA sensitivity through the indirect pathway and disinhibiting the thalamo-
cortical response. Overall, neuroimaging techniques have facilitated a greater description 
and linkage to the structural and molecular changes in the brain and how this translates 
to the broad disease phenotype associated with HD. 
 
1.1.5 Disease symptoms and progression of Huntington’s disease 
1.1.5.1 Natural course of HD  
 
In the UK, any person that has a parent with HD or shows symptoms associated 
with HD has the option to have a genetic test to confirm their prognosis from 18 years of 
age. People who are gene positive for HD will develop symptoms, although it is not 
possible to know the exact age at which symptoms will develop.  There is often a period 
of time where the person with HD shows no disease symptoms, which is known as 
“asymptomatic” or “pre-manifest HD” (Duff et al., 2010). Prodromal HD is when a gene 
positive person starts to show symptoms or signs relating to HD but does not meet the 
criteria for ‘manifest’ (Misiura et al., 2017). Cognitive and behavioural abnormalities are 
prevalent in the prodromal phases of disease and can occur up to 15 years before motor 
symptoms manifest (Paulsen et al., 2008). This supports findings that showed caudate and 
putamen (striatal) changes can begin more than a decade prior to disease onset (Aylward 
et al., 2004; Paulsen et al., 2006; Tabrizi et al., 2012), and may therefore initiate subtle 
clinical symptoms. As a result, researchers are keen to develop therapeutics that target 
this stage of disease before neurodegenerative changes become too extensive and 
irreversible. However, as few outcome measures are sensitive  to subtle changes in people 
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with pre-manifest HD (Paulsen et al., 2014), this makes it particularly difficult to estimate 
how close someone at this stage is to manifest onset.  
 
Disease onset in HD is diagnosed clinically when motor abnormalities begin, 
termed “motor manifest”. This diagnosis is usually made by a neurologist who uses a 
range of HD specific assessments known as the Unified Huntington’s disease rating scale 
(UHDRS) (Kieburtz, 1996). The motor manifest stage can be divided into five disease 
stages. These stages are arbitrary and based on scores from the UHDRS-Total Functional 
Capacity (UHDRS-TFC). Stages of HD are described in more detail in Section 1.1.7 (page 
15).  
 
The fact that the HD gene is dominant and penetrant has facilitated longitudinal 
studies such as REGISTRY and ENROLL-HD (https://www.enroll-hd.org/). The aim of these 
longitudinal, multi-national studies is to optimise methods to assess disease progression 
in HD and have enabled a greater understanding of the disease phenotype (Orth et al., 
2010; CHDI Foundation, 2012). These were initiated to  understand disease progression 
in people with all stages of HD (Orth et al., 2010), and involves annually recruiting and 
testing any person at risk for HD on a battery assessments. The assessments include those 
from the UHDRS (Described in Section 1.3, page 27), demographic information, quality of 
life, medication and HD characteristics. Other longitudinal studies include PREDICT-HD 
and TRACK-HD. These are two now completed large observational studies that were 
designed to identify potential outcome measures and biomarkers for people with pre-
manifest HD (Biglan et al., 2009; Tabrizi et al., 2012). Ultimately, these studies have 
allowed better characterisation of HD, putting the field in a good position to develop 
interventions to improve standards of living (Mestre and Ferreira, 2012; Reilmann, Leavitt 
and Ross, 2014).  
 
1.1.6 Clinical symptoms  
1.1.6.1  Motor  
 
Chorea is the most recognised involuntary movement in people with HD (Albin, 
Young and Penney, 1989; Joel, 2001). This typically begins with subtle motor signs in the 
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distal extremities such as the fingers and in small facial muscles, which for bystanders 
often go undetected (Roos, 2010). Chorea increasingly affects all parts of the body with 
disease progression and plateaus around the mid-stages of HD. As chorea lessens, 
dystonia progresses. Dystonia is caused by sustained muscle contractions leading to 
involuntary twisting in the trunk and limbs (Louis et al., 1999), and is typically present in 
several body regions (Louis et al., 1999). Towards the advanced stages of disease, more 
evident motor features of HD include bradykinesia and rigidity (Fenney, Jog and Duval, 
2008).  Other movement abnormalities that can feature in HD include tics (Roos, 2010) 
and oculomotor dysfunction (Gajdusek, 1982; Leigh et al., 1983). During the course of HD, 
people gradually lose the ability to swallow (dysphagia) and articulate words (dysarthria), 
leading to slurring, respiratory issues and problems with eating (Hartelius et al., 2010; 
Alves et al., 2016).   
 
1.1.6.2 Cognitive  
 
The cognitive profile in people with HD includes problems with executive 
function, attention, mental flexibility, emotional recognition, psychomotor function, and 
learning and memory retrieval which gradually worsen over time (Lawrence et al., 1998; 
Ho et al., 2003; Georgiou-Karistianis et al., 2013; Ross et al., 2014). Subtle cognitive 
changes can be detected many years prior to motor onset (Tabrizi et al., 2011) and highly 
correlate with volumetric loss in the striatum (Aylward et al., 2011). A previous study 
revealed that 40% of people estimated to be over 14 years from motor onset had 
problems with episodic memory, executive function and processing speed (Duff et al., 
2010). Furthermore, another study found that people with pre-manifest HD had problems 
with word list learning and odour recognition 15-20 years prior to disease onset (Paulsen 
et al., 2008). However, as symptom progression at this stage is subtle, this makes 
symptom changes this makes them difficult to track change over time. A previous study 
revealed no evidence of cognitive decline in people with pre-manifest HD after 24 months, 
whereas a significant decline was detected 12 months in people with early manifest HD  
(Stout et al., 2012). One explanation for the undetectable changes in pre-manifest disease 
could be that more cognitively demanding tasks are required to measure the subtle 
cognitive decline associated with this stage of HD (Stout et al., 2012). Overall, cognitive 
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symptoms are believed to have the greatest impact on the rate of functional decline in 
HD  and appear to place the greatest burden on people with HD and their families 
(Paulsen, 2011).  
 
1.1.6.3  Behavioural changes 
 
Similar to cognitive abnormalities, behavioural problems are thought to arise 
potentially decades prior to motor onset (Tabrizi et al., 2011). A previous study evaluated 
REGISTRY data from 1766 people gene positive with HD and revealed that 87% had some 
form of behavioural disturbance (Orth et al., 2010). Furthermore, the extent of 
behavioural symptoms varied from one individual to the next. The most common 
behavioural disturbances include depression, irritability, obsessiveness and apathy 
(Marder et al., 2000; Craufurd and Snowden, 2002; van Duijn et al., 2014). Depression and 
suicidal ideation are frequent in people gene positive with HD, affecting up to 60% of 
individuals (Orth et al., 2010; van Duijn et al., 2014). A prominent and progressive 
behavioural feature in HD is apathy, which can be defined as “disengagement with 
passivity and loss of enthusiasm, interest, empathy and interpersonal involvement” 
(Marin, 1991), and affects about of 48% of  the HD population (Kingma et al., 2008; Tabrizi 
et al., 2013; van Duijn et al., 2014).  
 
1.1.6.4 Function and quality of life 
 
Health related quality of life can be defined as the “optimum levels of physical 
role (e.g., work, carer, parent) and social functioning, including relationships and 
perceptions of health, fitness, life satisfaction and well-being” (Bowling, 2005). Given the 
progressive nature of HD, this gradually results in reduced quality of life (Ho et al., 2004, 
2009). A previous study recruited 77 people with all stages of HD and revealed that they 
had severe impairments in domains that included work and alertness, forgetfulness, 
attentional and problem-solving (Helder et al., 2001). In addition, the same study revealed 
that 51% of people had retired from work, a factor which increases self-esteem in people 
that suffer from a mental illness (Van Dongen, 1996). Other problems that affect 
performance in common daily tasks include  planning and inhibition, managing finances, 
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shopping  and dividing attention between multiple tasks (Helder et al., 2001; Delval, 
Krystkowiak, Delliaux, Dujardin, et al., 2008). 
 
The primary cause of decreased quality of life is unknown, where one study found 
that depressive mood and functional incapacity were the greatest contributors (Ho et al., 
2009), whereas another study revealed that neuropsychiatric symptoms were not 
associated with patient or caregiver quality of life (Ready et al., 2008). The methodological 
differences between these studies make them difficult to compare as the latter used 
combined self- and caregiver- reports to analyse patient quality of life, whereas structured 
questionnaires that were given to the patient was used in other studies (Ho et al., 2004, 
2009). As a result, a more extensive study used multiple quality of life assessments, as 
well as cognitive tests for executive function and the UHDRS motor score (Eddy and 
Rickards, 2013). They found that apathy and responses related to daily activities that 
require executive dysfunction, such as performing two tasks simultaneously, best related 
to quality of life. These findings suggest that factors that affect quality of life in HD are 
multidimensional. Furthermore, interventions that address functions that relate to daily 
activities could lead to the most significant positive changes in wellbeing (Eddy and 
Rickards, 2013). 
 
1.1.7  Assessing disease stage in HD 
 
There is no defined way to assess disease stage in people with HD. A common 
method used to identify disease stage is using assessments from the Unified Huntington’s 
disease rating scale (UHDRS). This consists of a group of six standardised assessments 
used to determine the range of clinical features associated with HD, and includes  a motor, 
cognitive, functional capacity, behavioural, functional assessment and an independence 
scale (Kieburtz, 1996). In particular, the UHDRS total motor score (UHDRS-TMS) and the 
total functional capacity (UHDRS-TFC) are most frequently used to identify disease stage. 
Although these are described individually in Section 1.3 (page 27), in brief, the UHDRS-
TMS is performance based, whereas the UHDRS-TFC is a questionnaire. Both of these are 
rated on an ordinal scale by a neurologist and each summed to give an overall score. A 
greater score in the UHDRS-TMS equates to more advanced motor symptoms (Ranges 
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from 0 (no symptoms) to 124 (advanced)), whereas a lower UHDRS-TFC score equates to 
more advanced functional difficulties (Ranges from 0 (functional incapacity) to 13 (normal 
function)).  Some researchers use the UHDRS-TFC score to categorise subjects into 5 
disease stages, where stage 1 is the earliest disease stage and stage 5 is the most 
advanced ( 
Figure 4a) (Shoulson and Fahn, 1979; Enrolled, 2006; Paulsen et al., 2010). 
However, as people in the early disease stages manifest very subtle clinical symptoms, the 
questions in the UHDRS-TFC may be too vague to capture functional decline (Paulsen et 
al., 2010). To increase sensitivity, some researchers use both the UHDRS-TMS and the 
UHDRS-TFC to define people with pre-manifest HD, where a UHDRS-TFC score equal to 13 
and a UHDRS-TMS score less than 5 defines people with pre-manifest HD, and people with 
a UHDRS-TMS score greater than 5 are classed as manifest (Busse et al., 2014) ( 
Figure 4b). Again, this method of grouping people with HD is not ideal, as this 
means that the manifest group ranges from people with early HD to advanced, but gives 
no indication of any stages in between. Another alternative to understanding stage of 
disease is to use the CAG disease burden score (Zhang et al., 2011) (refer to Section 1.1.3; 
page 9). This calculation uses the subject’s ages and CAG repeat length and can be used 
estimate how close someone with pre-manifest HD is to developing manifest symptoms. 
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Figure 4: Figure a is adapted from (Ross et al., 2014), which shows the progressive disease 
symptoms and different disease stages in HD. No changes are typically detected in 
asymptomatic/pre-manifest subjects (low CAG disease burden score). As neurodegeneration 
progresses, subtle cognitive and almost undetectable motor changes manifest (prodromal). 
Functional abilities remain fairly stable until the motor manifest stage where they more rapidly 
decline. Other symptoms include behavioural problems. However these tend to be more variable 
from one individual to the next. Manifest stages of HD can be classified using the UHDRS-TFC 
assessment, that was developed by (Shoulson and Fahn, 1979) (Figure b). Throughout these stages, 
motor and cognitive abilities progressively worsen leading to the requirement of full time care and 
support during the advanced stages of HD (stage 5). 
 
 
a) 
b) 
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1.1.8 Animal models of HD 
 
Genetic and lesion models have been crucial in understanding disease 
mechanisms that cannot ethically be studied in people, such as the development of new 
treatments and sensitive tracking of HD pathology. There is currently no perfect HD 
animal model, as each elicits different behavioural phenotypes linked to the disease.  
 
1.1.8.1  Lesion models of HD 
 
The first model for HD was generated in 1976 (Coyle and Schwarcz, 1976) and was 
developed on the basis that glutamate is the major excitatory corticostriatal 
neurotransmitter (McGeer et al., 1977). Glutamate release and N-methyl-D-aspartate 
(NMDA) receptor hypersensitivity causes striatal cell death, largely due to an excessive 
calcium influx, triggering apoptotic pathways (Watkins and Jane, 2006). Thus, the initial 
hypothesis for neurodegeneration in HD was excitotoxicity (DiFiglia, 1990). One of the 
first HD models that supported this theory was an intra striatal injection of kainic acid, a 
potent analogue of glutamate with pronounced selectivity for MSNs (Coyle and Schwarcz, 
1976). However, as kainic acid destroys both GABAergic and cholinergic neurons, 
quinolinic acid is currently the excitotoxin of choice. This has a high affinity for NMDA 
receptors positioned on the post-synaptic membrane of striatal specific projection 
neurons (MSNs).  
 
Quinolinic acid better replicates the neuropathology of HD due to the sparing of 
the striatal interneurons and increased sensitivity for MSNs (Schwarcz, Whetsell and 
Mangano, 1983; Cepeda et al., 2010). The impact of the toxin can be controlled by giving 
unilateral or bilateral lesions and modifying the toxin dose, infusion rate, injection 
placement and number of injection sites. The benefit of using a unilateral lesion means 
that the intact striata can be used as a histological control. For example, in skilful grasping 
tasks, rats with unilateral lesions continue performing accurately using the paw ipsilateral 
to the lesion, whereas performance using the paw contralateral to the lesion is severely 
impaired. Unilateral lesions are particularly useful for assessing certain behaviours in 
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transplantation studies as only one unilateral graft is required to observe functional 
improvement, for example in a grasping task (Döbrössy and Dunnett, 2003), compared to 
two, which are required in some cognitive tasks (Dunnett and White, 2006).  Although 
lesion models do not necessarily improve the understanding behind the natural disease 
course, as neurodegeneration using this method is not progressive, they remain a 
valuable model to study striatal specific behaviours and the development and 
optimisation of treatments such as cell transplantation. 
 
1.1.8.2  Genetic models of HD 
 
The discovery of the huntingtin gene spurred the development of genetically 
modified animal models for HD. These have provided an understanding behind the 
neuropathological mechanisms that underlie HD (Kumar, Kalonia and Kumar, 2010). One 
noticeable difference between the human condition and animal models is that many of 
the mouse models carry much longer CAG repeats in order to show a HD phenotype, 
which is probably due to the shorter life span of rodents. Therefore, a number of mouse 
models have been developed with different CAG lengths to characterise early symptoms, 
and more aggressive forms (that have longer CAG repeats) that are associated with later 
clinical onset in HD. Detailed reviews on animal models used for HD are reviewed by 
(Ramaswamy, McBride and Kordower, 2007; Kumar, Kalonia and Kumar, 2010). In brief, 
mouse models fall into one of three main categories. Firstly; the generation of fragment 
models, where mice carry a small fragment of the human huntingtin gene that causes an 
expanded CAG repeat. This has resulted in four R6 lines that carry between 115-156 CAG 
repeats and show accelerated and severe disease progression. Secondly; insertion of the 
full length human huntingtin gene carried in a yeast or bacterial artificial chromosome. 
These present slower disease progression more representative of the human condition. 
Thirdly; knock-in models, where an expanded CAG repeat is inserted into the existing 
huntingtin homologue (Ramaswamy, McBride and Kordower, 2007; Kumar, Kalonia and 
Kumar, 2010). It should be noted that the type of mouse model selected for research 
depends very much on the experimental question and the disease stage targeted. 
Therefore, there is now a need to develop animal models that more closely depict the 
natural progression in HD, allowing for better direct comparisons in clinic and the 
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laboratory, and the ability to track neuropathological features in longitudinal studies 
(Kumar, Kalonia and Kumar, 2010). 
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1.2 Part 2: Cell transplantation in Huntington’s disease 
 
There is currently no cure for people with HD. Current medication is prescribed 
to ameliorate downstream symptoms, such as motor abnormalities and depression (albeit 
with limited success) (Mestre and Ferreira, 2012). However, there is now a drive to 
develop therapeutics that target the specific neuropathological hallmarks identified in HD, 
as a way of preventing disease onset and slowing disease symptoms. This has included 
potential treatments looking at reducing excitotoxicity, targeting mHtt aggregates, mHtt 
gene silencing, and drugs for mitochondrial dysfunction (Kumar et al., 2015). One 
potential disease modifying treatment is cell transplantation, which can be used to 
replace degenerating MSNs with a healthy MSN source.  Whilst it is acknowledged that 
both foetal tissue and stem cells have been used for transplantation therapy in HD 
(reviewed in: Perrier and Peschanski, 2012; Dunnett and Rosser, 2014; Rosser and 
Svendsen, 2014; Kumar et al., 2015), cell transplantation using foetal tissue will be the 
focal therapeutic referred to throughout this section.  
 
1.2.1  What is cell transplantation and what has been done in HD? 
 
Cell transplantation is a promising therapy for people with HD. The aim of this 
surgical procedure is to replace the degenerating striatum with a high proportion of 
healthy MSNs that will integrate, form synapses and in time reconnect lost striatal 
circuitry (Figure 5) (Döbrössy and Dunnett, 2005a; Kendall et al., 1998). In the majority of 
preclinical and clinical trials, the donor cells of choice have been the whole ganglionic 
eminences (WGE) dissected from foetal tissue, as this collective region gives rise to the 
highest proportion of DARPP-32 positive cells (a marker used to stain for MSNs) (Watts, 
Dunnett and Rosser, 1997). Transplanting WGE produces regions in the graft referred to 
as P-zones, which upon histological staining using striatal specific markers, results in 
dense, patchy regions (Graybiel, Liu and Dunnett, 1989). Furthermore, the amount of P-
zones present are  proportional to the extent of functional recovery (Nakao et al., 1996). 
In previous studies, the greatest P-zones were evident in WGE, followed by lateral GE 
grafts, and then medial GE grafts (Pakzaban et al., 1993; Watts, Dunnett and Rosser, 1997; 
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Olsson, Björklund and Campbell, 1998). Although the lateral GE is understood to be the 
primary site of MSN generation (Olsson, Björklund and Campbell, 1998), these findings 
suggest that both the medial and lateral WGE are required to develop a mature striatal 
phenotype.   
 
 
Another important consideration, when preparing for transplantation, is the age 
of the embryonic tissue used. In development, the WGE is first seen at embryonic age (E) 
10.5 in rats and 42 days post conception in the human foetus (Pauly et al., 2012). Striatal 
neuronal sub populations are generated through several developmental waves, where 
each wave binds the cells closer striatal phenotype (Schackel et al., 2013). To understand 
the optimal donor age for transplantation, a previous study grafted lesioned rats with E14 
or E16 WGE, lateral GE or medial GE tissue (Watts, Brasted and Dunnett, 2000). They 
revealed that using E14 WGE generated the largest volume of striatal grafts. This supports 
another study which transplanted different donor age WGE (E13, E14, E15) into lesioned 
rats (Schackel et al., 2013), and found that E14 WGE transplants contained the largest 
volume of striatal grafts, but E13 WGE contained the largest P-zones. As all transplanted 
rats showed behavioural recovery, the higher percentage of DARPP-32 in E13 suggests 
that a younger age may have the greatest potential when translating cell transplantation 
into clinic.  
 
Figure 5: A schematic to illustrate the striatal circuitry in the intact (a), lesioned (b) and grafted (c) 
rodent brain. Efferent GABAergic projections from the cortex and the substantia nigra to the 
striatum, and afferents from the striatum to the globus pallidus degenerate in the lesioned striatum.  
This breaks the cortico-basal ganglia-thalamo circuitry. Following a striatal graft, afferent and 
efferent projections begin to reform, but not to the same extent as a control (a). 
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Once the donor tissue is dissected, the next stages of the transplantation 
procedure is to prepare the tissue into a dissociated cell suspension and, using stereotaxic 
injection, transplant this homotopically into the diseased striatum. This results in 
functional afferent, efferent and synaptic anatomical connections with the host brain 
(Wictorin et al., 1992; Clarke and Dunnett, 1993; Chin et al., 1999), and over time, this 
theoretically gives the striatum a platform to bridge the missing circuitry in HD. 
  
Much of the transplantation research to date has been performed in rats and 
primates that have sustained excitotoxic lesions to the striatum (Walsh et al., 1988;  
Mayer et al., 1992; Kendall, Rayment and Torres, 1998; Nakao and Itakura, 2000; Döbrössy 
and Dunnett, 2006; Pauly et al., 2012). Such models are beneficial as the relevant cell loss 
is specified, and also, striatal specific behaviours can be assessed pre and post 
transplantation to test graft functionality. Lesion models also better replicate the 
neurodegeneration in the human condition compared to transgenic mouse models of HD. 
The first transgenic transplantation study was performed by Dunnett and colleagues in 
the R6/2 line (Dunnett et al., 1998). They revealed that striatal grafts survived, however 
functional improvements were modest and did not significantly improve behaviour. One 
explanation for this could be because the R6/2 mouse model was used, which develops a 
particularly accelerated and aggressive disease phenotype. Furthermore, pathology in 
genetically modified mouse models is not striatal specific and is far more widespread 
(Morton et al., 2001). This suggests that a striatal transplant may not be sufficient to 
ameliorate the behavioural deficits observed in current transgenic mouse models. 
Although there is a risk of non-specific damage using the cannula to lesion animals, the 
excitotoxic lesion model remains the model of choice for transplantation studies. 
 
Promising cell transplantation results in pre-clinical models of HD (Wictorin, 1992; 
Dunnett, 1995) led to the first clinical trial in 4 patients in 1992 (Sramka et al., 1992), 
followed by two clinical trials in the mid and late nineties (Madrazo et al., 1995; Philpott 
et al., 1997; Kopyov et al., 1998). Since then several other studies have taken place across 
the world, with some suggestion of improvement in elements of the UHDRS, albeit 
modest (Philpott et al., 1997; Kopyov et al., 1998; Bachoud-Lévi et al., 2000, 2006; Hauser 
et al., 2002; Rosser et al., 2002; Keene et al., 2007; Reuter et al., 2008; Gallina et al., 2010), 
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as well as motor and cognitive improvement and stabilization over 5-6 years (Bachoud-
Lévi et al., 2006; Reuter et al., 2008).  A number of factors have made previous HD 
transplantation trials difficult to compare; in particular heterogeneity in study design, 
surgical procedure and assessment of efficacy. Such differences range from the age of the 
donor embryo and number of embryos transplanted to the use of immunosuppression 
and the size of the cannulae used for transplantation. In summary, the optimal method 
for cell transplantation is yet to be determined (Freeman et al., 2011; Cisbani and 
Cicchetti, 2014).  
 
Post mortem studies have also provided an insight into the composition of the 
graft, including the cell content of the graft, the impact of the immune system on the 
graft, whether mHtt accumulated in the graft, and graft-host integration (Cisbani and 
Cicchetti, 2014). Findings from previous studies revealed that transplants were capable of  
making afferent connections after they showed positive staining for tyrosine hydroxylase 
(Freeman et al., 2000; Keene et al., 2007, 2009; Capetian et al., 2009; Cicchetti et al., 2009; 
Cisbani et al., 2013). In addition, other studies revealed that grafts stained positively with 
the MSN marker, DARPP-32 in people that died between 6 months to 6-7 years post 
transplantation (Freeman et al., 2000; Keene et al., 2007; Capetian et al., 2009), but to 
date not in older grafts (9-12 years) (Cicchetti et al., 2009; Keene et al., 2009; Cisbani et 
al., 2013). This suggests that the HD graft environment could have a negative impact on 
the graft survival over time. This is supported by other findings that showed an increased 
immune reaction (Freeman et al., 2000; Keene et al., 2007; Capetian et al., 2009; Cicchetti 
et al., 2009) and some evidence of mHtt accumulation in the grafts (Freeman et al., 2000; 
Keene et al., 2007; Cicchetti et al., 2009). Furthermore, as microglia increases with age, 
this could also have an effect on graft survival (Luo, Ding and Chen, 2010). The age of graft 
recipients in previous trials were very different (they ranged from 29-64 years of age), and 
the disease duration in patients ranged from 2-17. As MSNs progressively regress in 
people with HD  (Han et al., 2010), transplanting into an advanced patient could make it 
harder for the graft to integrate with host striatum, and limit the graft potential. To 
summarise, this evidences the need for standardised transplantation procedures and 
methodology to allow for accurate comparisons between studies. In addition, it suggests 
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that people that are younger and in the earlier stages of disease could be the target 
population to benefit from cell replacement therapies. 
 
1.2.2 Learning to use the graft in pre-clinical models 
 
Numerous studies have revealed that grafts have the ability to alleviate a broad 
range of motor and cognitive symptoms resulting from excitotoxic lesions in rodents and 
non-human primates (for reviews see: Nakao, 2000; Döbrössy and Dunnett, 2005; 
Dunnett and Rosser, 2007). However, graft survival and anatomical integration alone is 
not sufficient to achieve such improvements. Thus, for optimal graft functionality, 
extended striatal specific behavioural training may be required to allow the recipient to 
‘learn to use the transplant’ (Dobrossy and Dunnett 2005a; Dobrossy and Dunnett 2003; 
Dunnett and White 2006; Mayer et al. 1992; Brasted et al. 1999). This concept was first 
introduced by Mayer and colleagues (Mayer et al., 1992) who found that after intra-
striatal grafting of foetal tissue, striatally-dependent behaviours need to be re-established 
through targeted training, which requires appropriate integration of the graft into the 
host tissue for circuit reconstruction. For example, previous studies revealed that lesioned 
rats which received striatal grafts, and then striatal specific training, gradually improved 
behavioural performance to a level that was significantly better than lesion only rats, and 
a similar level as controls (Brasted et al., 1999a; Brasted et al., 2000; Dobrossy and 
Dunnett, 2003; Dunnett and White, 2006). Other factors that affect graft functionality and 
integration includes the type of pre-training received prior to transplantation and the 
extent of environmental enrichment received post transplantation (Döbrössy and 
Dunnett, 2005; Pauly et al., 2012). Environmental enrichment generally refers to 
stimulating living conditions that promote more social interaction through play and motor 
activity, compared to standard housing conditions that are relatively impoverished, 
standard cages (Rosenzweig et al., 1978). In an experimental setting, enriched housing is 
generally more complex compared to standard laboratory cages with the addition and 
regular changing of toys, tunnels, running wheels, nesting material, as well as bigger cages 
and larger group sizes permitting more frequent and varied social interactions. Previous 
studies revealed that animals living in an enriched environment, post transplantation, had 
larger grafts and contained neurons with greater spine density (Döbrössy and Dunnett, 
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2008). These effects were also time-dependent whereby animals in full time 
environmental enrichment had the largest grafts compared to those given daily exposure 
for one hour. In summary, previous research suggests that conditions post 
transplantation, such as environmental enrichment and striatal-specific training is 
necessary for optimal graft morphology and functionality.  
  
1.2.3 Learning to use the graft in people with HD 
 
The implication of ‘learning to use the transplant’ in human transplant trials is 
that graft functionality may be enhanced by striatal-specific training. This may be 
improved further with environmental stimulation, suggesting that it may be important to 
combine transplantation with a carefully developed rehabilitation program. Although the 
benefits from learning to use the transplant have consistently shown positive results in 
preclinical models (See previous section), clinical trials have not, thus far, adopted this 
strategy post transplantation. In fact, no strategy has been developed for people with HD 
following transplantation, other than return visits to perform various outcome measures 
to (Quinn et al., 1996). Similar to the grafting studies previously discussed in pre-clinical 
models, previous studies in people with HD have shown that rehabilitative interventions 
alone  could benefit functional mobility (Busse and Rosser, 2007; Quinn, Hamana, et al., 
2016; Quinn, Trubey, et al., 2016). Such strategies could be adopted in people with HD to 
encourage graft-host interaction post transplantation, with the aim of translating the 
learning to use the transplant concept from the laboratory, into clinic.  
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1.3 Part 3: Outcome measures used in HD 
 
Assessing disease stage, symptoms and progression using valid and reliable 
outcome measures is crucial to characterise clinical phenotype and to accurately assess 
interventions. The following section describes the importance of disease-specific 
outcome measures and the methods that should be considered when these are selected 
for a study or a clinical trial, and indeed for evaluation of cell transplantation. This section 
also describes the commonly used outcome measures to assess the symptoms and 
disease progression in people with HD. Specific outcomes measures used for cell 
transplantation are reviewed in Part 4.  
 
1.3.1 What are outcome measures? 
 
Outcome measures provide a way of assessing a clearly defined construct or 
concept. These are recognised as the most credible characteristics to translate how a 
person functions and feels, can be used as a way to monitor the progression and severity 
of disease symptoms over time, and to interpret the results of a clinical trial (Fleming and 
Powers, 2012; Iansek and Morris, 2013). Selecting an appropriate outcome measure(s) for 
an intervention is crucial. An outcome measure that is not specific to the population or 
the construct of interest can result in outcomes being missed or misinterpreted. A number 
of theoretical and practical considerations can guide the selection of suitable outcome 
measures. For instance, it is important that the outcome measure used has established 
clinometric properties; a term used to describe the overall quality of an outcome 
measure, such as validity, reliability and responsiveness (Iansek and Morris, 2013). 
Validity is used to ensure the outcomes from an assessment or clinical trial measure what 
they intend to measure, and can be divided into internal, external and test validity (Iansek 
and Morris, 2013). Internal validity is more commonly used following clinical trials to 
establish if any other factors could have led to the outcomes shown (See Figure 6). 
External and test validity are used to ensure an outcome measure is appropriate for the 
purpose intended. Reliability is used to assess the consistency of an assessment (Kimberlin 
and Winterstein, 2008). This includes participant consistency (whether the test score 
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varies in a short space of time when all other factors remain consistent) and rater 
reliability (whether the rater gives the same score when all other factors remain 
consistent) (Pin, 2014), which are more applicable to assessments that are rated 
subjectively. Another consideration when selecting an outcome measure is if the results 
are prone to floor and ceiling effects. An example of a floor effect is when a test is too 
difficult for a population, resulting in the poorest possible performance. A ceiling effect 
occurs when a test is too easy, leading to close to maximum scores. The risk of floor and 
ceiling effects means that they are insensitive to either further deterioration in 
performance (floor effect), or improvement (ceiling effect) over time (Rasmussen et al., 
2001). Other factors that should be considered when selecting an appropriate outcome 
measure in clinical research are presented in (Table 1). 
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Figure 6: The different types of validity used to establish how well outcomes used for research or a clinical trial measures what it intends to measure. For a review 
see (Kimberlin and Winterstein, 2008). 
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This table was adapted for use from (Iansek and Morris, 2013).
Primary consideration Relevant questions
To identify the impact of specific symptoms on the individual?
To establish a baseline measure to monitor change over time?
To evaluate the response to an intervention?
To diagnose a patient?
Impairments of body structure and function?
Activity limitations?
Participant restrictions?
Quality of life?
Do the study samples have the same movement disorder/condition?
Was the assessment performed in people of a similar ethnicity?
Is the study sample similar in disease severity?
Is the study sample similar in disease specific factors that are considered 
important. For example, level of mobility, age, presence of co-existing medical 
problems
Are the assessment results consistent at a participant level? 
Are the assessment results consistent at a rater level?
Has the assessment been tested for criterion, construct and content validity in a 
population similar to the population of interest?
What was the sample size of the previous studies?
Are the participants previously tested similar to the population of interest 
demographically? For example, age, weight, education.
Is the outcome measure responsive to change? Is there a known minimum clinically important difference? 
Is there a cost for the assessment?
Is a licence needed for the assessment?
Is equipment needed?
Is special equipment needed?
Is more than one researcher/clinician required to carry out the assessment?
Is there enough space available?
Does the assessment take a long time to set up?
How much time is needed to complete the assessment?
How difficult is the assessment?
Is it realistic to ask the participant to return to redo the assessment?
Does the participant need privacy when doing the assessment?
Does the participant require a translator?
Does the assessment need to be done face to face with the researcher/clinician 
or can it be sent to the participant to do at home?
Does the assessment include questions the participant my feel sensitive 
answering?
Could items within the questionnaire be interpreted differently due to 
differences in language/ethnicity?
Is the questionnaire written in a language that can be easily understood by the 
participant?
Does the assessment account for fluctuations in cognitive/behavioural or 
motor symptoms. For example a change in medication.
Does the assessment need to be performed a certain time of day to account for 
periods where for example, medication may be waring off.
Is the outcome of the assessment in a language that is useful to the clinician 
and researcher? 
Can the outcome of the assessment be interpreted efficiently?
Are there normative data for healthy people of similar ages?
Data storage
If the outcome measure is provided online, where is the data stored and can all 
elements be accessed?
Is there a financial consideration?
Implementation: resources
Implementation: client and carer
For patient-reported outcome measures 
(questionnaires) 
Cognitive/Behavioural/motor fluctuations
Interpretability
Why is the outcome measure being used?
What is being measured?
Have the clinometric properties of this tool 
been assessed in a sample of people similar to 
those in this study? 
Is the outcome measure reliable?
Is the outcome measure valid?
Table 1: Considerations to ensure that an appropriate outcome measure is selected for purpose.  
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1.3.2 Outcome measures used in people with HD 
1.3.2.1 Outcome measures to assess motor symptoms  
 
The UHDRS-TMS is the current gold standard for assessing motor severity in 
people with HD and is the most commonly used outcome measure for this population 
(Bilney, Morris and Perry, 2003). This covers a broad range of motor domains including 
bradykinesia, chorea, dystonia, rigidity, gait and oculomotor function. The limitations of 
this assessment are acknowledged in a number of papers (Tabrizi et al., 2009; Bechtel et 
al., 2010; Reilmann et al., 2011), with the main problem being the way performance is 
rated. In this assessment, subjects are rated by a neurologist, where each item is scored 
on a five point rating scale (0 = normal and 4 = severe impairment) and summed, equating 
to a score out of 124. Due to this subjective scoring method this limits inter rater 
reliability. Furthermore, previous studies revealed that the UHDRS-TMS led to floor and 
ceiling effects in people with early and advanced stages of HD (Hogarth et al., 2005; Tabrizi 
et al., 2011; Youssov et al., 2013). This suggests that additional motor assessments should 
be used alongside the UHDRS-TMS to sensitively capture people with all stages of HD.  
 
The Quantitative (Q)-motor assessments provide quantitative motor feedback via 
a force based transducer (Reilmann et al., 2013). These were originally developed for the 
HD population to overcome the limitations that arise using the UHDRS-TMS (Reilmann, 
2012). The Q-motor assessments include finger tapping (Bechtel et al., 2010), tongue 
force (Reilmann, Bohlen, Klopstock, Bender, Weindl, Saemann, Auer, E. Bernd Ringelstein, 
et al., 2010) and grip force tests (Reilmann, Bohlen, Klopstock, Bender, Weindl, Saemann, 
Auer, Erich B. Ringelstein, et al., 2010)  and have proven their ability to distinguish 
between people with pre-manifest HD and both healthy controls and manifest people 
with HD (Tabrizi et al., 2009; Reilmann, 2012). Although these assessments require 
specialist equipment, they are scored objectively, and therefore may be more sensitive 
than subjective scoring methods used for the UHDRS assessments. This makes them a 
useful biomarker to track subtle motor changes that otherwise go unnoticed using ordinal 
based measures (Reilmann, 2012). Furthermore, a previous study revealed that Q-motor 
performance highly correlated with caudate and putamen volume reduction (Scahill et 
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al., 2013), presenting a link between brain atrophy and some of the earliest clinical 
symptoms in HD. 
 
1.3.2.2 Outcome measures to assess mobility and balance  
 
The Berg Balance Scale (Berg et al., 1992) and Tinetti Mobility Test (Tinetti, 
Williams and Mayewski, 1986) are consistently used as outcome measures to assess 
mobility and balance following a physical intervention in people with HD (Quinn et al., 
2013; Busse et al., 2014). However, as they were originally developed for the elderly, 
these include a number of redundant items, such as sitting unsupported (Busse et al., 
2014), which makes their use unnecessarily time consuming. Furthermore, the lack of 
item specificity means that many items are too easy for people with early-mid stage HD, 
which combined with the ordinal rating scales, frequently results in both floor and ceiling 
effects (Quinn, Khalil and Dawes, 2013; Busse et al., 2014) and limits the ability to measure 
meaningful change over time.  
 
1.3.2.3 Outcome measures to assess cognition  
 
Cognitive function in HD is commonly evaluated using the UHDRS cognitive test, 
which includes three executive function tests: the letter fluency test (LVF), Symbol Digit 
Modalities test and the Stroop test (Kieburtz, 1996). These are tests that tap into 
executive function abnormalities, an umbrella term for processes such as  task-switching, 
planning, and working memory (Elliott, 2003). 
 
The LVF test requires the spontaneous generation of words beginning with a given 
letter (Benton, 1968). Typically, subjects are asked not to repeat themselves or say any 
pronouns. This tests attention, inhibition and retrieval processes which heavily rely on the 
fronto-striatal and temporal regions that are known to degenerate in HD (Ho et al., 2002). 
LVF tasks have been well validated in this disease population, revealing that people with 
HD consistently recite significantly less words in LVF tasks compared to healthy controls 
(Butters et al., 1986; Hodges, Salmon and Butters, 1990; Rosser and Hodges, 1994).  
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However, as lifestyle factors could affect the performance in this task, such as education, 
hobbies (e.g. reading) and type of job, this could improve the baseline score, suggesting 
that a participant is earlier in the disease stage than they actually are. This should 
therefore be considered when interpreting LVF results.  
 
The Symbol digit modality test involves translating geometric shapes into 
numbers by following a number-shape reference key (Smith, 1968). This is used to assess 
perceptual speed, motor speed, visual scanning and visual tracking. A previous study 
revealed that this test significantly distinguished between healthy controls and people 
with pre-manifest HD (Tabrizi et al., 2013). In addition, another study revealed that 
performance in the Symbol digit modality test significantly deteriorated in people with 
manifest HD over a period of 16 months (Beglinger et al., 2010), suggesting this may be a 
useful measure to track change over time. However, as subjects are required to translate 
their answers onto paper using a pencil, motor symptoms could also affect performance 
in this test as this test. Therefore, defining how much the Symbol digit modality test 
assesses cognition over motor ability can be challenging. 
 
The Stroop task requires a participant to read colour-words (congruent) or name 
the coloured ink of colour-words (incongruent) (Stroop., 1935). The simpler, congruent 
task is where colour-words are written in their coloured ink (e.g. BLUE written in the 
colour blue). The complex task involves saying the coloured ink which is incongruent to 
the colour-word (e.g. BLUE is written in the colour yellow).  As reading words is more 
common in everyday life than acknowledging the coloured ink of the word, responses in 
the incongruent task are often slower, leading to lower performance accuracy (MacLeod 
and MacDonald, 2000). This task is described in more detail in Chapter 2 and Chapter 3.  
 
Increased understanding regarding the cognitive symptoms associated with HD 
means that a larger HD-specific, cognitive assessment battery was recently developed and 
was called  the HD Cognitive assessment battery (Stout et al., 2014). This consists of six 
cognitive assessments that assess attention, processing speed, visuospatial processing, 
timing, emotion processing, memory, and executive function. The aim is for this to 
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become a standardised cognitive battery for people with HD, to allow for accurate 
comparisons between sites and treatments for future clinical trials.  
 
1.3.2.4 Psychiatric/behavioural outcome measures 
 
The Problem Behaviour Assessment is a questionnaire used to assess the 
behavioural symptoms in people with HD, including apathy, depression and irritability 
(Craufurd, Thompson and Snowden, 2001). In a previous systematic review, this was 
reported as the recommended method to assess behavioural symptoms in people with 
HD  (Carlozzi et al., 2014). Furthermore, additional studies have revealed this is valid, 
reliable and responsive to change over time in people with HD (Kingma et al., 2008; 
Thompson et al., 2012).  
 
1.3.2.5 Function and Quality of life assessments  
 
The current lack of treatments available for HD means that disease symptoms 
gradually worsen and negatively impact quality of life (Ho et al., 2004). As a result, 
functional and quality of life assessments are crucial to gain an understanding about how 
standards of living change as HD progresses, and also following an intervention.  
 
Functional capacity in HD is commonly rated using the UHDRS-TFC questionnaire. 
This is used to understand how people with HD manage their work, finances, daily living, 
domestic chores and their care arrangements (Shoulson and Fahn, 1979). Answers from 
the patient are rated by a neurologist on an ordinal scale ranging from 0 (unable) to 3 
(normal function). These are summed to produce an overall score, where 13 equates to 
normal function and 0 equates to severe functional incapacity.  As mentioned in Section 
1.1.7, this measure is also frequently used to class people into different disease stages. 
However, given that this scoring method is arbitrary, alternative measures are also 
required when determining disease stage in HD. 
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The Short Form-36 (SF-36) and the SF-12  assessment is one method used to 
measure quality of life in people with HD (Ware, Kosinski and Keller, 1996). This requires 
subjects to rate 36 or 12 items on an ordinal scale based on how they have been feeling 
and how this has affected performing social and physical activities. Both surveys have 
shown to be valid and reliable tools used for the HD population (Ho et al., 2004), and in 
particular have implicated functional ability as a key factor that impacts health related 
quality of life (Ho et al., 2009).  
 
The functional component of the Late-Life Functional Disability Instrument (LL-
FDI) is a 32 item questionnaire that focuses on common daily activities, including how the 
person manages when using kitchen utensils to prepare meals, and getting into and out 
of a car (Haley et al., 2002). Questions are scored on an ordinal scale ranging from no 
difficulty (=0) to cannot do (=5). The novel component of this questionnaire is that it can 
be subcategorised into items involving upper extremity function and, basic and advanced 
lower extremity function, where each domain is scored and transformed; resulting in 
linear scaled scores from 0 to 100. Although the LL-FDI was originally developed and 
validated in community dwelling older adults (Sayers et al., 2004), the items within the 
questionnaire are applicable to any person with or at risk of reduced functional mobility. 
The LL-FDI has not yet been evaluated in HD. However, as this assessment focuses on a 
range of common daily activities, and scoring allows disease progression to be sensitively 
tracked, the LL-FDI may be a useful measure of functional impairment in this disease 
population.  
 
A limitation of giving questionnaires about general function to people with HD is 
that there can be discrepancies between what the patient reports and what they can 
actually do. Therefore, the Physical Performance test has previously been used to 
measure functional performance in people with HD (Reuben and Siu, 1990; Quinn et al., 
2013; Busse et al., 2014). This uses time as a primary measure to rate activities such as 
‘put on and removing a jacket’ and ‘pick up a penny from the floor’. A  previous study 
revealed that the Physical Performance test had excellent reliability and low minimal 
detectable change across disease stage in HD (Quinn et al. 2013). However, a limitation 
of this assessment is that 2 of the 9 items require the participant to climb a flight a stairs, 
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which is not always possible in a clinical setting. Furthermore, although the Physical 
Performance test adopts a quantitative scoring method, timing categories were devised 
for use in the elderly (Reuben and Siu, 1990). As a result, this reduces the sensitivity of 
this assessment across people with different stages of HD (Quinn et al. 2013).  
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1.4 Part 4: Outcome measures to assess graft functionality in HD 
 
Well designed, sensitive outcome measures and clinical tools are required to 
assess the effectiveness of HD clinical trials, such as cell transplantation. Furthermore, 
selecting outcome measures that test behavioural functions that target the neurocircuitry 
effected in HD, will permit sensitive tracking of neurodegeneration, and could also be 
used to assess the outcomes of therapies that target this specific neural region.  As a 
primary goal of cell transplantation in HD is to improve standards of living, this suggests 
that performance based outcome measures could be a useful way to translate assessment 
outcomes at clinic to common behavioural tasks performed at home. Therefore, this 
section begins with a review on previously used outcome measure for transplantation 
studies in HD, and then focuses on functional tasks that could be used to assess the 
effectiveness of cell transplantation in clinical trials, such as dual task paradigms.  
 
1.4.1 CAPIT-HD 
 
The Core Assessment Protocol for Intrastriatal Transplantation in Huntington’s 
disease (CAPIT-HD) was originally developed as a way to standardise the outcome 
measures used pre and post transplantation (Quinn et al., 1996). This is typically used 
before transplantation and 6-12 months post-surgery, from which it assesses a wide range 
of outcome measures, including; motor, cognitive, psychiatric function, 
neuropsychological and neuropsychiatric tests, as well as undergoing magnetic resonance 
(MRI) and positron emission tomography (PET) imaging (Quinn et al., 1996; Kopyov et al., 
1998; Bachoud-Lévi et al., 2000; Hauser et al., 2002; Rosser et al., 2002). Although the 
development of CAPIT-HD represented the standard baseline of current knowledge, a 
wealth of research has since improved our understanding behind the neuropathology and 
the clinical symptoms seen in people with HD. As a result, it is important that CAPIT-HD is 
updated to ensure that the research advancements made over the last two decades result 
in more sensitive assessments that better capture disease progression, and any changes 
that result from cell transplantation. 
 
General Introduction  Chapter 1: Part 4 
38 
 
1.4.2 Neuroimaging post transplantation 
 
Neuroimaging is routinely used to assess graft placement, graft volume and to 
quantify morphological and metabolic changes. Techniques such as MRI, PET and single 
photon emission computed tomography are routinely used as part of CAPIT as a way of 
tracking and assessing graft morphology, graft function, graft-host integration and circuit 
reconstruction (Quinn et al., 1996; Rosser and Bachoud-Lévi, 2012). Such techniques 
revealed that the minimum follow up time to allow the graft to mature, to the point of 
exhibiting functional signs, that can be attributable to grafted connections, is estimated 
as 12-24 months (Rosser and Bachoud-Lévi, 2012). Similar to pre-clinical studies, this 
suggests that graft integration is gradual. However, whether or not this improvement 
could be optimised or appear sooner than 12-24 months using the ‘learning to use the 
transplant’ concept, is unknown. 
 
  Although neuroimaging is beneficial to demonstrate graft survival, graft 
placement and graft function, it is not currently an informative method to determine 
neuronal type (proportion of striatal to non-striatal neurons), or the functional impact of 
the graft on behaviour. As a result, neuroimaging, as well as appropriate clinical outcome 
measures and post-mortem studies are fundamental to gain a true understanding behind 
how the graft develops and if this improves the standards of daily living in HD patients. 
 
1.4.3  What outcome measures are missing in transplantation trials? 
 
Since individual UHDRS items do not necessarily test known striatal dependent 
behaviours, using UHDRS assessment(s) as a primary outcome measures in 
transplantation trials risks rating functions reliant on compensatory neural networks that 
bypass the striatum, rather than directly testing the effects of the transplanted tissues on 
their primary target i.e., the striatal circuitry itself. In addition, it is critical to assess not 
only graft integration, but to include outcome measures representative of a variety of 
domains in relation to function.  
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1.4.3.1 Functional assessments  
 
Whereas the majority of outcome measures are performed in a laboratory 
setting, there are few performance based assessments available to understand how 
people with HD function in everyday life. Such tasks are required to improve the ecological 
validity of currently used outcome measures.  
 
Assessing lower limb function in HD 
 
Gait, sitting, standing and stepping are different examples of lower limb 
functional tasks that are used in people with HD. Gait is assessed using the UHDRS-TMS, 
and is purely observational. More sensitive measures of gait impairment have been 
observed using objective measures, such as the GaitRite and motion analysis (Rao, Quinn 
and Marder, 2005a; Delval, et al., 2008; Grimbergen et al., 2008; Rao et al., 2008a, 2011; 
Dalton, et al 2013). The GaitRite is an electronic walkway that was found to be a reliable 
and valid method to measure gait parameters in HD (Hausdorff et al., 1998; Rao et al., 
2008). In a longitudinal study, 10 pre-manifest people with HD were recruited to perform 
gait analysis tests at baseline and after 1 and 5 years (Rao et al., 2011). They found that 
step length reduced and swing time increased 1 year after baseline, whereas no changes 
were detected using the UHDRS-TMS gait item.  Previous findings also revealed that the 
GaitRite was sensitive to changes in pre-manifest people with HD and controls, and 
revealed that the pre-manifest group had decreased gait velocity and stride length, and 
an increased time in double limb support, with a more variable stride length and step time 
(Rao et al., 2008). These findings are consistent with other studies that used the GaitRite, 
as well as other objective methods to analyse gait, such as inertial measurement units 
worn on the trunk whilst walking (Dalton, Khalil, Busse, Rosser, van Deursen, et al., 2013; 
Collett et al., 2014; Danoudis and Iansek, 2014). To summarise, these findings suggest that 
gait variability is a common feature in HD. Furthermore, the use of objective measures to 
analyse gait parameters are likely to reveal more subtle changes in people with pre-
manifest HD that cannot be detected using the UHDRS-TMS.  
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People with HD find it increasingly difficult to step as the disease progresses, 
whether that is going up and down the stairs or clearing an obstacle. This requires both 
strength and balance, which are features known to deteriorate in people with HD (Panzera 
et al., 2011). Such deficits are reflected in stepping tasks in people with HD, as a previous 
study revealed that manifest subjects were generally slower performing a stepping task 
than healthy controls (Goldberg et al., 2010). This slowness could be due to a problem 
automating movements, such as stepping, and/or a problem with timing control, both of 
which are regulated through basal ganglia thalamo-cortical motor circuits (Kim and 
Hikosaka, 2015; Dudman and Krakauer, 2016) and could explain why people with HD have 
problems performing such tasks. Stepping is reviewed in more detail in Chapter 2 (page 
58).  
 
The Sit to stand (Rikli and Jones, 1999) and the Timed up and go (TUG) (Dorman, 
2009) both require lower limb strength to stand up and sit down to and from a sitting 
position. The difference between the two tests being, the sit to stand requires the subject 
to repeatedly stand up and sit down from a chair over a set period of time, whereas the 
TUG is timed, and requires the subject to start by sitting, walk 3 metres, turn and return 
back to the chair, finishing by sitting. The TUG appears to be used more often than Sit to 
Stand. This may be because floor effects have been reported in the Sit to Stand in a 
previous study (Khalil et al., 2010), and could be because, similar to the Sit to Stand, the 
TUG includes sitting and standing as well as a walk and turn. A previous study revealed 
that performance in the TUG deteriorated with HD disease progression, where it took 
longer for people to complete the task in people with more advanced disease stages 
compared to healthy controls and those in early disease stages (Rao et al., 2009; Quinn et 
al., 2013). This suggests that the multiple constructs required to perform the standing, 
sitting and turn required in the TUG is sensitive to disease progression. This is described 
in more detail in Chapter 2 (page 57). 
 
Assessing upper limb function in HD 
 
Performance based outcome measures used for people with HD commonly focus 
on lower limb function (Quinn et al., 2013; Busse et al., 2014). However, another 
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important motor impairment seen in this population is the loss of upper limb dexterity, 
which can have a major impact when performing daily activities (Quinn, Busse and Dal 
Bello-Haas, 2013). The combination of the voluntary and involuntary symptoms 
associated with HD means could explain why people with HD have altered arm 
trajectories, grasp impairments, accuracy, problems with timing and hand rotation when 
compared to healthy controls (Quinn et al., 2001; Fenney et al, 2008; Reilmann, et al., 
2010; Klein et al., 2011a). Problems with upper limb movement is also observable in pre-
manifest subjects, where this population were slower performing a speeded metronome 
finger tapping task (Bechtel et al., 2010) and had more variable grip force (Rao, Gordon 
and Marder, 2011) compared to healthy controls. This demonstrates the importance of 
using objective, quantifiable instrumentation to capture subtle movement abnormalities 
that might not be captured when using subjective rating scales. Other upper limb 
assessments that have been used in people with HD are reviewed in Chapter 2 (Table 13). 
Given that many of these are limited due to the subjective rating scale, or because they 
were developed for another population, and so they do not capture all symptoms seen in 
HD, this suggests that an assessment that rates functional grasping and dexterity using 
quantitative feedback could provide a useful measure to assess upper limb function in 
people with HD. 
 
Dual tasking 
 
Dual or multitasking is the performance and synchronisation of multiple activities. 
There is no set definition for dual tasking, but it can be described as; dividing attention 
between two or more tasks performed simultaneously with distinct, dissociable goals 
(McIsaac, Lamberg and Muratori, 2015). Examples of dual tasking include, walking whilst 
texting, or driving whilst talking, with the main purpose being to be maximise efficiency. 
Furthermore, the type of tasks combined as well as the task complexity will impact 
performance, which is exacerbated in people with a neurological disorder such as HD 
(Delval, Krystkowiak, Delliaux, Dujardin, et al., 2008; McIsaac, Lamberg and Muratori, 
2015; Vaportzis et al, 2015b). In many cases, for people with no neurological disorder, one 
task becomes automated, such as walking or balance, freeing the cortical regions to 
attend to the secondary task (Saling and Phillips, 2007). To our knowledge, twelve 
General Introduction  Chapter 1: Part 4 
42 
 
previous studies have investigated dual task performance in HD, which are presented in 
Table 2. These consistently reveal that dual task ability is compromised in people with HD, 
leading to deterioration in one or both tasks performed, which is known as ‘dual task 
interference’ (McIsaac, Lamberg and Muratori, 2015). One explanation for increased dual 
task interference in HD patients compared to controls is that automatic tasks could 
become attention demanding, resulting in a demand for greater cognitive resources 
(Saling and Phillips, 2007; Kelly, Eusterbrock and Shumway-Cook, 2012). In a previous 
study, walking was combined with a secondary motor task (carrying four glasses on a tray) 
or a cognitive task (counting backwards) (Delval, Krystkowiak, Delliaux, Dujardin, et al., 
2008). This revealed that gait parameters including; walking speed, cadence and stride 
length, reduced in both dual tasks compared to baseline, whereas no dual task 
interference was observed in healthy controls. Furthermore, people with HD were even 
more impaired in the motor-cognitive task (walking whilst counting backwards) than the 
motor-motor dual task (walking whilst carrying a tray), suggesting that motor-cognitive 
tasks might be more attentionally demanding than motor-motor tasks.  Another study 
revealed no difference in a motor-cognitive task, which used a zig-zag drawing test 
combined with a simple cognitive task (Georgiou et al., 1997). This suggests that the 
complexity of the secondary cognitive task could play an important role when designing 
dual task assessments and could have an affect on dual task interference (McIsaac, 
Lamberg and Muratori, 2015).  
 
Multiple theories have been developed to explain performance deterioration in 
attentional demanding tasks. The first was the bottleneck theory, which proposed that in 
a given scenario where multiple stimuli are presented, information serially enters the 
brain (Broadbent, 1966). This is held long enough that a primary stimulus is selected and 
attended to, whilst the others are filtered out, and suggests that stimuli never run in 
parallel, meaning a performance decrement always occurs. However, although dual task 
interference is common, previous studies reveal that this is not always the case  (reviewed 
in: Saling and Phillips, 2007). The limited capacity theory resolves this problem as it 
suggests there is an attention pool with limited capacity for processing information 
(Kahneman, 1973). Therefore, attention can be allocated to one complex task or divided 
between multiple tasks concurrently. If the tasks do not require the full capacity, both are 
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performed simultaneously and do not result in dual task interference. The multiple 
resources theory is more task dependent and postulates that there are multiple resource 
pools each with a limited capacity (Wickens, 2002). Thus, a motor-motor dual task will 
consume attention from the same pool and will theoretically be more difficult than for 
instance an auditory-visual task or a cognitive-motor task, which would require attention 
from different pools. However, using the study previously described by Delval and 
colleagues as an example; the motor-cognitive task resulted in greater dual task 
interference than motor-motor (Delval, Krystkowiak, Delliaux, Dujardin, et al., 2008), 
suggesting that motor-cognitive modalities are not completely separate (Vaportzis et al., 
2014). 
 
The problem with these theories is that they do not explain skilled motor or 
automatic behaviours. These are often performed faster than tasks that require 
information processing (Saling and Phillips, 2007). As dual tasking does not always result 
in increased neural activity, it suggests that automaticity may employ a different neural 
network which, given that the basal ganglia is implicated in automatic, habitual tasks, 
suggests that it could be involved in automating aspects of dual task performance (Saling 
and Phillips, 2007; Ashby, Turner and Horvitz, 2010; Kim and Hikosaka, 2015). Therefore, 
it may be that with increasing basal ganglia circuit degeneration, the difficulties in multi-
tasking that are experienced by people with HD may be two-fold.  Not only do they have 
a limited attentional capacity, but they may also have difficulty carrying out simple, 
automatic tasks, such as walking whilst talking. 
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Table 2: Dual task studies performed in HD to date 
 
Study 
reference 
Dual task testing 
domains 
Dual task method Population tested Main findings 
(Brown, 
Jahanshahi and 
Marsden, 1993) 
motor-motor 
Subjects had to tap a button with one 
finger and perform the Perdue 
pegboard test with the other 
People with all stages of HD: 
n=6 (a mean of  4-7 years of 
disease duration) and n=12 
healthy controls, n=7 people 
with PD, n=7 people with 
cerebellar degeneration 
The HD group was significantly 
slower than controls performing 
the pegboard test and tapping in 
the dual task. There was no 
significant difference between 
the disease groups although 
people with HD generally 
performed better than the PD 
group and people with 
cerebellar degeneration. 
(Dujardin et al., 
2013) 
visual-acoustic task 
(and a motor 
element) 
Subjects had to press a button on a 
keyboard when four 'x' that were 
superimposed on a 16 dot matrix, made 
a square. At the same time subjects 
listened to high and low pitched 
alternating tones. If the tone was the 
same pitch as the previous then the 
subject had to react by pressing a 
button on a keyboard 
People with all stages of HD: 
n=20 (the average duration of 
disease 3.8 ± 0.62) and n=27 
healthy controls 
The HD group made significantly 
more errors and omissions than 
controls in both baseline and the 
dual task condition. 
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(Georgiou et al., 
1997) 
motor-cognitive 
Subjects had to draw zig-zags to 
markers. The markers were printed 
close together (small zig zags) or far 
apart (large zig zags). They did this with 
and without performing a digit span 
task 
12 people with HD with a 
mean duration of 3.12 (SD, 
2.58) and TFC stage 1-3. 12 
age matched controls 
HD subjects were generally 
slower drawing longer zig-zag 
strokes and were slower 
decelerating strokes in the 
baseline and dual tasks. The 
concurrent task was associated 
with shorter movement times 
compared to baseline in the HD 
group. More digit span errors 
were made in the HD group 
compared to controls, especially 
when drawing the longer strokes 
(Müller et al., 
2002) 
 
visual-acoustic task 
(and a motor 
element) 
The same as dual task as Sprengelmeyer 
People with mid stage HD: 
n=13 (average TFC 8.08 ± 
0.89) and n=13 age matched 
controls 
No baseline data. People with 
HD took significantly longer to 
respond and made significantly 
more errors and omissions 
compared to healthy controls in 
the dual task condition. 
(Delval, 
Krystkowiak, 
Delliaux, 
Dujardin, et al., 
2008) 
motor-cognitive and 
motor-motor 
Walk with tray, and walk whilst 
counting backwards 
Early to mid-stage HD: n=15 
(TFC range 4-12) and n=15 
healthy controls 
The motor-cognitive dual task 
resulted in a greater 
performance decline than the 
motor-motor dual task 
(Delval, 
Krystkowiak, 
Delliaux, Blatt, et 
al., 2008) 
motor-cognitive and 
motor-motor 
Walking to a metronome whilst either 
carrying a tray or counting backwards 
Early to mid-stage HD: n=15  
(TFC range 9 ± 2.4) and n=15 
healthy controls 
There was a trend towards 
improvement when subjects 
walked to a metronome, 
although this was not significant. 
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(Mazzoni and 
Wexler, 2009) 
auditory-motor 
Subjects were asked to make dual 
explicit and dual implicit reaching 
actions. After hearing a tone, subjects 
used their finger to guide a cursor to a 
target in a location previously seen or 
reflected at a different angle. 
Asymptomatic HD: (n=13) 
and n=13 healthy controls 
People with HD were impaired in 
the dual task conditions 
compared to controls 
(Thompson et 
al., 2010) 
motor-motor 
Finger tapping using one and both 
hands to a metronome 
Early-mid stage HD: n=14 
(TFC stage  8.9 ± 1.9) and 
n=14 healthy controls 
In the HD group there was 
greater tapping variability when 
two hands were used compared 
to one, whereas the opposite 
pattern was true for controls. 
(Vaportzis et al., 
2014) 
motor-cognitive 
serial subtraction in 2s or 3s whilst circle 
tracing 
All stages of HD: n=15 (range 
3-13) and n=15 healthy 
controls 
Simple tasks placed greater 
attentional demands on HD 
participants compared with 
controls. 
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(Vaportzis, 
Georgiou-
Karistianis, 
Churchyard and 
Julie C. Stout, 
2015) 
auditory-motor 
Subjects performed a letter cancellation 
task where they had to identify the 
letter 'O' amongst easy and hard 
distractor letters. Whilst doing this they 
were asked to count the number of high 
pitched tones presented on their own 
(easy) and with low pitched tones (hard) 
Early-mid stage people with 
HD: n=14 (Mean TFC 10.1 ± 
3.04) and n=14 ages matched 
healthy controls 
The HD group were not 
significantly slower or less 
accurate compared to controls. 
Dual task costs were significantly 
greater in people with HD 
relative to controls in terms of 
time to complete the dual task. 
People with HD with greater 
cognitive impairment were 
significantly slower performing 
the hard dual task relative to the 
easy. 
(Vaportzis, 
Georgiou-
Karistianis, 
Churchyard and 
Julie C Stout, 
2015) 
cognitive-motor 
Subjects performed an easy and a hard 
choice reaction time task (selecting 4 or 
5 target letters over non-target letters) 
whilst reciting an easy and hard digit 
forward and digit backward task. 
Early-mid stage HD: n=13 
(Mean TFC 10.08 ± 3.17) and 
n=13 healthy controls. 
The HD group were significantly 
slower than the control group in 
the dual task but not less 
accurate. In the hard dual task, 
people with HD were 
significantly less accurate than 
healthy controls. 
(Fritz et al., 
2016) 
motor-cognitive 
Walk and talk. Subjects walked and 
recited the alphabet and every other 
letter of the alphabet 
Early to mid-stage: n=32 
(n=16 UHDRS-TMS<35 and 
n=16 UHDRS-TMS >35) 
Gait speed declined under 
simple and complex dual task 
conditions. The simple walking 
whilst talking task correlated 
with the UHDRS-TMS but not the 
UHDRS-TFC. The opposite 
pattern was observed for the 
complex walking whilst talking 
task. 
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Neural regions implicated for dual task performance 
 
The neural regions responsible for dual tasking is variable and seems to depend 
largely on the dual task paradigms employed (Wu and Hallett, 2008). The brain regions 
most commonly associated with dual task processing include the prefrontal cortex (PFC), 
specifically the  anterior cingulate cortex  and the infralimbic cortex, (Kondo, Osaka and 
Osaka, 2004; Manuscript, 2013; Ohsugi et al., 2013; Watanabe and Funahashi, 2014), as 
well as the  precuneus (Wenderoth et al., 2005; Wu et al., 2013), left inferior frontal sulcus 
(Swick, Ashley and Turken, 2008), and sub-regions of the cerebellum (Wu et al., 2013). 
These studies have led to contrasting results, where some studies revealed that the 
regions required for single task performance were more strongly activated during dual 
task performance (Nijboer et al., 2014; Chan, Kucyi and DeSouza, 2015), suggesting 
greater attentional load. Conversely, other studies revealed that regions required for 
single task performance were less activated during the dual task condition, which could 
suggest limited attentional resources (Just et al., 2001; Chan, Kucyi and DeSouza, 2015).  
 
Models of basal ganglia thalamo-cortical circuitry suggest that cortico-striatal 
cross talk could influence dual tasking. In the healthy brain, the prefrontal cortex and the 
basal ganglia closely interact (Leisman, Braun-Benjamin and Melillo, 2014). Thus, one 
explanation for difficulty in dual tasking in people with HD could be because the 
anatomical and functional connections between such brain regions become dysfunctional 
and degenerate (Cepeda et al., 2007), meaning cross talk is limited and resulting in 
reduced attentional capacity. Furthermore, reported deficits in  resource allocation 
(Georgiou et al., 1997), attentional set shifting (Lawrence et al., 1998) and fixed, 
automatic behaviours (Thompson et al., 2010) are likely to affect performance when 
carrying out multiple tasks simultaneously, which also to some extent all require basal 
ganglia function. 
 
Anatomically, automatic behaviours result in reduced neural activity between 
brain regions involved in task performance, tighter connections and greater efficiency 
between these regions (Wu and Hallett, 2008).  Automatic (also referred to as ‘habitual’) 
behaviour is a dynamic process known to depend on basal ganglia circuitry and in 
particular the striatum (Ashby, Turner and Horvitz, 2010). Automatic behaviours emerge 
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from initial learning of planned actions in response to a stimulus. With repetition, this 
results in an ingrained memory that has potential to dominate other alternative 
outcomes. In a series of pioneering pre-clinical studies that were performed in lesioned 
rats, Yin et al identified regions of the striatum specifically involved in the management 
of goal directed (action-outcome) responses and habit (i.e. automatic) formation (Yin, 
Knowlton and Balleine, 2004). They found that the neural processes utilized could be 
manipulated from learned outcome value, showing that rats with lesions to the 
dorsolateral striatum were unable to form habitual behaviour, but maintained goal 
directed behaviour (Yin et al. 2004; Yin, Knowlton, et al. 2005; Yin, Ostlund, et al. 2005). 
To summarise, this suggests that intact striatal function could be required to form habitual 
(i.e. well –practiced, automatic tasks), that require relatively little attentional resources. 
As this is mediated by the basal ganglia, this could lead to increased dual task interference 
in people with HD compared to healthy controls (Yogev-Seligmann, Hausdorff and Giladi, 
2012; Wu et al., 2013) 
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1.5 Thesis aims, objectives and hypothesis 
 
The overall aim of the studies presented in this thesis were to develop and 
evaluate outcome measures that target the neurobiology that is affected in Huntington’s 
disease. Although numerous outcome measures are available, they are limited as they do 
not capture people with all stages of disease. Furthermore, as questionnaires are 
commonly used to measure functional changes in this population i.e. behaviours that 
translate to daily activities, performance based functional outcome measures are 
required to directly test behaviours that involve basal ganglia circuitry. This is particularly 
important to assess the effectiveness of therapies that directly target the basal ganglia, 
such as cell transplantation. For this reason, it is also important that outcome measures 
used in pre-clinical models tap into the circuitry affected in HD so Phase 1 clinical trials 
can be accurately assessed. 
 
In this thesis, the first objective was to develop and assess dual task paradigms 
for use in people with HD.  Dual task paradigms were selected due to their high ecological 
validity, but also because people with HD are deficient when performing two tasks 
simultaneously, and, this could be due to a breakdown in cortico-striatal cross talk as HD 
progresses. A second objective was to evaluate the performance of rats in a rodent 
analogue of the Stroop task. Although the striatum has been implicated for successful 
performance in the human Stroop task, whether striatal regions were required to perform 
aspects of the same task in rodents is currently unknown.  
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Chapter 2 
Optimising dual task assessments in Huntington’s 
disease 
 
 
Chapter Summary 
 
Current functional assessments for people with HD are limited. These are either 
questionnaire based, or they were developed for another disease population, which makes 
them insensitive to people with HD and difficult to track change over time. The aim of the 
experiments in this Chapter was to develop a functional, performance based assessment 
for people with HD, which consisted of behavioural tasks that involve the basal ganglia 
circuitry, and more specifically the striatum. Such tasks are particularly important when 
assessing disease progression, but also to assess the effectiveness of potential 
therapeutics that directly target the striatum, such as cell transplantation.  Given that 
people with HD have difficulties performing more than one task simultaneously (See 
Chapter 1, page 41), and striatal involvement is implicated in such tasks, a range of dual 
task assessments were identified, developed and tested in people gene positive with HD. 
The dual tasks in Part 1 of this study targeted lower limb function. Since current upper limb 
assessments are not applicable to a disease population with a broad phenotype, the study 
in Part 2 involved the design and development of a new upper limb, dual task assessment.  
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2.1 Introduction 
 
There are currently no disease modifying treatments for people with HD; 
however, advances in regenerative medicine and drug trials are rapidly changing 
prospects. In anticipation of impending clinical trials, there is an imperative for well-
defined clinical endpoints (outcome measures). Such assessments are required to 
detect symptom change over time following an intervention. Using cell transplantation 
as an example, the main aim is to reconnect lost basal ganglia circuitry anatomically 
and restore lost functional connectivity. Where neural circuitry is restored this should 
be reflected in functional improvement in the patient’s daily life. However, a major 
challenge is the lack of outcome measures that can be used to measure the extent of 
graft functionality and the resulting impact on daily function. From here on in, when 
referring to function it is important to clarify this is in relation to activities of daily 
living. There is no one definition for function. Previous definitions include  “those 
activities identified by an individual as essential to support physical, social, and 
psychological well-being and to create a personal sense of meaningful living” and “any 
movement at the level of the person that is task related, goal oriented, 
environmentally germane and involves the integration of multiple body systems and 
structures.”  (Reiman and Manske, 2009).  
 
A list of recommended outcome measures for the HD population was previously 
established by The National Institute for Neurological Disorder and Stroke (NINDS) 
(Grinnon et al., 2012). This was important to improve and promote data quality and 
sharing in research and clinical practice. Through this work, it became apparent that 
all functional outcome measures were questionnaire based. Such questionnaires are 
often rated on an ordinal scale, which makes them vulnerable to observer bias and 
reduced sensitivity. Thus, to sensitively track change over time, it is important that 
scoring methods are consistent across raters (Hobart, Freeman and Thompson, 2000), 
which can be difficult using descriptive, ordinal scoring methods as it requires ongoing 
rater training. In addition, self-reported questionnaires are not always a true reflection 
of people with HD and their capabilities, given that this population are not always 
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aware of the extent of their symptoms (Snowden et al., 1998; Hoth et al., 2007; Sitek 
et al., 2013; McCusker and Loy, 2014). In a previous study, symptoms reported by 
people with HD significantly differed from gene negative companions in motor, 
cognitive and emotional control (Hoth et al., 2007). These findings also supported 
another study that revealed no relationship between self-reported motor and 
cognitive function, and objective outcomes used to assess these domains. To 
overcome this problem, performance based functional outcome measures can be 
used. This includes assessments such as the Physical performance test, which consists 
of 9 items which relate to daily activities, such as ‘putting on a coat’ and ‘standing 
balance’ (described in Chapter 1, page 35; Mathias et al., 1986; Reuben and Siu, 1990). 
However, as this test was originally developed for the elderly, it means that some of 
the assessment items are not applicable for a broad disease phenotype, such as HD 
(Quinn et al., 2013).  Although the Physical performance test is quantitatively assessed 
using a time based measure, time ranges are formed into categories that are not 
applicable for people with HD, meaning sensitive data is lost. There is also a general 
assumption that faster performance, in assessment items is better, which for HD is not 
always the case. For instance, a previous study revealed that people with a greater 
UHDRS total motor score (UHDRS-TMS) (indicative of greater motor impairment) 
performed the Timed up and Go (this involves standing from sitting, walk 3 metres and 
back), faster than those with a lower UHDRS-TMS (Quinn et al., 2013).  This suggests 
that precipitous movement caused by involuntary deficits may aid speed in some 
cases, leading to a faster performance time. As quality and accuracy of the movement 
is not reflected when time is the only rating measure, this suggests a score combining 
time with test accuracy may better reflect performance.  
 
The next question is how best to develop paradigms that measure functional 
improvement following complex interventions such as cell transplantation. Given that 
the expectation is that the graft will restore functional striatal pallidal connections with 
subsequent restoration of connectivity in frontostriatal loops, it is important to 
understand the behaviours attributed to this circuitry. For instance, intact 
frontostriatal circuitry is required when two behaviours are required to run in parallel, 
so called “multi-tasking” (Bloem et al., 2006; Yogev-Seligmann, Hausdorff and Giladi, 
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2008; Isoda and Hikosaka, 2011). The ability to dual task or multitask can be defined 
as the simultaneous performance of two or more activities with distinct goals 
(McIsaac, Lamberg and Muratori, 2015). This ability is important to maintain a 
functional and an independent lifestyle (Foley, Kaschel and Sala, 2013). Previous 
reports suggest that dual tasking is a common difficulty in people with HD in day to 
day life (Craufurd and Snowden, 2002), which often results in decreased performance 
in one or both tasks. (Delval, Krystkowiak, Delliaux, Dujardin, et al., 2008; Thompson 
et al., 2010; Vaportzis et al., 2014; Fritz et al., 2016) and is also associated with 
increased risk of falling (Grimbergen et al., 2008). This suggests that dual tasking may 
be a useful means by which to assess function and track disease progression in HD.  
 
Optimal dual task performance is achieved if one behaviour can be automated, 
whilst the other requires attention, such as walking whilst talking. This allows familiar 
behaviours to be performed with minimal attention, freeing limited attentional 
resources for other tasks (Thompson et al., 2010). In many ways, this makes life more 
efficient when performing routine activities. Typically, people with HD perform tasks 
in a serial, goal directed fashion which is slower and not automatic, and limits 
attentional resources that could otherwise allocated to other tasks (Bloem et al., 2006; 
Redgrave et al., 2010; Thompson et al., 2010). Furthermore, performance 
deterioration is even more obvious when the secondary task is more complex 
(Vaportzis et al., 2014), suggesting that increased cognitive load may stress cortico-
basal ganglia circuitry further, resulting in performance decline (Fritz et al., 2016).  This 
decline is known as dual task interference, and is calculated by measuring the 
percentage change from baseline to dual task performance (known as dual task cost) 
(Friedman et al., 1982; Fritz et al., 2016). As well as the complexity of the secondary 
task being an important factor in dual task development, a previous study revealed 
that motor-cognitive dual tasks (walking whilst performing mental arithmetic) resulted 
in greater dual task interference compared to motor-motor dual tasks (walking whilst 
carrying a tray (Delval, Krystkowiak, Delliaux, Dujardin, et al., 2008). This suggests that 
the neurodegeneration in HD may be more sensitive to motor-cognitive performance 
compared to motor-motor.  
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A limitation in previous dual task studies is that people with HD were not 
grouped based on disease stage, but instead by pre-manifest and manifest HD (Delval, 
Krystkowiak, Delliaux, Blatt, et al., 2008; Delval, Krystkowiak, Delliaux, Dujardin, et al., 
2008; Thompson et al., 2010; Vaportzis et al., 2014; Vaportzis, Georgiou-Karistianis, 
Churchyard and Stout, 2015). As a result, whether or not people with different stages 
of manifest HD have different coping strategies when performing dual tasks is 
unknown. Therefore, the aim of this study was to select, develop and evaluate motor-
cognitive dual task assessments that were sensitive to the deficits associated with all 
stages of HD and could be used as a functional outcome measure for HD in the future.   
 
Using the clinometric table presented in Chapter 1 (Table 1), the following criteria 
for each dual task assessment were: 
 
 sensitive to the functional deficits seen in HD 
 no longer than 10-15 minutes to carry out  
 easy to administer 
 Measureable using time and/or other quantified method  
 
This chapter includes findings from two clinical studies. Part 1 describes the 
rationale and testing of three lower limb dual task assessments. Part 2, was stimulated 
by the thinking that developed whilst running Part 1, but was also largely performed 
in parallel. It describes the design, development and testing of a new upper limb dual 
task assessment. The study was conducted as part of one protocol in the same setting. 
Therefore, the methodology is described in detail in Part 1 and referred to where 
necessary in Part 2. A discussion is presented following Part 1 and Part 2, with final 
conclusions and future work presented at the end of the chapter. 
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2.2 Part 1 
 
The aim of this study was to select and develop motor-cognitive dual task 
assessments, sensitive to the deficits associated with HD. These were then tested in a 
cohort of people gene positive with HD.  
 
2.2.1 Rationale and study design 
 
Analysis of the literature for dual tasks previously used in people with HD 
(Chapter 1: Table 1) revealed that the only the only lower limb motor task previously 
tested in HD is walking (Delval, Krystkowiak, Delliaux, Blatt, et al., 2008; Delval, 
Krystkowiak, Delliaux, Dujardin, et al., 2008; Fritz et al., 2016). For the cognitive 
components, secondary tasks previously tested include; serial subtractions (Delval, 
Krystkowiak, Delliaux, Blatt, et al., 2008; Delval, Krystkowiak, Delliaux, Dujardin, et al., 
2008; Vaportzis et al., 2014), digit span (Georgiou et al., 1997; Vaportzis, Georgiou-
Karistianis, Churchyard and Stout, 2015) and reciting the alphabet (Fritz et al., 2016). 
As the specific motor vs cognitive tasks used can lead to different amounts of dual task 
interference (Carmela et al., 2017), the next stage was to develop several different 
motor-cognitive dual tasks to see which best distinguished between disease stage. One 
dual task was taken from the literature (Walk and talk); the other two (Timed up and 
go and letter verbal fluency (TUG and LVF), and the Step and Stroop) combined two 
existing tasks to form a new dual task.  
 
2.2.1.1 Selection of motor and cognitive items for the dual tasks 
 
Three motor-cognitive dual tasks were taken forward for testing in people with 
HD. An explanation as to why each dual task was selected/developed is given below. 
The dual task procedure for each test can be located in the Methods (Section 2.2.2.4).  
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2.2.1.2 Walk and Talk 
 
The Walk and talk is an established dual task that requires a participant to walk 
whilst reciting the alphabet (simple) or every other letter of the alphabet (complex) 
(Verghese et al., 2002). This was previously tested in 32 people with early to mid-stage 
HD, and revealed that performance in both tasks decreased in the dual task condition 
compared to baseline, suggesting mutual interference (Fritz et al., 2016). As they 
measured time taken to walk 40 feet and back, another more sensitive method to analyse 
gait is motion analysis or the GaitRite electronic walkway. These were previously validated 
in HD and revealed that people with HD walked slower and had decreased, velocity and 
cadence and increased stride variability and duration of double limb support compared 
to controls (Hausdorff et al., 1998; Delval, Krystkowiak, Delliaux, Blatt, et al., 2008; Delval, 
Krystkowiak, Delliaux, Dujardin, et al., 2008; Rao et al., 2008). Furthermore, motion 
analysis revealed that these parameters got worse when walking was combined with a 
secondary task (Delval, Krystkowiak, Delliaux, Blatt, et al., 2008; Delval, Krystkowiak, 
Delliaux, Dujardin, et al., 2008). As the only gait measure in the previous Walk and talk 
test was time, it is possible other gait parameters changed in the dual task but were 
undetected. Therefore, in this study we used the same Walk and talk employed by (Fritz 
et al., 2016), but used the GaitRite system to see if additional gait parameters changed in 
the dual task condition.  
 
2.2.1.3 The Timed Up and Go and Letter Verbal Fluency 
 
The Timed Up and Go (TUG) and the Letter Verbal Fluency (LVF) are two well 
established outcome measures that are regularly used in people with HD. These were 
previously combined to form a dual task and tested in the elderly (van Iersel, 2007). 
However, the TUG and LVF dual task has never been tested in people with HD.  
 
The TUG is a measure of dynamic and static balance (Christofoletti et al., 2014), 
which times participants to stand from sitting position, walk 3 metres, turn around a cone 
and finish by sitting. This outcome measure has been well validated in people with HD 
(Busse, Wiles and Rosser, 2009; Busse et al., 2014) and, along with the Sit to Stand test 
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(the participant stands from sitting repeatedly over 30 seconds), these form the only 
performance based functional assessments tested in ENROLL-HD (See Chapter 1, page 12  
for information on the ENROLL-HD study). Similar to the Sit to Stand, the TUG consists of 
a standing and sitting element, but it also includes a walk and a turn. As the TUG relates 
to a range of motor tasks that are commonly performed on a daily basis (sit, standing, 
walking and turning), and as it consistently correlates with UHDRS measures (Quinn et al., 
2013; Busse et al., 2014), whereas the Sit to Stand does not (Khalil et al., 2010), the TUG 
was selected over the Sit to Stand to form the motor item of a dual task.  
 
Letter verbal fluency (LVF) tasks involve recalling words that begin with a given 
letter, and are considered an executive function task (Shao et al., 2014). The participant 
must supress the tendency to say names of people or places, whilst also using working 
memory so that previously said words are not repeated. This outcome measure forms one 
of the UHDRS cognitive assessments and is used in the ENROLL-HD, along with categorical 
verbal fluency. In categorical verbal fluency, the participant is asked to say as many words 
as possible that relate to a given category, such as animals. Arguably, the latter 
assessment may better relate to functional tasks required on a daily basis, such as forming 
a shopping list. However, it is understood that the LVF may tap more into the 
frontostriatal circuitry whereas performance in categorical tasks requires more temporal 
lobe function (Rosser and Hodges, 1994; Ho et al., 2002). Due to the direct 
neuroanatomical relevance to HD, the LVF was selected for this study and was combined 
with the TUG. 
 
2.2.1.4 The Step and Stroop 
 
The Step and Stroop are two individual tests, which for this study were combined 
to form a new dual task. To our knowledge, this has never been tested in any population. 
  
The ability to step is an important function of daily living, from avoiding obstacles 
to going up a flight of stairs. A previous study, tested the ability of fourteen symptomatic 
people with HD to step as quickly as possible from one sensored foot pad to another 
following an auditory cue (Goldberg et al., 2010). This revealed that people with HD 
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reacted significantly slower than healthy controls. Although this could suggest that 
stepping is a problem for this population, stepping ability is not currently assessed in the 
UHDRS or in ENROLL-HD. Stepping is however tested in one item of the Physical 
Performance test, which  requires participants to climb a flight of stairs (Reuben and Siu, 
1990). However, as previously mentioned, the Physical Performance test was developed 
for the elderly meaning that the categorical time ranges used to assess performance are 
not sensitive to people with HD. In addition, climbing a flight of stairs is not always 
possible in a clinical setting, meaning it is difficult to assess. As stepping on the spot 
requires little clinical space, stepping onto and off an aerobic step was selected to form 
the motor component of a dual task.  
 
The Stroop task is often employed to test attention and forms part of the UHDRS 
cognitive battery (Kieburtz, 1996). This requires participants to read colour words 
presented on paper written in their coloured ink (e.g. BLUE in the colour blue) or say the 
coloured ink of colour words which are incongruent (e.g. BLUE in the colour red) (Bullard 
et al., 2012). The Stroop task is one of the few cognitive tasks that can measure cognitive 
decline in HD and significantly correlates with striatal degeneration (Sanchez-Pernaute et 
al., 2000). To see how participants responded to the Stroop task when combined with a 
motor test, the Step and Stroop was developed. The Stroop task is traditionally performed 
whilst sitting and presented on a piece of paper. However, this presentation of the Stroop 
task would restrict its use with a lower limb motor task. Therefore, the Stroop task in this 
study was shown as a PowerPoint presentation on a laptop. This provided a display which 
could be reliably viewed by the patient whilst they performed the stepping task. 
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2.2.2 Methods 
 
2.2.2.1 Design 
 
This was an observational, cross sectional study. People positive for the HD 
gene, were recruited to perform a maximum of three dual task assessments.  Initial 
evaluation of the dual task results revealed the Step and Stroop to be most sensitive 
to disease stage and so this was tested in a larger cohort of patients.  
 
2.2.2.2 Setting  
 
People with HD were recruited from the South Wales research and 
management clinic. Recruitment began in January 2015 and continued to January 
2017. Ethical approval was obtained from South East Wales Research Ethics 
Committee (REC reference: 14/WA/1195).   Many patients attending the HD clinic were 
already enrolled in the ENROLL-HD study (04//WSE05/89), and so their disease 
progression had been followed longitudinally, some for several years. One of the 
optional components within the ENROLL-HD study was permission by participants to 
be contacted about other additional and affiliated HD research projects. In consenting 
to be enrolled in the ENROLL-HD study, participants also gave their permission for their 
unidentifiable data to be accessed by researchers conducting other HD related 
research. 
    
Potential participants were approached at the beginning of clinic, and, if 
interested, were given an information sheet on the study. Participants were given as 
much time as needed to decide if they wanted to take part. If willing, participants 
signed a consent form prior to participation, and also had the option to take part in 
the study at a future clinic visit.   
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2.2.2.3 Participants 
 
Participant data recruited for this study are presented in the Results of this 
chapter (page 68) and the number of people that performed each dual task item is 
presented in Appendix 1. 
Inclusion criteria  
1) Must be confirmed to carry the HD gene through genetic testing 
2) Must be 18 years or above 
3) Must be enrolled in the Registry/ENROLL-HD study 
 
Exclusion criteria  
1) The inability to approve consent 
2) Comorbid condition that has the potential to confound the results of the study 
 
2.2.2.4 Dual task procedures 
 
A brief description of the Step and Stroop, the TUG and LVF and the Walk and 
talk is described below. Each dual task assessment consisted of assessment items. A 
full description of the testing procedures can be found in Appendix 2. Following initial 
observation of dual task performance, a performance threshold was set for each 
assessment item so participants had to ‘pass’ set criteria to proceed to the simple and 
complex dual tasks (Appendix 2).  
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Walk and talk 
 
This consisted of 5 assessment items: walk baseline, alphabet simple baseline, 
alphabet complex baseline, walk and talk (alphabet) simple, walk and talk (alphabet) 
complex (Figure 7). Participants were first asked to walk for 30 seconds along a GaitRite 
mat. Next, participants were timed to recite the alphabet as quickly as possible (alphabet 
baseline simple) and then say every other letter of the alphabet (alphabet baseline 
complex). For the dual task, participants were asked to walk for 30 seconds whilst 
performing the alphabet simple (Walk and talk simple) and then the alphabet complex 
tasks (Walk and talk complex). Spatiotemporal parameters recorded for each walking test 
related to speed (velocity (m/s), cadence(steps/min)), balance (duration of double limb 
support (s)) and stride variability (coefficient of variation for stride length) (Rao et al., 
2009). The number of correct letters said per second were calculated for each alphabet 
test.  
 
 
Figure 7: Walk and talk setup. Participants walked up and down a GaitRite mat whilst reciting the 
alphabet (dual simple) and then every other letter of the alphabet (dual complex). 
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The TUG and LVF 
 
This consisted of 5 assessment items: TUG baseline, LVF simple baseline, LVF 
complex baseline, TUG and LVF simple, TUG and LVF complex. Participants were timed to 
stand from sitting, walk 3 metres, turn around a cone and walk back, finishing by sitting 
in a chair (TUG baseline). Next participants were given 30 seconds to recite as many 
different words they could think of that began with R (LVF simple) and N (LVF complex). 
The simple and complex letters were selected according to (Fu et al., 2002), and differed 
from the letters used in the ENROLL-HD battery to reduce the chances of practice effects.  
Participants were asked not to repeat themselves or say the names of people or places. 
The dual tasks involved simultaneous performance of the TUG and LVF simple and LVF 
complex. The time taken to perform the TUG and the number of correct answers given 
were recorded. 
 
The Step and Stroop 
 
The Step and Stroop consisted of 6 assessment items: stepping baseline, colour 
and word reading test, Stroop simple baseline, Stroop complex baseline, Step and Stroop 
simple, Step and Stroop complex (Figure 8). Participants were first asked to step onto and 
off an aerobic step as quickly as possible for 45 seconds (step baseline). The colour and 
word reading test was performed next to ensure participants could distinguish between 
the colours and colour-words: yellow, pink and grey. Originally the traditional colours: 
red, blue and green were used in this assessment (Bullard et al., 2012). However as these 
same colours are used as part of the ENROLL-HD battery, which the participant performed 
earlier that day, the colours were changed to yellow, pink and grey, to reduce the chances 
of practice effects. These have not been used in previous Stroop tasks, however they were 
selected as they are not colours that are sensitive to people that are colour blind.   
 
For the Stroop simple, the participant had to name colour words, which were 
written in their coloured ink (e.g. the word PINK written in the colour pink; Stroop simple 
baseline). Participants were next asked to say the coloured ink of the words, which were 
incongruent to the colour-word (e.g. the word PINK written in the colour yellow). For the 
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dual tasks participants were asked to perform the simple and complex Stroop tasks whilst 
stepping for 45 seconds. The number of steps and/or correct answers were recorded for 
each test. The Stroop tasks were presented via a PowerPoint presentation positioned on 
a table in front of the participant. Four colour options were presented vertically on each 
slide.  As soon as the participant gave their fourth answer, the researcher changed the 
slide using a USB pen revealing a new colour sequence. 
 
 
 
 
Figure 8: Step and Stroop setup. Participants stepped up and down off the step whilst reading 
colour-words (Stroop simple) and the coloured ink of the words (Stroop complex) presented via a 
PowerPoint presentation. 
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2.2.2.5 Rating participant performance 
 
To quantify participant performance, all assessments were video recorded, 
allowing an accurate timing measure. To calculate the dual task cost the following 
equation was used (Friedman et al., 1982) :  
 
The difference between baseline and dual task performance 
                   Baseline performance 
 
For example, if participants performed the TUG in 15 seconds in the TUG baseline 
and then took 20 seconds to perform the TUG in the TUG and LVF dual simple, the 
difference of 5 seconds was taken and divided by 15 (the TUG baseline), and then 
multiplied by 100. This would give 33.33% cost in the dual task relative to baseline 
performance. This percentage difference could also be negative if dual task performance 
was better than baseline.  
  
2.2.2.6 Additional data collected 
 
As part of the ENROLL-HD assessment, participants had already supplied 
demographic data, current medications, and were assessed on the UHDRS assessments, 
including the UHDRS-TMS, UHDRS-TFC, UHDRS Cognitive score, UHDRS Functional 
Assessment scale, UHDRS independence scale, Short Form-12 (SF-12) (See Section 1.3.2.5) 
and Problem Behaviours Assessment (PBA) (See Section 1.3.2.4). Performance in many of 
these assessments change little over a period of weeks, thus it was decided that these did 
not need to be repeated if the participant had been assessed for ENROLL-HD within six 
weeks.  
 
2.2.2.7 Statistics 
 
SPSS version 20 (PASW) (IBM Corporation, USA) was used to evaluate the results 
of the study. 
x 100   = Dual task cost 
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The following variables were recorded for each dual task:  
 Walk and talk: Velocity (m/s), cadence(steps/min), duration of double limb 
support (s) and coefficient of variation (CoV) for stride length (Rao et al., 2009). 
The number of correct answers given per second for the simple and complex 
alphabet tasks. 
 TUG and LVF: Time taken to perform the TUG and the number of correct answers 
given per second for the simple and complex LVF. 
 Step and Stroop: The number of steps performed in 45 seconds and the number 
of correct answers given in 45 seconds.  
 
Participant data were grouped in two ways: i) by group [pre-HD, TMS ≤ 5 and TFC = 
13; Manifest, TMS>5 and TFC<12); ii) TFC disease stage (TFC scores 11–13 = stage 1 
(earliest symptomatic stage); 7–10 = stage 2; 3–6 = stage 3; 1–2 = stage 4; 0 = stage 5 
(most advanced stage). For the TUG and LVF, and the Walk and talk, stages 3 and 4 were 
combined (stage 3,4) due to the small sample sizes. Furthermore, for the Step and Stroop, 
stages 4 and 5 were combined again due to the small sample size recruited (stage 4,5). 
 
All graphical data are presented as performance means and standard error of the 
mean (SEM). Performance results between Pre-HD and manifest groups were compared 
using an independent t-test, using time taken (TUG), the number of correct responses 
(LVF, Stroop tasks), alphabet rate, and walking parameters as dependent variables.   
 
Comparisons between TFC stages were made for all dual task items using analysis of 
variance (ANOVA). TFC stage (stage 1, stage 2, s3,4) for the TUG and LVF and Walk and 
talk dual tasks, and (stage 1, stage 2, stage 3, s4,5) for the Step and Stroop were used as 
independent variables. Dependent variables were the same as those used for the t-test 
described in the above paragraph.  
 
A two way repeated ANOVA was used to identify if there was an interaction between 
item performance (within subject factor) and TFC disease stage (between subject factor). 
A Bonferroni post-hoc was used to account for multiple comparisons if significance 
returned being p < 0.05. 
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A Pearson correlation was performed to identify the relationship between each dual 
task item for the Walk and talk, TUG and LVF, Step and Stroop with UHDRS assessment 
scores (UHDRS-TMS, TFC, functional assessment score, independence scale and cognitive 
measures from the UHDRS LVF, Stroop task and symbol digit), as well as the quality of life 
SF-12 mental and physical summaries, and the Problem behaviour assessment to measure 
apathy and executive function scores. The CAG disease burden score was also measured 
((CAGn – 35.5)*Age) (Penney et al., 1997) as an indicator of disease progression (See 
Section 1.1.7).
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2.2.3 Results 
 
2.2.3.1 Participants 
 
Demographic data from participants that performed the first item of each dual 
task assessment is presented in Table 3. Sixty-six people with HD consented to take part 
in this study, from which twenty-eight people attempted all three dual task assessments. 
Thirty-one people attempted the TUG and LVF, from which seventeen completed the dual 
task assessment. Thirty-one people attempted the Walk and talk from which eighteen 
completed the assessment. Fifty-four people attempted the Step and Stroop from which 
forty eight people completed the assessment. Because of the set criteria developed for 
each dual task, a different number of people completed each assessment item. The 
number of people that completed each of these is presented in Appendix 1. 
For the TUG and LVF, and Walk and Talk people in stage 3 and 4 were combined 
given the limited number of people recruited in stage 4 (n=1). No people in stage 5 were 
recruited. Final TFC disease stage groups for the TUG and LVF, and Walk and Talk were 
stage 1, stage 2, stage 3,4. A larger cohort of people with HD were recruited for the Step 
and Stroop and therefore more people in stage 4 were recruited (n=3). Data from people 
in stage 4 and 5 were combined given the limited number of people recruited in stage 5 
(n=1). Final TFC disease stage groups for the Step and Stroop were stage 1, stage 2, stage 
3, stage 4, 5.  
There was a significant age difference in the Pre-HD and Manifest group for the 
Step and Stroop, and also between TFC groups for the Walk and talk, TUG and LVF and 
the Step and Stroop (analysis presented in Table 3). The number of years in education was 
significantly different between people in stage 3 and stage 4,5 for the Step and Stroop, 
but not for any other dual task assessment. Body mass index significantly differed 
between stages in the Step and Stroop, but for no other dual task assessment.   
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1 2 3,4 4,5
n (male:female) n=4 (3:1) n=27 (15:12) / n=13 (8:5) n=5 (2:3) n=15 (9:6) /
Age 38.25 (8.54) 53.15 (15.44) t (29) = -1.982, p = n.s. 39.08 (9.22) 52.8 (15.39) 61.07 (11.19) F (2,28) = 13.77, p < 0.001 (s1 vs s3 and s2)
TMS 0.75 (0.96) 48.48 (26.02) t (30) = -3.542, p < 0.001 12.92 (12.12) 41.6 (7.09) 67.79 (18.12) F (2,29) = 69.97, p < 0.001 (s1 vs s2 and s3; s2 vs s3)
TFC 13 (0) 7.15 (3.92) t (30) = 2.731, p < 0.01 12.5 (0.8) 8.4 (1.34) 3.79 (0.97) F (2,29) = 307.52, p < 0.001 (s1 vs s2 and s3; s2 vs s3)
Functional scale 25.00 16.96 (16.76) t (29) = 2.253, p < 0.05 24.25 (1.14) 21.8 (0.45) 10.85 (3.46) F (2,28) = 122.7, p < 0.001 (s3 vs s1 and s2)
Independence 
scale
100.00 73.8 (18.16) t (28) = 2.69, p < 0.05 96.25 (6.44) 80 (0) 59.23 (10.17) F (2,27) = 76.78, p < 0.001 (s1 vs s2 and s3; s2 vs s3)
CAG disease 
burden score
214.88 (45.86) 412.63 (84.39) t (28) = -4.261, p < 0.001 300.21 (88.84) 405.2 (70.96) 458.42 (67.47) F (2,27) = 16.12, p < 0.001 (s1 vs s3)
Years of 
education
13 (1) 12.72 (4.27) t (29) = 1.862, p = n.s. 11.89 (3.44) 14 (5.66) 13.3 (4.37) F (2,28) = 0.13, p = n.s.
BMI 32.34 (8.24) 26.73 (4.89) t (29) = 1.838, p = n.s. 29.52 (6.37) 24.81 (6.07) 26.84 (4.44) F (2,28) = 1.42, p = n.s.
n (male:female) n=4 (3:1) n=26 (16:11) / n=12 (8:4) n=5 (2:3) n=14 (9:5) /
Age 38.25 (8.54) 53.56 (14.92) t (29) = -1.982, p = n.s. 40 (8.66) 52.8 (19.29) 61.07 (11.19) F (2,28) = 10.04, p < 0.001 (s1 vs s3)
TMS 0.75 (0.96) 48.26 (26.33) t (30) = -3.713, p < 0.001 12.42 (12.1) 41.6 (7.09) 67.79 (17.12) F (2,29) = 67.92, p < 0.001 (s1 vs s2 and s3; s2 vs s3)
TFC 13 (0) 7.22 (4.01) t (30) = 2.844, p < 0.01 12.67 (0.65) 8.4 (1.34) 3.79 (0.97) F (2,29) = 301.28, p < 0.001 (s1 vs s2 and s3; s2 vs s3)
Functional scale 25.00 17.07 (6.87) t (29) = 2.271, p < 0.05 24.5 (0.9) 21.8 (0.45) 10.85 (3.46) F (2,28) = 127.11, p < 0.001 (s1 vs s3; s2 vs s3)
Independence 
scale
100.00 74.2 (18.63) t (28) = 2.764, p < 0.01 97.08 (6.2) 80 (0) 59.23 (10.17) F (2,27) = 78.2, p < 0.001 (s1 vs s2 and s3; s2 vs s3)
CAG disease 
burden score
214.88 (45.86) 413.58 (84.85) t (28) = -4.268, p < 0.001 286.83 (80.8) 405.2 (70.96) 458.42 (67.47) F (2,27) = 19.53, p < 0.001 (s1 vs s2 and s3)
Years of 
education
13 (1) 12.94 (3.99) t (29) = 0.371, p = n.s. 12.33 (2.78) 14 (5.66) 13.3 (4.37) F (2,28) = 0.502, p = n.s.
BMI 32.34 (8.24) 26.48 (4.73) t (29) = 1.838, p = n.s. 29.01 (6.34) 24.81 (6.07) 26.84 (4.44) F (2,28) = 1.191, p = n.s.
n (male:female) n=8 (6:2) n=49 (30:19) / n=22 (14:8) n=14 (8:6) n=18 (13:5) n=3 (1:2) /
Age 35.88 (6.33) 53.11 (14.23) t (54) = -3.284, p < 0.01 35.67 (11.11) 40.69 (9.43) 58.25 (15.14 55.11 (12.84) F (3,52) = 6.147, p < 0.001 (s1 vs s2 and s3)
TMS 1.13(1.13) 44.56 (25.26) t (54) = -4.7, p < 0.001 11.04 (10.56) 42.92 (15.83) 59.67 (22.55) 65.67 (13.32) F (3,52) = 28.63, p < 0.001 (s1 vs s2,s3,s4,5 and s2 vs s3)
TFC 12.88 (0.35) 7.43 (3.82) t (54) = 3.828, p < 0.001 12.68 (0.64) 8.53 (1.33) 4.44 (1.15) 1.33 (1.15) F (3,52) = 247.74, p < 0.001 (all stages s.d.)
Functional scale 24.88 (0.35) 17.78 (6.18) t (52) = 3.113, p < 0.01 24.64 (0.73) 20.46 (3.15) 12.13 3.74) 14 (1.73) F (3,50) = 72, p < 0.001 (all stages s.d. except s3 vs s4)
Independence 
scale
99.38 (1.77) 76.98 (16.62) t (50) = 3.651, p < 0.001 97.27 (6.12) 79.17 (8.48) 65 (10.64) 60 (14.14) F (3,48) = 45.1, p < 0.001 (all stages s.d. except s3 vs s4)
CAG disease 
burden score
225.06 (42.93) 397.86 (88.36) t (52) = -5.563, p < 0.001 294 (83.96) 406.67 (75.41) 446.47 (84.22) 440.33 (10.6) F (3,50) = 12.49, p < 0.001 (s1 vs s2,s3,s4,5)
Years of 
education
13.14 (2.79) 11.69 (3.44) t (42) = 0.79, p = n.s. 12.74 (2.51) 11.11 (2.62) 13.38 (3.93) 7.33 (5.69) F (3,40) = 3.39, p < 0.05 (s3 vs s4,5)
BMI 30.86 (6.01) 26.89 (5.37) t (48) = 2.441, p < 0.05 27.79 (5.58) 26.54 (4.32) 26.57 (4.77) 29.1 (5.37) F (3,52) = 28.63, p < 0.001 (all stages s.d. except s4 vs s3 and s2)
Group differencesManifest
TFC disease stage
Group differences
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 All values are shown mean (Standard deviation) for those recruited in the baseline motor dual tasks. Groups were categorised as pre-HD (total functional capacity 
(TFC) = 13, Unified Huntington’s disease total motor score (TMS) <5), and manifest (all symptomatic stages). For the TUG and LVF and walk and talk, the manifest 
group was further delineated by TFC disease stage (stage 1, TFC =11-13; stage 2, TFC=7-10; stage 3,4, TFC=1-6. For the Step and Stroop manifest groups were 
split so (stage 1, TFC =11-13; stage 2, TFC=7-10; stage 3, TFC=3-6; stage 4,5, TFC=0-2). A t-test was used to compare groups differences between pre-HD with 
manifest subjects, where the t (degrees of freedom) = t value. An ANOVA was used to compare TFC group differences, where F (error, degrees of freedom) =F 
value. A Bonferroni post-hoc was used if significance was met, where p < 0.05. Demographic data was missing from a maximum of two participants in the Walk 
and talk, and the TUG and LVF. Data was missing from a maximum of twelve participants in the Step and Stroop. TFC = Total Functional Capacity; TMS= total 
motor score; BMI = body mass index.  
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2.2.3.2 Walk and talk 
 
For clarity, a reference of the Walk and talk assessment items are presented 
in Table 4: 
 
Measures reported include the velocity, cadence, duration of double limb support and the stride 
length CoV for items 1, 4 and 5; the number of correct letters of the alphabet recited per second 
for items 2-5. 
 
Walk and talk performance scores and statistical outcomes between Group 
and TFC disease stage are presented in Table 5.  
 
The results revealed no significant difference between pre-HD and manifest 
participants for any walking measure during the baseline or dual simple and dual 
complex tasks. For the alphabet tests, pre-HD participants recited significantly more 
correct letters per second than manifest in the alphabet complex baseline but not for 
the dual complex, dual simple or baseline simple tasks.  
 
When participants were grouped based on TFC stage, people in stage 1 had a 
significantly greater velocity and a significantly smaller stride length CoV than stage 3,4 
in the baseline and dual simple task (Figure 9a-d). There was no significant difference 
for cadence between disease stage in any assessment item and no significant 
difference for any walking measure in the dual complex task. For the alphabet tasks 
participants in stage 1 said significantly more correct letters of the alphabet per second 
compared to participants in stage 2 and stage 3,4 in the alphabet baseline simple and 
dual simple task (Figure 9e). There was no performance difference between disease 
stage for the complex baseline or dual tasks.
Test order Dual task item Brief procedure
1 Walk baseline Walk for 30 seconds
2 Alphabet baseline simple Recite the alphabet
3 Alphabet baseline complex Recite every other letter of the alphabet
4 Walk and talk simple Walk whilst reciting the alphabet simple (30 seconds)
5 Walk and talk complex Walk whilst reciting the alphabet complex (30 seconds)W
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The mean test scores are presented and recorded to 2 decimal places ± SEM. Groups were categorised as pre-HD (total functional capacity (TFC) = 13 and Unified 
Huntington’s Disease total motor score <5) and manifest (all symptomatic stages). The manifest group was further delineated by TFC disease stage (stage 1, TFC 
=11-13; stage 2, TFC=7-10; stage 3,4, TFC=1-6). All measures in light blue are spatiotemporal measures recorded from the GaitRite. For velocity, cadence and 
duration of double limb support, a lower measure is indicative of worse performance. For stride length CoV, a higher measure is indicative of worse performance. 
t value (df) p value  F value (df, error) p value
Velocity bl (m/s) 131.85 ± 8.51 103.41 ± 7.22 1.453(30) p = n.s. 131.71 ± 8.28 113.76 ± 13.53 81.56 ± 7.98 9.659(2,29) p < 0.01 s1 vs s3 p<0.001
Velocity dual simple (m/s) 133. 78 ± 7.5 102. 18 ± 7.24 1.734(26) p = n.s. 129.45 ± 7.32 107.08 ± 11.81 76.93 ± 8.35 11.185(2,25) p < 0.001 s1 vs s3 p<0.001
Velocity dual complex (m/s) 123.68 ± 10.23 102.1 ± 9.31 1.134(17) p = n.s. 114.18 ± 9.75 103.05 ± 16.89 81.27 ± 19.5 1.168(2,16) p = n.s. /
Cadence bl (steps/minute) 110.23 ± 3.79 109.53 ± 3.7 0.07(30) p = n.s. 113.87 ± 5.18 106.62 ± 8.36  106.73 ± 5 0.568(2,29) p = n.s. /
Cadence dual simple (steps/minute) 112.38 ± 2.99 108.29 ± 4.79 0.341(26) p = n.s. 113.43 ± 6.1 99.7 ± 9.84 107.54 ± 6.96 0.732(2,25) P = n.s. /
Cadence dual complex (steps/minute) 107.83 ± 2.66 97.53 ± 6.08 0.851(17) p = n.s. 105.42 ± 5.93 96.28 ± 10.26 81.4 ± 11.86 1.713(2,16) p = n.s. /
Duration of double limb support bl (s) 0.31 ± 0.02 1.27 ± 0.75 -0.486(30) p = n.s. 0.281 ± 1.02 1.14 ± 1.84 1.95 ± 0.99 0.692(2,28) p = n.s. /
Duration of double limb support dual simple (s) 0.3 ± 0.01 0.58 ± 0.26 -0.435(26) p = n.s. 0.29 ± 0.33 0.29 ± 0.53 0.98 ± 0.37 1.119(2,25) p = n.s. /
Duration of double limb support dual complex (s) 0.33 ± 0.01 0.75 ± 0.36 -0.594(17) p = n.s. 0.79 ± 0.38 0.31 ± 0.65 0.61 ± 0.75 0.215(2,16) p = n.s. /
Stride length CoV bl 3.11 ± 0.08 16.75 ± 4.18 -1.215(30) p = n.s. 3.62 ± 5.23 12.57 ± 8.43 26.54 ± 5.04 5.039(2,29) p < 0.05 s1 vs s3,4 p<0.05
Stride length CoV dual simple 2.71 ± 0.25 13.38 ± 3.72 -1.152(26) p = n.s. 4.23 ± 4.36 10.85 ± 7.03 22.27 ± 4.97 3.731(2,25) p < 0.05 s1 vs s3,4 p<0.05
Stride length CoV dual complex 5.55 ± 1.64 9.74 ± 2.43 -0.861(17) p = n.s. 9.05 ± 2.61 7.39 ± 4.53 10.03 ± 5.23 5.039(2,25) p = n.s. /
Alphabet bl simple (letters/s) 2.81 ± 0.33 2.33 ± 0.23 0.836(26) p = n.s. 3.12 ± 0.26 1.97 ± 0.37 1.79 ± 0.28 6.844(2,25) p < 0.01 s1 vs s2 p<0.05; s1 vs s3,4 p<0.01
Alphabet dual simple (letters/s) 1.43 ± 0.3 1.71 ± 0.19 -0.454(20) p = n.s. 2.22 ± 0.21 1.45 ± 0.3 1.09 ± 0.25 6.266(2,19) p < 0.01 s1 vs s3 p<0.01
Alphabet bl complex (letters/s) 0.75 ± 0.08 0.47 ± 0.05 2.322(18) p < 0.05 0.62 ± 0.61 0.44 ± 0.1 0.32 ± 0.12 2.91(2,17) p = n.s. /
Alphabet dual complex (letters/s) 0.67 ± 0.04 0.41 ± 0.07 1.383(14) p = n.s. 0.53 ± 0.08 0.33 ± 0.12 0.33 ± 0.14 1.253(3,13) p = n.s. /
Velocity simple dtc (%) -1.76 ± 3.33 6.86 ± 1.46 -0.435(26) p < 0.05 1.894.2 7.33 ± 3.04 9.93 ± 2.15 4.354(2,25) p < 0.05 s1 vs s3,4 p<0.05
Velocity complex dtc (%) 6.03 ± 6 20.23 ± 4.41 -0.435(17) p = n.s. 14.86 ± 4.87 14.69 ± 8.43 30.17 ± 9.74 1.048(2,16) p = n.s. /
Cadence simple dtc (%) -2.08 ± 1.87 1.49 ± 3.26 -0.435(26) p = n.s. 0.37 ± 4.2 6.66 ± 6.77 -1.06 ± 4.79 0.453(2,25) p = n.s. /
Cadence complex dtc (%) 1.76 ± 4.78 14.31 ± 4.07 -0.435(17) p = n.s. 7.7 ± 4.06 10.64 ± 7.04 28.89 ± 8.13 2.73(2,16) p = n.s. /
Duration of double limb support simple dtc (%) -0.99 ± 4.07 76.05 ± 81.31 -0.435(25) p = n.s. 3.07 ± 100.18 -36.16 ± 180.6 184 ± 114.22 0.42(2,24) p = n.s. /
Duration of double limb support complex dtc (%) 7.25 ± 5.92 99.8 ± 100.37 -0.435(17) p = n.s. 147.28 ± 101.82 -60.86 ± 176.36 0.66 ± 203.64 0.613(2,16) p = n.s. /
Stride length CoV simple dtc (%) 51.4 ± 38.05 78.23 ± 24.77 -0.435(26) p = n.s. 77.65 ± 33.19 67.72 ± 53.52 73.52 ± 37.84 0.13(2,25) p = n.s. /
Stride length CoV complex dtc (%) 44.36 ± 37.69 79.38 ± 68.25 -0.435(17) p = n.s. 112.47 ± 70.12 16.31 ± 121.45 -15.61 ± 140.24 0.467(2,16) p = n.s. /
Alphabet simple dtc (%) 47.62 ± 21.35 22.19 ± 4.87 -0.435(19) p = n.s. 24.4 ± 7.52 24.91 ± 10.63 24.73 ± 9.71 0.001(2,18) p = n.s. /
Alphabet complex dtc (%) 76.94 ± 3.89 81.46 ± 2.66 -0.435(13) p = n.s. 79.23 ± 3.42 82.62 ± 4.84 82.85 ± 5.59 0.244(2,12) p = n.s. /
Pairwise compairsons
ANOVA results
Stage 1 Stage 2 Stage 3,4
Walk and talk Pre-HD Manifest
t-test results
TFC stage
Table 5: Walk and talk performance scores 
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The alphabet scores are highlighted in dark blue as the number of correct letters of the alphabet recited per second. A lower score is indicative of worse 
performance. Dual task cost is shown in orange and presented as a percentage where a lower score is indicative of better performance. A positive percentage is 
indicative of slower or worse dual task performance relative to baseline, whereas a negative dual task cost is indicative of better performance in the dual task 
compared to baseline. Significance was set so p < 0.05 and followed by a Bonferroni post-hoc test.   
Where TFC= total functional capacity; ANOVA = analysis of variance; bl = baseline; CoV = coefficient of variation; dtc = dual task cost; n.s. = not significant; df = 
degrees of freedom. 
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For dual task cost, stage 3,4 presented greater velocity costs from baseline to 
the dual task condition in the Walk and talk simple compared to stage 1 ( 
Figure 10a). There were no differences for any other Walk and talk dual task 
item between disease stage. 
 
Results from a two way repeated measures ANOVA are presented in Table 6. 
This revealed that Stride length CoV in the Stage 3 group was better (significantly less) 
in the dual complex relative to baseline performance. Performance in no other 
measure from the Walk and talk significantly differed from the baseline to the dual 
task.  
 
  
This table presents results from a two way repeated measures ANOVA. If this returned as 
significant (where p < 0.05), a Bonferroni post-hoc was used to identify which disease stage this 
was relevant to. This is presented in the ‘Stages’ column. The results in this table and in Table 5 
revealed that stage 3 had a significantly lower stride length coefficient of variance (CoV) in the 
dual complex relative to baseline. No other results were significant (n.s.). Significance was met 
so p < 0.05.
Dual task item Baseline vs dual simple Stages Baseline vs dual complex Stages
Velocity F(2,25)=1.556, p = n.s. / F(2,16)=0.572, p = n.s. /
Cadence F(2,25)=0.474, p = n.s. / F(2,16)=2.805, p = n.s. /
Duration of double limb support F(2,24)=1.495, p = n.s. / F(2,15)=1.764, p = n.s. /
Stride length CoV F(2,25)=0.073, p = n.s. / F(2,16)=3.974, p < 0.05 Stage 3: p<0.05
Alphabet F(2,18)=0.807, p = n.s. / F(2,13)=0.562, p = n.s. /
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2.2.3.3 TUG and LVF 
 
For clarity, a reference of the TUG and LVF test items are presented in Table 7: 
 
Measures reported includes the time taken to perform the TUG for items 1, 4 and 5. The number 
of correct words said per second is recorded for items 2-5. TUG = timed up and go; LVF = letter 
verbal fluency. 
 
TUG and LVF performance scores and statistical outcomes between Group and 
TFC disease stage are presented in Table 8.  
 
There was no difference in TUG performance time between pre-HD and 
manifest participants in the baseline or dual simple and dual complex tasks. For the 
LVF, pre-HD participants said significantly more correct LVF answers per second than 
Manifest in the LVF simple baseline test.  Although pre-HD participants generally said 
more correct answers per second than Manifest this did not reach significance for the 
LVF complex baseline or dual simple and dual complex tasks.  
 
When data was grouped by TFC stage, participants in stage 1 performed the TUG baseline, dual 
simple and dual complex tasks significantly faster than participants in stage 3 (Figure 9f). For 
the LVF, participants in stage 3,4 said significantly more correct words per second than stage 1 
in the LVF dual simple task ( 
Figure 10g). There was also a significant effect of disease stage for the LVF 
simple baseline task, but following a Bonferroni post-hoc, this revealed no differences 
between any particular disease stage. There was no difference between disease stage 
for the LVF baseline complex or LVF complex dual task. 
Test 
order
Dual task item Brief procedure
1 TUG baseline Stand from sitting, walk 3 metres, turn, walk back and sit down
2 LVF simple Say words beginning with the letter R
3 LVF complex Say words beginning with the letter N
4 TUG and LVF simple Perform the TUG whilst doing the LVF simple
5 TUG and LVF complex Perform the TUG whilst doing the LVF complexT
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Table 7: TUG and LVF assessment procedure 
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Mean test scores are recorded to 2 decimal places ± SEM. Groups were categorised as pre-HD (total functional capacity (TFC) = 13 and Unified Huntington’s Disease 
total motor score <5) and manifest (all symptomatic stages). The manifest group was further delineated by TFC disease stage (stage 1, TFC =11-13; stage 2, TFC=7-
10; stage 3,4, TFC=1-6). All measures in dark blue are recorded as time taken in seconds, where a higher score is indicative of worse performance. All measures in 
light blue show the number of correct answers given per second where a lower score is indicative of worse performance. Dual task cost is shown in orange and 
presented as a percentage. A positive percentage is indicative of slower or worse dual task performance relative to baseline,  whereas a negative dual task cost is 
indicative of better performance in the dual task compared to baseline. Significance was set so p < 0.05 and followed by a Bonferroni post-hoc test.  
Where TFC= total functional capacity; ANOVA = analysis of variance; TUG = Timed Up and Go; LVF = Letter verbal fluency; bl = baseline; n.s. = not significant; dtc = 
dual task cost; $ = In the LVF bl simple post-hoc analysis revealed no significant difference between individual TFC disease stages. 
 
t value (df) p value F value (df, error) p value
TUG bl (s) 9.57 ± 0.82 15.05 ± 2.23 -0.919(30) p = n.s. 9.04 ± 2.97 12.05 ± 4.2 19.97 ± 2.75 3.85(2,29) p < 0.05 s1 vs s3,4 p<0.05
TUG dual simple (s) 11.04 ± 1.13 17 ± 1.9 -1.34(23) p = n.s. 10.63 ± 1.73 13.61 ± 2.56 24.02 ± 1.91 14.06(2,22) p < 0.001 s1 vs s3,4 p<0.001; s2 vs s3 p<0.01
TUG dual complex (s) 12.41 ± 1.88 16.93 ± 2.66 -0.736(16) p = n.s. 10.39 ± 2.84 12.66 ± 3.76 23.98 ± 2.84 6.27(2,15) p < 0.01 s1 vs s3,4 p<0.05
LVF bl simple 0.29 ± 0.04 0.16 ± 0.02 2.894(25) p < 0.01 0.23 ± 0.03 0.13 ± 0.04 0.15 ± 0.03 3.63(2,24) p < 0.05 
$ n.s.
LVFdual simple 0.38 ± 0.03 0.31 ± 0.04 0.739(23) p = n.s. 0.43 ± 0.05 0.31 ± 0.07 0.19 ± 0.52 5.63(2,22) p < 0.05 s1 vs s3 p<0.01
LVF bl complex 0.17 ± 0.03 0.15 ± 0.02 0.414(19) p = n.s. 0.16 ± 0.02 0.14 ± 0.32 0.16 ± 0.02 0.11(2,18) p = n.s. n.s 
LVF complex dual 0.31 ± 0.03 0.26 ± 0.04 0.548(15) p = n.s. 0.33 ± 0.06 0.3 ± 0.07 0.2 ± 0.05 1.39(2,14) p = n.s. n.s.
TUG simple dtc (%) 15.6 ± 6.48 36.43 ± 9.72 -0.913(23) p = n.s. 21.24 ± 11.48 12.39 ± 17.02 59.09 ± 12.69 3.371(2,22) p = n.s. /
TUG complex dtc (%) 20.19 ± 13.2 28.44 ± 13.18 -0.261(23) p = n.s. 5.98 ± 15.31 9.79 ± 21.65 61.23 ± 16.36 3.447(2,16) p = n.s. /
LVF simple dtc (%) -40.77 ± 27.92 -76 ± 15.51 0.932(17) p = n.s. -84.33 ± 19.13 -112.79 ± 28.37 -29.72 ± 21.15 3.231(2,22) p = n.s. /
LVF complex dtc (%) -75.74 ± 32.33 -64.06 ± 24.13 -0.2(17) p = n.s. -69.68 ± 31.63 -116.84 ± 44.73 -32.48 ± 33.81 1.144(2,16) p = n.s. /
Pairwise compairsons
ANOVA results
Stage 1 Stage 2 Stage 3,4
TUG and LVF Pre-HD Manifest
t-test results
TFC stage
Table 8: TUG and LVF performance scores 
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There was no difference in dual task cost between disease stage for the TUG 
and LVF simple or complex (Figure 9b).  
 
Results from a two way repeated measures ANOVA are presented in (Table 9). 
This revealed that people in stage 3 took significantly longer to perform the TUG in the 
simple and complex dual task relative to baseline. Performance from no other TUG and 
LVF measure significantly differed from baseline to the dual task.  
 
  
This table presents results from a two way repeated measures ANOVA. If this returned as 
significant (where p < 0.05), a Bonferroni post-hoc was used to identify which disease stage this 
was relevant to. This is presented in the ‘Stages’ column. The results from this table and those 
presented in Table 8 revealed that Stage 3 performed the TUG significantly slower in the dual 
task conditions compared to baseline. Performance in the LVF did not significantly differ in the 
dual task compared to baseline (n.s.). Significance was met so p < 0.05. 
TUG = Timed up and go, LVF = letter verbal fluency. 
 
Dual task 
item
Baseline vs dual simple Stages Baseline vs dual complex Stages
TUG F(2,22)=6.596, p < 0.01 Stage 3: p < 0.001 F(2,14)=0.574, p < 0.05 Stage 3: p < 0.001
LVF F(2,22)=3.124, p = n.s. / F(2,14)=1.598, p = n.s. /
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Table 9: TUG and LVF two way repeated measures ANOVA 
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2.2.3.4 Step and Stroop 
 
For clarity, a reference of the Step and Stroop test items are presented in Table 
10. 
 
 
 
Measures reported in the results includes: number of steps performed in items 1, 4 and 5; The 
number of correct answers were recorded in items 2-5. 
 
Step and Stroop performance scores and statistical outcomes between Group and TFC 
disease stage are presented in Table 11. 
 
For the stepping tasks, pre-HD participants stepped significantly more than the 
Manifest group for the baseline, and simple and complex dual tasks. For the Stroop tasks, 
the pre-HD group gave significantly more correct answers than manifest for all simple and 
complex baseline and dual tasks.  
 
When participant data were grouped based on TFC stage, stage 1 participants 
stepped significantly more than stage 2, stage 3 and stage 4,5 for the baseline, dual simple 
and dual complex (Figure 9h). For the Stroop simple baseline and dual tasks, participants 
gave significantly less correct Stroop responses with increasing disease stage (Figure 9i). 
The Stroop simple baseline better distinguished disease stage compared to the baseline 
complex. The Stroop complex dual task better distinguished disease stage compared to 
the Stroop complex baseline. 
  
For dual task cost, stage 3 presented greater dual task costs in the Stroop simple 
compared to stage 1. There was no difference for any other Step and Stroop dual task 
item between disease stage. 
Test 
order
Dual task item Brief procedure
1 Step baseline Step onto and off an aerobic step 
2 Stroop baseline simple Colour words were presented in their coloured ink. For example, pink was printed in the colour pink
3 Stroop baseline complex Colour words were presented in a different coloured ink. For example, pink was printed in the colour grey
4 Step and Stroop simple Step whilst performing the Stroop simple
5 Step and Stroop complex Step whilst performing the Stroop complex
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 Mean test scores are recorded to 2 decimal places ± SEM. Groups were categorised as pre-HD (total functional capacity (TFC) = 13 and Unified Huntington’s Disease 
total motor score <5) and manifest (all symptomatic stages). The manifest group was further delineated by TFC disease stage (stage 1, TFC =11-13; stage 2, TFC=7-
10; stage 3, TFC=3-6; stage 4,5, TFC=0-2). All measures in dark blue are recorded as number of steps performed in 45 seconds, where a lower score is indicative of 
worse performance. All measures in light blue show the number of correct answers given in 45 seconds where a lower score is indicative of worse performance. Dual 
task cost is shown in orange and presented as a percentage where a lower score is indicative of better performance. A positive percentage is indicative of slower or 
worse dual task performance relative to baseline, whereas a negative dual task cost is indicative of better performance in the dual task compared to baseline.  No 
participants in stage 4,5 were recruited in the complex dual task. Significance was set so p < 0.05 and followed by a Bonferroni post-hoc test. 
Where TFC= total functional capacity; ANOVA = analysis of variance; bl = baseline; n.s. = not significant; s = stage; dtc = dual task cost.
t value (df) p value F value (df, error) p value
Step bl 40.13 ± 1.98 28.72 ± 1.99 2.252(56) p < 0.05 40.83 ± 2. 16 28.78 ± 2.76 20.72 ± 2.44 14 ± 5.97 15.668(3,54) p < 0.001 s1 vs s2 p<0.01; s1 vs s3, s4,5 p<0.001
Step dual simple 36.5 ± 2.9 26.98 ± 1.89 2.018(52) p < 0.05 37.43 ± 2.01 26.29 ± 2.58 17.56 ± 2.41 23 ± 9.65 13.768(3,51) p < 0.001 s1 vs s2 p<0.01; s1 vs s3,4 p<0.001
Step dual complex 35.88 ± 2.72 25.65 ± 2.21 2.064(43) p < 0.05 36 ± 2.11 24 ± 3.13 15.68 ± 2.74 / 18.013(2,42) p < 0.001 s1 vs s2 p<0.01; s1 vs s3,4 p<0.001
Stroop simple bl 79.63 ± 4.14 56 ± 2.72 3.153(63) p < 0.01 77.54 ± 2.96 58.25 ± 3.61 41.32 ±3.08 42.33 ± 8.35 25.469(3,61) p < 0.001 s1 vs s2, s3, s4,5 p<0.001; s2 vs s3 p<0.01
Stroop dual simple 73.13 ± 3.58 48.43 ± 3.23 3.112(52) p < 0.01 69.22 ± 3.19 49.5 ± 4.09 32.35 ± 3.83 12 ± 15.31 20.984(3,50) p < 0.001
s1 vs s3 p<0.001; s1 vs s2, s4,5 p<0.01; s2 vs s3 
p<0.05
Stroop complex bl 51 ± 1.92 27.41 ± 1.88 5.109(52) p < 0.001 41.46 ± 2.19 28.67 ± 3.1 18.53 ± 2.6 15 ± 10.73 16.188(3,50) p < 0.001 s1 vs s2 p<0.01; s1 vs s3 p<0.001
Stroop dual complex 51.5 ± 1.68 29.38 ± 2.52 4.01(43) p < 0.001 44.91 ± 2.38 28.9 ± 3.53 17.08 ± 3.1 / 26.342(2,42) p < 0.001 s1 vs s2 p<0.01; s1 vs s3 p<0.001; s2 vs s3 p<0.05
Step simple dtc (%) 9.6 ± 3.76 7.5 ± 4.19 5.109(52) p = n.s. 7.14 ± 5.57 0.21 ± 7.14 15.4 ± 6.52 -1.31 ± 26.88 0.857(3,51) p = n.s. /
Step complex dtc (%) 11.11 ± 3.37 21.63 ± 4.15 5.109(52) p = n.s. 12.14 ± 4.85 28.62 ± 7.19 25.83 ± 6.31 / 2.459(2,42) p = n.s. /
Stroop simple dtc (%) 7.98 ± 1.54 21.16 ± 3.19 5.109(52) p = n.s. 10.94 ± 3.63 12.64 ± 4.65 32.94 ± 4.22 70 ± 17.39 8.78(3,51) p < 0.001
s1 vs s3 p<0.001; s1 vs s4,5 p<0.01; s2 vs s3 and 
s4,5 p<0.05
Stroop complex dtc (%) -1.31 ± 2.42 2.3 ± 4.35 5.109(52) p = n.s. -4.11 ± 4.84 -4.66 ± 7.18 16.3 ± 6.3 / 3.797(2,42) p < 0.05 s1 vs s3 p<0.05
Pairwise compairsons
ANOVA results
Stage 1 Stage 2 Stage 3 Stage 4,5
Step and Stroop Pre-HD Manifest
t-test results
TFC stage
Table 11: Step and Stroop performance scores 
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Results from a two way repeated measures ANOVA are presented in Table 12. 
This revealed that stepping and Stroop performance did not significantly differ in the dual 
task compared to baseline.  
 
This table presents results from a two way repeated measures ANOVA. This revealed that 
performance in the Step and Stroop did not significantly differ in the dual task relative to baseline. 
Where n.s. = not significant.  
 
 
 
Dual task item Baseline vs dual simple Stages Baseline vs dual complex Stages
Step F(3,50)=0.873, p = n.s. / F(2,42)=0.734, p = n.s. /
Stroop F(2,50)=2.488, p = n.s. / F(2,42)=1.878, p = n.s. /
St
ep
 
an
d
 
St
ro
o
p
Table 12: Step and Stroop two way repeated measures ANOVA 
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Figure 9 continues on page 833. 
a) b) c) 
d) e) 
Dual simple Dual Complex Dual simple Dual Complex Dual simple Dual Complex 
Dual simple Dual Complex Dual 
Simple 
Baseline 
Simple 
Dual 
Complex 
Baseline 
Complex 
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Baseline Simple 
f) 
h) 
g) 
i) 
Dual simple Dual Complex Dual simple Dual Complex Baseline Complex 
Dual simple Dual Complex Dual simple Dual Complex Baseline Complex Baseline Simple 
li  i l  
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Figure 9: Bar graphs represent the mean performance across each dual task assessment, with standard error of the mean error bars. Figures a-e show the velocity 
(metres/second), cadence (steps/minute), duration of double limb support (seconds), stride length CoV (%) and the alphabet score (correct letters per second) for the 
Walk and talk. A greater measure for velocity, cadence and alphabet scores are indicative of better performance, whereas a lower measure is indicative of better 
performance for duration of double limb support and stride length CoV. Figures f and g show the time taken to perform the Timed up and go (TUG; f) and the letter 
verbal fluency scores (LVF; g). The TUG is measured in seconds, where a lower time is indicative of better performance and the LVF is measured as number of correct 
words said per second, where a greater score equates to better performance. Figures h and i show the number of steps and correct answers given for the Step and 
Stroop, where a greater score is indicative of better performance. Values show averages ± SEM. Where * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 10: Dual task cost (Chapter 2, Part 1): Graphs represent the mean dual task cost (dtc) percentage for each TFC disease stage in each dual task assessment, 
across the simple and complex tasks. Figure a presents the dtc for the Walk and talk and revealed that the dtc for velocity was significantly more in stage 3,4 
compared to stage 1. All other parameters were widely variable. Figure b presents the dtc from the TUG and LVF which showed no significant differences between 
groups. Figure c shows the dtc from the Step and Stroop, which shows stage 3 and stage 4,5 had significantly greater costs that stage 1 and stage 2 in the Stroop 
simple. Stage 3 also had significantly greater costs compared to stage 1 in the Stroop complex. Where *p<0.05, **p<0.01.  
DTC = dual task cost; DoDLS = duration of double limb support; Alpha = alphabet; TUG = Timed up and go; LVF = letter verbal fluency. 
Cadence 
Simple 
Cadence 
Complex 
Velocity Simple 
and Complex 
 Simple 
and Complex 
DoDLS Simple 
and Complex 
Stride Simple 
and Complex 
Alpha Simple 
and Complex 
TUG Simple  TUG Complex  LVF Simple  LVF Complex  
Step Simple  Step Complex  Stroop 
Complex  
Stroop 
Simple 
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2.2.4 Discussion 
 
In this study, motor-cognitive dual tasks were selected and developed. This led 
to three lower limb assessments that were tested in people with HD. Dual tasks 
included the Walk and talk, the TUG and LVF, and the Step and Stroop. As the Step and 
Stroop distinguished between disease stage more than the other dual tasks, this was 
evaluated in a larger cohort of people with HD.   
 
The Step and Stroop simple dual task best distinguished between disease stage 
 
As part of the Step and Stroop, performance in the Stroop baseline and dual 
tasks distinguished primarily between stage 1 and all other disease stages. In the 
Stroop simple differences between disease stage were marginally greater than those 
in the Stroop complex. This finding is in line with previous studies that found that as 
HD progressed, the greatest changes were in less cognitively demanding tasks, like the 
Stroop colour and word naming (Stroop simple) compared to the word-colour 
interference (Stroop complex) (Snowden et al., 2001; Ho et al., 2003). One explanation 
for this could be because the basal ganglia, specifically the dorsolateral striatum, is 
implicated in automating behaviour (Ashby, Turner and Horvitz, 2010; Kim and 
Hikosaka, 2015).  Thus, as the same four colour words are repeatedly read in the Stroop 
simple, this could lead to responses being automated (Flaudias and Llorca, 2014). 
However, as this circuitry progressively degenerates in HD, the ability to automate 
tasks may become increasingly difficult (Thompson et al., 2010), meaning more 
attention is required and less words are recited. Alternatively, speech impairment is 
another common symptom in people with manifest HD (Rusz et al., 2014; Skodda et 
al., 2014). As this includes problems with speech rate, it could be that as HD 
progresses, the ability to promptly respond to verbal tasks, such as the Stroop, 
becomes increasingly impaired, leading to fewer words recited. 
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The stepping item from the Step and Stroop revealed that on average, the stage 1 
group stepped significantly more than stages 2, 3 and 4,5. One explanation for this is 
that people with HD have problems initiating movement, leading to slower response 
times (Delval et al., 2007; Goldberg et al., 2010). This is supported by a previous study 
found that people with manifest HD had problems with self-initiating movement prior 
to a walking, leading to a slower speed during the first few walking steps, compared to 
controls (Delval et al., 2007). Anatomically, self-triggered movements, which are 
required during the stepping task in the Step and Stroop, involve activation of the 
supplementary motor area and the dorsolateral prefrontal cortex (Jahanshahi et al., 
1995). As these regions innervate the basal ganglia (reviewed in: Lanciego et al., 2012; 
Nambu et al., 2002), the progressive loss of GABAergic neurons which forms the basis 
of this circuitry (Storey and Beal, 1993), may lead to greater attention and activation 
of more indirect, compensatory networks required to initiate stepping. Other 
explanations for a slower stepping rate includes postural disturbances due to 
increased movement abnormalities leading to imbalance (Delval et al., 2007), or as 
people with HD become progressively less mobile (Roos, 2010), they may simply tire 
quicker.  
 
The TUG and LVF dual task 
 
Although the TUG and LVF are used as individual tests in the HD population, 
they have never been combined and tested as a dual task in HD. In this study, the LVF 
baseline simple was the only LVF item that revealed a significant difference between 
pre-HD and manifest participants. Surprisingly, when LVF performance was compared 
across disease stage, this revealed that people in stage 3,4 gave significantly more 
correct answers than those in stage 1. This was largely influenced by a stage 4 
participant who performed particularly well in the LVF, and admitted that she liked to 
read in her spare time. Although the LVF task has proven sensitive in people with HD 
in the past (Rosser and Hodges, 1994; Jardim Azambuja et al., 2007), future studies 
should consider controlling for lifestyle factors such as education and certain hobbies, 
such as reading. This will allow a greater understanding behind how verbal fluency 
tasks deteriorate as HD progresses.  
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As a dual task, the LVF items were also prone to practice effects indicated by the 
negative dual task costs. As a result, the LVF may not be useful in assessments where 
a baseline test is required, and then soon repeated, such as in dual tasks.  
 
For the TUG, performance in the TUG and LVF dual simple best distinguished 
between disease stage, over the TUG baseline and TUG dual complex task. This 
revealed that TUG performance took significantly longer with increasing disease stage. 
The results in this study suggest that the TUG may be more sensitive when used as part 
of a dual task rather than a single outcome measure, which is how it is currently used 
in the observational study, ENROLL-HD. Future research should therefore consider 
testing different cognitive items that could be combined with the TUG to see how and 
if this influences TUG performance.  
 
The Walk and Talk dual task 
 
Performance in the Walk and talk was tested in people with HD in a previous 
study (Fritz et al., 2016), and revealed that the majority of people experienced mutual 
interference, and that performance in both the walking and the talking task declined 
in the dual task. As they only measured speed to rate walking performance, in this 
study, the GaitRite mat was used to measure a range of spatiotemporal walking 
parameters during dual task performance. Both velocity and stride length CoV 
significantly differed across disease stage, where stage 1 had a significantly greater 
velocity and a smaller stride length CoV, compared to stage 3. However, contrasting 
with the findings from (Rao, Quinn and Marder, 2005) there was no difference 
between pre-HD and manifest for any walking measure.  One explanation for this is 
some subjects in our study walked off the sensors on the mat, reducing the mean data 
that could be collected. Furthermore, to conform with the Walk and talk performed in 
HD before (Fritz et al., 2016), each assessment item was for 30 seconds long. Therefore 
some subjects only completed one length of the GaitRite, limiting the number of steps 
that could be analysed. To avoid this problem, a previous study standardised the 
number of steps participants performed to improve the consistency of gait measures 
(Khalil, 2012). Although this should be considered in future studies that use the 
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GaitRite, increasing the number of steps or the length of walking time could lead to 
fatigue, especially in dual task studies where walking would be repeatedly assessed.  
 
Did the dual task have an impact on performance? 
 
In this study, dual task cost was calculated to compare the percentage 
difference between baseline and dual task performance. When percentage changes 
were compared across disease stage, this revealed that the Stroop simple best 
distinguished between disease stage, where stage 3 and stage 4,5 subjects had 
significantly greater costs compared to stage 1 and stage 2. As there was no significant 
difference in stepping rate this suggests that participants may have prioritised the 
motor (stepping) task over the cognitive (Stroop) cognitive tasks when both were 
performed simultaneously. Interestingly, the opposite pattern was true for the TUG 
and LVF, where TUG performance decreased in the dual condition and performance in 
the LVF improved. This supports previous findings that suggests dual task interference 
is dependent upon the motor-cognitive items combined (reviewed in: Carmela et al., 
2017), and indicates the importance of validating different dual tasks in a larger group 
of people with HD in the future.  
 
Part 1 Conclusions 
 
Overall, the results in this study revealed that the Step and Stroop assessment 
items best distinguished different stages of HD compared to the TUG and LVF and the 
Walk and talk. In particular the Stroop simple items were most sensitive to disease 
stage compared to the Stroop complex, suggesting that this may better reflect striatal 
degeneration than more highly complex cognitive tasks (Snowden et al., 2001). 
However, a limitation of the Step and Stroop dual task was that it required at least two 
researchers; one to ensure the participant is safe during performance and the other to 
rate the assessment, which may not be available in all clinical settings. 
Taking this study forward, the next step was to correlate dual task performance with 
HD specific assessments. This analysis is presented in Section 2.3.3.2 of this Chapter. 
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2.3 Part 2 
 
The dual study in Part 1 was assembled using a combination of existing motor and 
cognitive tasks, but all involved the lower limb. For reasons described below, it was 
important to also generate an upper limb task. However, as no tasks existed that could 
be readily adapted for dual tasking, one had to be created.  
 
2.3.1 Rationale and study design 
 
Motor impairments in HD involves problems with upper limb function, such as 
problems performing dextrous movements (Klein et al., 2012; Quinn, Busse and Dal 
Bello-Haas, 2013).  Dexterity can be defined as “fine, voluntary movements used to 
manipulate small objects during a specific task” (Backman, Gibson and Parsons, 1992). 
There are two main types of dexterity; manual and fine motor. Manual dexterity 
involves the use of the whole hand, such as grasping the handle bars of a bike, whereas 
fine motor dexterity involves the manipulation of objects within the hand, such as 
screwing the lid on a bottle. As such functions form a prominent role in everyday life 
(Quinn, Busse and Dal Bello-Haas, 2013), it is important objective, ecologically valid 
outcome measures are available for clinicians and researchers to assess problems with 
upper limb function in HD. Indeed, there are numerous functional upper limb 
assessments that have been tested in this population (see Table 13). However, many 
of these are limited because of the way they are rated, the lack of standardisation and 
because they are not sensitive to people across all stages of HD. For instance, pegboard 
tests are well established fine motor tasks which consist of  transferring pins into holes 
on a board (Tiffin and Asher, 1948; Saft et al., 2003; Yancosek and Howell, 2009). A 
previous study revealed that people with manifest HD transferred pegs significantly 
slower than the pre-manifest group and healthy controls, but, there was no difference 
between people with pre-manifest HD and controls (Saft et al., 2003). Other time 
based functional upper limb tasks include the 10 euro neuro test which involves turning 
over ten 1 euro coins (van Vugt et al., 2007). The one study that tested this compared 
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performance in late stage people with HD and controls and found that people with HD 
were significantly slower performing the task, and 2 out of 10 could not complete it 
(van Vugt et al., 2007). The nut and bolt test also revealed that performance in people 
with manifest HD were slower than pre-manifest and controls (Collins et al., 2015). 
However, as the studies discussed here (Saft et al., 2003; van Vugt et al., 2007; Collins 
et al., 2015) were tested in people with manifest HD, and symptoms can vary 
significantly across this group, it is unknown if these would be sensitive across all 
manifest disease stages. Furthermore, the simplicity of these tests and those included 
in the Physical Performance test (see Table 13) (Reuben and Siu, 1990; Brown et al., 
2000) suggests that such simple tests that are rated only using time, may not capture 
people with different functional abilities, suggesting an accuracy measure is also 
required.  
 
Another dexterity task includes the reach to eat, which involves the subject 
transferring a small food item from a platform into their mouth (Whishaw et al., 2002; 
Klein et al., 2011). Using motion analysis, a previous study revealed that people with 
manifest HD commonly overshot the food target, had problems with wrist rotation, 
had jerky movement trajectories and impaired temporal sequencing of movements 
(Klein et al., 2011). However, as this was only tested in 12 people with HD who had 
very different UHDRS-TMS scores (scores ranged from 19-50 (out of a total of 124)), it 
is unknown how these deficits differed across people with different disease stages. 
Furthermore, this test is commonly rated using an ordinal scale, which could lead to 
subjective scoring. Importantly, the reach to eat task was previously translated for pre-
clinical use, and revealed that rats with excitotoxic lesions to the lateral striatum had 
problems with aiming for the food target, pronating and supinating the paw (Whishaw 
et al., 2007). A similar task used in rodents is the staircase test, which involves 
retrieving small pellets from a descending staircase (Montoya et al., 1991). Similar to 
the reach to eat, previous studies have shown that excitotoxic lesions to the lateral 
striatum results in dextrous impairment, which can gradually improve following cell 
transplantation therapy (Jeyasingham et al., 2001; Döbrössy and Dunnett, 2003; M. D. 
Döbrössy and Dunnett, 2005). Furthermore, upper motor tasks, such as finger tapping 
in HD progress over time (Klöppel et al., 2009; Klöppel et al., 2015), and neuroimaging 
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studies show that such tasks involves striatal function (Scahill et al., 2013; Tabrizi et 
al., 2013). Together, this suggests that a speed based, quantitative, dextrous 
assessment could be useful to assess upper limb function following an intervention, 
such as transplantation in HD. Furthermore, to capture the different stages in HD, 
including different levels of difficulty may help prise apart different disease stages.  
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Table 13: Functional upper limb tasks used for HD patients 
Test Procedure Main scoring method 
Pegboard tests (Tiffin and 
Asher, 1948)  
 
Subjects are timed to 
transfer a set number of 
pegs into appropriate holes, 
or asked to transfer as many 
pegs as possible in a given 
time. This is performed 
twice (once for the left and 
right hand). 
Time taken 
10 Euro Neuro test (van 
Vugt et al., 2007) 
The subject is timed to turn 
over ten 1-euro coins  
Time taken 
Nut and bolt test (Collins et 
al., 2015) 
The subject uses one hand to 
screw on three different 
sized nuts onto bolts. 
Time taken 
Reach to eat (Whishaw et 
al., 2002; Klein et al., 2011) 
 
Using one hand, the subject 
is asked to reach for a small 
food item (Cheerio™ or 
Haribo Gummy Bear™) 
positioned on a pedestal in 
front of them. This is 
performed twice (once for 
the left and right hand). 
The test is typically video 
recorded to qualitatively 
rate movement 
performance via a 
movement element rating 
scale 
Modified Physical 
performance test (Brown et 
al., 2000): 
Pick up a penny 
 
 
 
Lift a book 
 
 
 
 
 
The subject is asked to pick 
up a penny from the floor 
placed 12 inches in front of 
their feet. 
The subject is asked to lift a 
book and put it on a shelf 
(above shoulder height, 
starting position hands at 
side and standing in front of 
a table).  
 
 
 
 
 
 
 
Ordinal scoring method 
where: 
≤ 2 sec = 4; 2.1-4 sec = 3; 
4.1- 6 sec = 2; > 6 sec = 1; 
unable = 0 
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Physical performance test 
(Reuben and Siu, 1990): 
Write a sentence 
 
Simulated eating 
 
Subjects are asked to write: 
Whales live in a blue ocean. 
Subjects are asked to 
transfer five kidney beans 
into a tin can using a 
teaspoon. 
Ordinal scoring method 
where: 
≤ 10 sec = 4; 10.5-15 sec = 3; 
15.5 – 20 sec = 2; >20 sec = 1; 
unable = 0. 
 
A table presenting previously used functional upper limb assessments in HD. A general limitation 
of these is that they are either rated using time taken alone, with no accuracy measure, or they 
are rated on an ordinal scale. In addition, no assessment presented in this table looked at 
performance in different stages of manifest HD. 
 
2.3.1.1 The development of the Clinch token transfer test 
 
The aim of this study was to develop an upper limb dual task assessment that 
could be used as a quantitative, performance based functional outcome measure for 
people with all stages of HD. As a result, the Moneybox test was developed. This name 
later changed to the Clinch token transfer test (C3t). This section describes the 
development work that led to this assessment.  
 
The C3t was originally inspired by one of the items from the Physical 
performance test: Picking up a penny (Reuben and Siu, 1990). This task requires 
dexterity as well as postural stability to maintain balance when standing and bending 
(Blanchet et al., 2014), meaning that it does not directly target upper limb function. To 
study the Picking up a penny item further, a small data mining study was carried out 
using data collected by Busse and colleagues (Busse et al., 2014). This included data 
from 64 people with all stages of HD who performed a range of different outcome 
measures. As part of the Physical Performance test, the scores from assessment items 
are usually summed and the total score is then presented as a measure of functional 
mobility. However, it is unknown if individual item scores, such as Picking up a penny, 
are a useful individual outcome measure, and if they distinguish between different HD 
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stages. To investigate this, a Kruskall-Wallis H test was performed using the data from 
the Busse et al study (Busse et al., 2014) and revealed that there was no significant 
difference between people with pre-HD and manifest HD [X2 (1) = 1.161, p=n.s.], and 
no significant difference when subject data were grouped by TFC disease stage [X2 (3) 
= 1.118, p=n.s.]. Thus, it was concluded that Picking up a penny was not demanding 
enough to tease apart different disease stages in HD. It was therefore decided that a 
sitting task that focussed on upper limb mobility, which had increasing levels of 
difficulty could be a useful outcome measure for HD. 
 
To overcome some of the weaknesses associated with the functional upper 
limb assessments identified in Table 13, a list of criteria were assembled to help form 
the design and development of a new functional upper limb assessment (Table 14). 
This resulted in the Clinch token transfer test (C3t). This assessment consists of 3 main 
assessment items that involves transferring British coins between hands into a 
moneybox, in order of coin size (Baseline simple), coin value, without (Baseline 
complex) and whilst reciting the alphabet (Dual task). The information presented in 
Table 14 presents the criteria which aided the development of the C3t. 
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Table 14: A description of criteria used to develop the C3t 
Criteria Description C3t 
Limited to upper 
limb function 
People with manifest HD fall regularly (Busse, Wiles and Rosser, 
2009) and often require a wheelchair during the more advanced 
stages of disease. Therefore, an assessment restricted to upper 
limb function would allow wheelchair users and people with 
severe lower limb functional problems to be ‘functionally’ 
assessed.  
To isolate motor function to the upper limbs, the C3t is performed 
whilst sitting. In addition, the C3t was designed so both hands are 
required to perform the same functions: grasp the coins, transfer 
and release, the same number of times. Therefore, the C3t 
effectively measures bilateral function.  
A dual task with 
increasing levels of 
complexity 
Dual and multi-tasking is a common daily activity. People with HD 
have difficulty performing two tasks simultaneously and appear to 
have more problems performing motor-cognitive dual tasks 
compared to motor-motor dual tasks (Delval, Krystkowiak, 
Delliaux, Dujardin, et al., 2008).  
Easy and hard assessment items accommodate people with a 
range of functional abilities (Stout, Glikmann-Johnston and 
Andrews, 2016). This makes the test applicable to people that 
manifest a broad range of disease symptoms, such as HD.  
The C3t includes three levels of difficulty; the Baseline simple, 
Baseline complex and dual task. The aim was to develop C3t items 
simple enough that subjects were willing to attempt the items to 
their full capacity, ensuring maximum participation. For instance, 
word fluency and adding/subtracting based secondary tasks can 
result in a negative response before the test has begun if for 
instance the subject is not confident with mental arithmetic.  
Reciting the alphabet was selected for the dual task to increase 
task difficulty. It was hypothesized that as this is a fairly simple 
task, it would be more mentally approachable than for instance a 
secondary task that could be confounded by education or job 
type, such as adding or subtracting. It was hypothesized this 
would minimize the negative impact such tasks may have on 
performance. 
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Subjects should 
only continue with 
the complex 
assessment items 
if they pass set 
criteria in the 
easier tasks  
People in the more advanced stages of disease may struggle to 
complete more complex tasks due to limited attentional resources 
(Delval, Krystkowiak, Delliaux, Dujardin, et al., 2008; Vaportzis, 
Georgiou-Karistianis, Churchyard and Stout, 2015). A hierarchy of 
items with increasing levels of difficulty, and set criteria for each 
level could minimize the risk of floor and ceiling effects if the test 
is too easy or hard for people in different disease stages.   
Set criteria for each C3t item included completing the test item in 
a certain time and committing a limited number of errors. Errors 
consisted of, transferring the coins in the wrong order, dropping 
a coin or failing to transfer the coin between hands. Subjects that 
failed to meet criteria did not continue to the next C3t stage. 
The assessment is 
sensitive to  
functions that 
involve the 
degenerating 
neuroanatomy in 
HD 
HD is primarily caused by death of medium spiny neurons in the 
striatum and breakdown of the basal ganglia and cortical 
projections (Tabrizi et al., 2009; Lanciego, Luquin and Obeso, 2012; 
Novak et al., 2015).  Therefore an assessment, that targets 
behavioural functions that involve these regions, may correlate 
with disease progression, meaning the assessment is sensitive to 
all stages of HD.   
 
C3t items were developed to target:  
Dexterity: Previous pre-clinical research revealed the lateral 
striatum is required for fine motor tasks suggesting a task that 
incorporated dexterity may sensitively capture deficits caused by 
striatal degeneration in people with HD (Döbrössy and Dunnett, 
2003). To account for this, dexterity was required to pick up and 
accurately release different sized coins into a defined target (the 
moneybox slot). 
Repeated motor transitions: Rhythmic, repeated motor 
transitions leads to a change in neuronal firing patterns in the 
dorsolateral striatum (Ashby, Turner and Horvitz, 2010), and may 
relate to new skill learning (Turner and Desmurget, 2010). The C3t 
was designed to take advantage of this, as it requires the subject 
to repeatedly transfer eight coins as quickly as possible. 
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Oculomotor function (Harting and Updyke, 2005).: It was 
hypothesized optimal C3t performance would require occulo-
motor function to rapidly saccade the eyes to the next coin target. 
Attention (De Diego-Balaguer et al., 2008): The increasing levels 
of difficulty in the C3t were designed to demand increasing levels 
of attention. Subjects were required to remember to transfer 
coins between hands and in a given order. In the dual task, 
attentional capacity is challenged again as subjects are required 
attend to the C3t rules whilst simultaneously reciting the alphabet 
as quickly as possible.  
Alphabet recitation: Previous studies suggest that tasks with low 
cognitive demands were more sensitive than those with high 
cognitive demands (Snowden et al., 2001; Thompson et al., 2010). 
In addition, pre-clinical research suggests that the dorsolateral 
striatum is involved in performing fixed, automatic behaviours 
(Yin, Knowlton and Balleine, 2004). Reciting the alphabet is a fairly 
simple task that is regularly recited from a young age. For many, 
by early adulthood, it means that this recitation would pose little 
attentional demand as the memory is retrieved and automatically 
recited (Ashby, Turner and Horvitz, 2010; Turner and Desmurget, 
2010).  It was hypothesized reciting the alphabet would load extra 
stress on the fronto-striatal circuitry making the dual task even 
more challenging for people with striatal dysfunction. 
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Straight forward to 
train and 
administer 
It is important that outcome measures selected are easy and 
uncomplicated to set up, whilst also performed in a reasonable 
time frame to minimize the burden on subjects.  
The C3t takes between 5-10 minutes to perform. Due to the set 
criteria developed for each C3t item, the length of the C3t 
assessment is dependent on functional ability. In addition, as the 
C3t is used to measure bilateral function, it only needs to be 
performed once.  
Compact 
Clinic space is often limited. Also outcome measures may need to 
be transported to different clinical locations, therefore it is 
important assessments are compact and lightweight.  
The C3t was designed so construction involved few and small test 
components. This meant the deconstructed C3t is compact and 
requires little room for storage.   
Quantitatively 
scored 
Outcome measures that are quantitatively reduces subjectivity 
and also allows for more sensitive change over time (Hobart, 
Freeman and Thompson, 2000). 
The C3t is rated using time as a primary measure. Performance 
accuracy is also recorded and combined with time taken to 
produce a C3t total score.  
 
The table presents a list of the criteria which led to the development of the Clinch token transfer test (C3t).
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2.3.1.2 C3t test procedure 
 
The C3t consists of three assessment items: 1) C3t Baseline Simple; 2) C3t Baseline 
Complex; 3) C3t Dual task (Figure 11). The description for each assessment item are 
explained below.  
 
1. C3t Baseline Simple: The participant was asked to transfer British coins (£2, £1, 
50p, 20, 10, 5p, 2p, 1p) into a moneybox in size order, starting with the biggest 
coin (£2) to the smallest coin (5p). Coins were already presented to the 
participant in size order, with the £2 coin positioned furthest away from them 
and the 5p coin closest to them (Figure 11). This baseline test was required to 
see if participants could follow a simple set of task rules, and also pick up coins 
of varying sizes and release them accurately into a standardised moneybox 
slot.  
 
2. C3t Baseline Complex: British coins were presented in the same order as the 
Baseline Simple. This assessment item was designed to add cognitive load. The 
participant was asked to transfer British coins into a moneybox starting with 
the highest value coin, to the lowest.  
 
3. C3t Dual task: British coins were positioned in the same order as the Baseline 
tasks. In this assessment item, the participant performed the same test as the 
Baseline Complex, whilst also reciting the alphabet. This was designed to add 
a dual element to the assessment. The participant was required to perform 
two tasks simultaneously which required different overall outcomes; to 
transfer coins into a moneybox (motor element) and to continuously recite the 
alphabet (cognitive element).   
 
To ensure that poor performance in the Baseline Complex and the C3t Dual task 
was because of task complexity and not because the participant could not count 
backwards, or could not recite the alphabet, the participant was asked to perform a 
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Value Baseline and an Alphabet Baseline task. This was carried out whilst sitting, 
allowing full attentional capacity to be directed to these tasks alone. For the Value 
Baseline, the participant was presented with eight values (200, 100, 50, 20, 10, 5, 2, 1) 
printed on laminated card and asked to recite the highest value number in order to the 
lowest value number. For the Alphabet baseline, participants were asked to recite the 
alphabet once, as quickly as possible. Both the Value baseline and the Alphabet 
baseline were performed before the C3t Baseline Complex and the C3t dual task. If the 
participant ‘passed’ these tasks they proceeded to the C3t Baseline Complex and the 
C3t Dual task.   
 
 
Moneybox 
Non-slip mat British coins 
Coins are presented 
from largest to smallest 
Figure 11: The Clinch token transfer test (Version 1): British coins were positioned on a non-slip 
mat and presented in size order (largest to smallest). The participant was asked to transfer coins 
in order of size, to the non-dominant hand and into a moneybox (Baseline simple). For the 
Baseline complex, and the dual task, the coins were presented in the same order as the Baseline 
simple but they were instead asked to transfer the coins in order of value, without and whilst 
reciting the alphabet (Baseline complex and dual task respectively). 
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2.3.1.3 Rating the C3t  
 
The primary measure used to assess performance in the C3t was time taken. 
Time taken was selected rather than an ordinal scoring method to avoid observer bias. 
This would also allow a more precise method to measure change in disease symptoms. 
Consistency in time measures were established by asking participants to start with 
their hands placed on their legs. The time started when the participant was told to 
“Go” and the time was stopped as soon as the last coin was released from the 
participant’s fingers into the moneybox. Although a set of written instructions were 
read to participants prior to the test performance, it was soon clear that some 
participants would forget to transfer coins between their hands, resulting in a faster 
performance time. Another common problem was transferring coins in an order which 
contrasted those instructed. Therefore, a list of errors were developed, which were 
recorded by the researcher if the participant failed to follow the task rules. Any errors 
committed affected performance accuracy (Equation 1). It was also important that any 
coins dropped out of reach were also recorded. If a coin was dropped out of the test 
board then the participant was told to leave it and continue with the next coin. To 
incorporate test accuracy and the time taken to perform each C3t assessment item, an 
equation was developed to generate a C3t total score (Equation 2). 
 
Performance in the Alphabet Baseline task was recorded using time taken and 
the number of correct letters of the alphabet recited. From this, the number of correct 
letters of the alphabet said per second was calculated (Equation 3). This method was 
chosen as it meant both time and accuracy were combined to form one score 
(Alphabet rate). In the C3t Dual task the participant was asked to continuously recite 
the alphabet until they released the last coin into the moneybox. Calculating the 
alphabet rate meant that alphabet performance could be compared from the baseline 
and dual task.  
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If the subject committed an error presented in this table then this was recorded and 
acknowledged in the performance accuracy score (Equation 1).  
 
 
 
 (16 – The number of errors made)  * 100   = Accuracy (%) 
                       16      
Equation 1: Whilst the subject performed the C3t, the total number of transfer and rule errors 
committed were recorded (refer to Table 15). The C3t required participants to transfer 8 coins 
into the moneybox. This meant the participant could potentially make 8 transfer errors and 8 
rule errors (totalling 16 possible errors). During the C3t performance, any errors committed 
were recorded. These were summed, subtracted from 16, divided by 16 and multiplied by 100 
to give percentage accuracy.   
 
  
   (8 – The number of coins dropped out of reach)    
                   Time taken (s)  
Equation 2:  Before the test began, the participant was instructed that if a coin dropped or rolled 
off the test set up, then to leave it and to continue with the next coin. If a coin did drop out of 
reach, this was recorded by the researcher. At the end of the assessment, the number of coins 
dropped out of reach were summed. As the C3t setup involved 8 coins, any coins dropped out of 
reach were subtracted from 8. This was divided by the time taken to complete the C3t 
assessment item and multiplied by the accuracy calculated from Equation 1. Essentially this 
calculation equated to: the average time taken to transfer each coin, multiplied by the 
percentage accuracy (the number of errors made).   
 
 
* Accuracy (%)  = C3t total 
 
Error Type Error meaning
Transfer error
The subject fails to transfer tokens between 
hands.
Value error
The subject transfers the tokens in an 
incorrect size or value order.
Dropping a 
token
The token falls or rolls outside the test box.
Equation 1: C3t Performance accuracy 
Table 15: C3t errors 
Equation 2: C3t total score 
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Equation 3: Alphabet rate 
 
Number of correct letters of the alphabet recited    
                              Time taken (s)  
 
Equation 3: The number of correct letters of the alphabet recited during the alphabet baseline 
and dual task were recorded. This was divided by either by the time taken to complete the 
Alphabet Baseline or by the time taken to complete the C3t Dual task to give the alphabet rate.  
 
= Correct letters said per second 
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2.3.2 Methods 
 
Please refer to the Methods in Part 1 (Section 2.2.2) for information on the design, 
setting, participants, additional participant information and statistics on this study.  
 
2.3.2.1 Dual task procedures 
 
A brief description of the C3t is described in Section 1.3.1.1. A performance 
threshold was set for each assessment item so participants had to ‘pass’ set criteria during 
the Baseline tasks to move onto the complex items. A full description of the testing 
procedures can be located in Appendix 2. The manual developed for the C3t used in this 
Chapter is presented in Appendix 3. 
 
2.3.2.2 Rating participant performance 
 
Performance was rated using the time taken, performance accuracy, C3t total 
score and Alphabet rate and dual task cost, described on page 102.
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2.3.3 Results 
Demographic data from participants that attempted each dual task assessment are 
presented in Table 16. Twenty-nine people with HD attempted the C3t from which 
nineteen completed the full assessment. 
 
People in stages 3 and 4 were combined given the limited number of people recruited 
in stage 4 (n=1). No people in stage 5 were recruited. Final TFC disease stage groups 
were stage 1, stage 2, stage 3,4.  
 
The data in Table 16 revealed that stage 1 subjects were significantly younger than 
stage 3,4. There was no significant difference in the number of years in education or 
body mass index for any group.   
 
 
The table presents the mean values (Standard Deviation) for those recruited in the C3t baseline 
simple task. Groups were categorised as pre-HD (total functional capacity (TFC) = 13, Unified 
Huntington’s Disease total motor score (TMS) <5), and manifest (all symptomatic stages). The 
manifest group was further delineated by TFC disease stage (stage 1, TFC =11-13; stage 2, 
TFC=7-10; stage 3,4, TFC=1-6. A t-test was used to compare groups differences between pre-HD 
with manifest subjects, where the t (degrees of freedom) = t value. An ANOVA was used to 
compare TFC group differences, where F (error, degrees of freedom)=F value. A Bonferroni post-
hoc was used if significance was met, where p < 0.05. Demographic data was missing from a 
maximum of 11 participants. C3t = Clinch token transfer test; TFC = Total Functional Capacity; 
TMS= total motor score; BMI = body mass index.  
 
1 2 3,4
n (male:female) n=3 (3:0) n=26 (15:11) n=9 (7:2) n=5 (2:3) n=15 (9:6)
Age 39.67 (9.87) 54.88 (14.95) t (27) = -1.717, p = n.s. 40.44 (9.89) 52.8 (19.29) 61.2 (10.8) F (2,26) = 8.076, p < 0.01 (s1 vs s3)
TMS 0.33 (0.58) 51.62 (24.41) t (27) = -3.536, p < 0.001 13.67 (13.41) 41.6 (7.09) 67.47 (17.5) F (2,26) = 35.993, p < 0.001 (all s.d)
TFC 13 (0) 6.65 (3.86) t (27) = 2.804, p < 0.01 12.67 (0.71) 8.4 (1.34) 3.73 (0.96) F (2,26) = 245.675, p < 0.001 (all s.d)
Functional scale 25.00 16.36 (6.73) t (26) = 2.188, p < 0.05 24.56 (0.88) 21.8 (0.44) 11 (3.37) F (2,25) = 91.172, p < 0.001 (s3 vs s1 and s2)
Independence 
scale
100.00 72.08 (17.93) t (25) = 2.65, p < 0.05 97.22 (6.67) 80 (0) 59.64 (9.9)
F (2,24) = 57.8, p < 0.001 (all)
CAG disease 
burden score
235.5 (24.56) 413.58 (84.85) t (26) = 3.563, p < 0.01 301.56 (79.41) 405.2 (70.96) 440.43 (71.39)
F (2,25) = 11.154, p < 0.001 (s1 vs s3)
Years of education 12.5 (0.71) 12.875 (3.91) t (16) = -0.132, p = n.s. 11.67 (1.63) 14 (5.66) 13.3 (4.37) F (2,15) = 0.451, p = n.s. 
BMI 30.93 (9.48) 26.12 (5.4) t (23) = 1.332, p = n.s 29.23 (6.4) 24.81 (6.07) 25.8 (5.56) F (2,22) = 1.119, p = n.s.
Group differencesPre-HD Group differences
TFC disease stage
C
3t
 b
as
el
in
e 
si
m
p
le
Manifest
Table 16: Part 2: C3t Demographic data 
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2.3.3.1 Testing the C3t in people with HD 
 
For clarity, a reference of the C3t test items are presented in Table 17. 
 
Table 17: C3t assessment procedure 
 
 
Measures reported in the results includes: time taken for items 1, 2, 4, 5; Total score, which 
combines time and any errors, for items 1, 4, 5; Correct letters of the alphabet recited per second 
for items 3 and 5. Where C3t = Clinch token transfer test. 
 
C3t performance scores and statistical outcomes between Group and TFC 
disease stage are presented in Table 18. 
 
Pre-HD subjects achieved significantly greater total scores compared to the 
manifest group, indicative of faster performance and fewer errors in the baseline 
simple, complex and dual task. There was no significant difference between Pre-HD 
and manifest subjects for the time taken to perform the C3t for the baseline simple, 
baseline complex, dual, value baseline or alphabet recited in the baseline or dual task.   
 
When subject data was grouped based on TFC disease stage, performance 
progressively and significantly slowed with HD progression (Figure 12a). The same 
pattern of results were true for C3t total score (Figure 12b).  For the value baseline, 
there was an overall significant effect, however following a Bonferroni post-hoc no 
significant differences were met between groups at any TFC disease stage. 
Performance results in the alphabet tests revealed that stage 1 subjects performed 
Test 
order
Dual task item Brief procedure
1 C3t baseline simple Transfer coins in order of size 
2 Value baseline Counting backwards from values presented
3 Alphabet baseline Recite the alphabet
4
C3t baseline 
complex
Transfer coins in order of value 
5 C3t dual Transfer coins in order of value and recite the alphabet
C3t
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significantly better than stage 3, but no differences between any other disease stage 
for the alphabet were detected (Figure 12c). 
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The mean test scores are recorded to 2 decimal places ± SEM. Groups were categorised as pre-HD (total functional capacity (TFC) = 13 and Unified Huntington’s 
Disease total motor score <5) and manifest (all symptomatic stages). The manifest group was further delineated by TFC disease stage (stage 1, TFC =11-13; stage 
2, TFC=7-10; stage 3,4, TFC=1-6). All measures in dark blue are recorded in seconds, where a greater score is indicative of worse performance. All measures in 
light blue show scores where a lower score is indicative of worse performance. Total score has no units and combines time taken with number of errors made. 
The alphabet is assessed as the number of correct letters of the alphabet recited per second. Dual task cost is shown in orange and presented as a percentage. 
A positive percentage is indicative of slower or worse dual task performance relative to baseline, whereas a negative dual task cost is indicative of better 
performance in the dual task compared to baseline. Significance was set so p < 0.05 and followed by a Bonferroni post-hoc test.   
Where TFC= total functional capacity; ANOVA = analysis of variance; bl = baseline; n.s. = not significant; s = stage; dtc = dual task cost; $ = A difference reported 
but following a post-hoc this need not reach significance between any particular group. 
t value (df) p value
F value (df, 
error) 
p value
Time bl simple (s) 15.16 ±  1.8 35.41 ±  4.05 -1.667(27) p = n.s. 17.12 ± 5.14 22.27 ± 6.89 46.71 ± 3.98 11.92(2,26) p < 0.001 s1 vs s3,4 p<0.001; s2 vs s3,4 p<0.05
Time bl complex (s) 15.53 ± 1.99 33.56 ± 4.6 -1.485(21) p = n.s. 17.3 ± 5.02 26.18 ± 6.74 47.91 ± 5.02 9.64(2,20) p < 0.001 s1 vs s3,4 p<0.001
Time bl dual (s) 16.15 ± 1.68 30.75 ± 2.91 -2.05(18) p = n.s. 18.86 ± 2.77 32.31 ± 3.71 39.98 ± 3.39 12.33(2,17) p < 0.001 s1 vs s2 p<0.05; s1 vs s3,4 p<0.001
Total bl simple 54.14 ±  5.78 28.95 ± 3.43 2.423(27) p < 0.05 50.8 ± 3.83 36.86 ± 5.13 18.25 ± 2.96 23.28(2,26) p < 0.001 s2 vs s1 and s3,4 p<0.001
Total bl complex 53.1 ±  6.26 29.04 ±  3.21 2.76(21) p < 0.05 47.57 ± 3.07 30.09 ± 4.12 17.95 ± 30.7 23.48(2,20) p < 0.001 s1 vs s2 p<0.01; s1 vs s3,4 p<0.001
Total bl dual 50.64 ± 5.39 28.11 ± 3.06 2.93(18) p < 0.01 43.58 ± 3.18 24.28 ± 4.27 19.36 ± 3.9 13.49(2,17) p < 0.001 s1 vs s2 p<0.05; s1 vs s3,4 p<0.001
Value time bl (s) 5.98 ± 1.15 10.77 ± 1.65 -1.098(21) p = n.s. 6.53 ± 2.24 7.77 ± 2.84 14.23 ± 2.01 3.73(2,20) p < 0.05
$ n.s.
Alphabet bl (letters/s) 2.54 ± 0.24 1.75 ± 0.25 0.609(22) p = n.s. 2.63 ± 0.37 2.02 ± 0.49 1.29 ± 0.28 4.25(2,26) p < 0.05 s1 vs s3,4 p<0.05
Alphabet dual (letters/s) 1.61 ± 0.47 1.24 ± 0.2 0.73(18) p = n.s. 1.86 ± 0.22 0.98 ± 0.29 0.71 ± 0.26 4.25(2,17) p < 0.01 s1 vs s3,4 p<0.05
time bl cost (%) 2.12 ± 2.13 11.51 ± 3.63 -0.978(21) p = n.s. 1.98 ± 4.86 14.52 ± 6.52 16.23 ± 4.86 2.42(2,20) p = n.s. /
time dtc (%) 6.1 ± 4.89 17.84 ± 4.03 -1.132(21) p = n.s. 9.47 ± 5.02 27.64 ± 6.74 16.35 ± 6.15 2.336(2,17) p = n.s. /
total bl cost (%) 2.12 ± 2.13 15.12 ± 4.35 -1.176(21) p = n.s. 3.17 ± 5.78 16.4 ± 7.75 22.04 ± 5.78 2.761(2,20) p = n.s. /
total dtc (%) 6.1 ± 4.89 23.59 ± 4.37 -1.621(21) p = n.s. 11.4 ± 5.32 34.55 ± 7.13 24.01 ± 6.51 3.54(2,17) p = n.s. (0.052) /
alphabet dtc (%) 76.3 ± 35.77 184.12 ± 54.78 -0.805(21) p = n.s. 50.85 ± 62.21 200.21 ± 83.46 316.71 ± 76.19 3.752(2,17) p < 0.05 s1 vs s3,4 p<0.05
C3t Pre-HD Manifest
t-test results
TFC stage
Pairwise compairsons
ANOVA results
Stage 1 Stage 2 Stage 3,4
Table 18: C3t performance scores 
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When dual task cost was calculated, stage 3,4 subjects were significantly 
slower and less accurate in the dual task condition of the alphabet task compared to 
stage 1 (Figure 12d). There was no difference between any other disease stages for 
any other C3t item. 
 
Results from a two way repeated measures ANOVA are presented in Table 19. 
This revealed that people in stages 2 and 3,4 took significantly longer to perform C3t 
dual task compared to the Baseline simple. People in Stage 3,4 also took significantly 
longer to perform the Baseline complex compared to the simple. There was no 
significant difference in the alphabet performance in the dual task, or the C3t total 
score in the Baseline complex or dual task.  
 
Table 19: C3t two way repeated measures ANOVA 
 
This table presents the results from a two way repeated measures ANOVA. If this returned as 
significant (where p < 0.05), a Bonferroni post-hoc was used to identify which disease stage this 
was relevant to. This is presented in the ‘Stages’ column. The results from this table and those 
presented in Table 18 revealed that Stage 2 and stage 3 performed the C3t significantly slower 
in the dual task compared to Baseline simple. Stage 3 were also significantly slower in the 
Baseline complex compared to the Baseline simple. C3t total and the alphabet performance did 
not significantly differ (n.s.) in the Baseline complex or dual task, when compared to the Baseline 
simple. C3t = Clinch token transfer test. 
 
 
 
Dual task item
Baseline simple vs 
Baseline complex
Stages
Baseline simple vs 
dual task
Stages
Time F(2,20)=4.677, p < 0.05 Stage 3: p < 0.001 F(2,17)=3.634, p < 0.05 Stage 2: p < 0.001 and Stage 3: p < 0.01
Total F(2,20)=0.498, p = n.s. / F(2,17)=1.202, p = n.s. /
Alphabet  no test / F(2,16)=0.244, p = n.s. /
C
3t
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Figure 12: C3t Version 1 bar graphs. Bar graphs represent the mean C3t performance with SEM error bars. Figure a-c present C3t performance across the 
Baseline simple, complex and dual task. Figure a shows time taken (seconds), where a lower score is indicative of better performance. Figure b shows C3t total 
score (no unit), where a higher score is indicative of better performance. Figure c shows alphabet scores (letters/second), where a higher score is indicative of 
better performance. Figure d presents the dual task cost (%), where a higher percentage is indicative of greater costs in the complex and dual tasks relative to 
baseline.  Where * p<0.05, ** p<0.01, *** p<0.001.  
 
dual task. Figure a shows time taken (seconds), where a lower score is indicative of better performance. Figure b shows C3t total score (no unit), where a 
 
higher score is indicative of better performance. Figure c shows alphabet scores (letters/second), where a higher score is indicative of better performance. 
 
* 
* 
** 
a) 
c) 
b) 
d) 
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2.3.3.2 How does the C3t and the lower limb dual task costs compare with 
HD specific measures? 
 
Correlation results are presented in Table 20. 
 
Performance in the C3t and the Step and Stroop items correlated with UHDRS 
assessments more so than the TUG and LVF and Walk and Talk. The C3t total simple 
and complex baseline tasks correlated with the UHDRS TFC, TMS, FAS and 
independence scores more than any other dual tasks. All C3t items, except for the 
value and alphabet tasks strongly correlated with the CAG score, SF-12 mental 
summary, PBA apathy and executive function. C3t baseline simple and complex time 
and total scores also correlated with the SF-12 physical summary. The LVF hard 
(baseline and dual), cadence, duration of double limb support, stride length CoV (dual 
hard) and alphabet hard dual task correlated with the least amount of HD specific and 
quality of life measures. There was no correlation between any hard baseline or dual 
item and the UHDRS or quality of life measures for the Walk and talk dual task. 
Cadence and duration of double limb support baseline and dual measures also 
correlated with few UHDRS and quality of life scores. 
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Table 20: Correlation between dual task items and HD specific and functional questionnaires 
 
 
UHDRS 
TMS
UHDRS 
TFC
UHDRS 
TFC stage
UHDRS 
FAS
UHDRS 
Independe
nce scale
UHDRS 
symbol 
digit 
correct
UHDRS 
LVF
UHDRS 
Stroop 
colour 
naming
UHDRS 
Stroop 
word 
reading
CAG score
SF-12 
physical 
summary
SF-12 
mental 
summary
PBA 
apathy
PBA 
executive 
function
C3t Time bl simple .706
**
-.717
**
.717
**
-.759
**
-.768
**
-.656
**
-.636
**
-.756
**
-.630
**
.566
** -.469 -.679
**
.669
**
.692
**
C3t Time bl complex .607
**
-.720
**
.807
**
-.603
**
-.685
**
-.625
**
-.613
**
-.716
**
-.515
*
.425
*
-.639
*
-.661
*
.760
**
.642
**
C3t Time dt .627
**
-.787
**
.762
**
-.598
**
-.678
**
-.697
**
-.592
**
-.828
**
-.650
** .261 -.477 -.602
*
.599
** .330
C3t total bl simple -.799
**
.829
**
-.803
**
.791
**
.827
**
.779
**
.740
**
.807
**
.702
**
-.645
** .494 .571
*
-.648
**
-.608
**
C3t total bl complex -.765
**
.835
**
-.853
**
.711
**
.778
**
.777
**
.753
**
.833
**
.710
**
-.600
**
.612
*
.674
*
-.666
**
-.533
*
C3t total dt -.706
**
.768
**
-.752
**
.583
**
.689
**
.751
**
.606
**
.758
**
.668
**
-.447
* .505 .634
*
-.565
** -.361
Value bl .583
**
-.558
**
.528
**
-.631
**
-.634
**
-.543
**
-.505
*
-.603
**
-.573
** .403 -.082 -.219 .532
*
.615
**
Alphabet bl -.399 .554
**
-.553
**
.454
*
.530
*
.431
*
.542
**
.449
* .404 -.446
* .142 .283 -.362 -.407
*
Alphabet dt -.419 .632
**
-.636
** .438 .506
*
.474
* .413 .638
**
.490
* -.301 .529 .518 -.395 -.189
TUG bl .479
**
-.496
**
.461
**
-.549
**
-.531
**
-.487
**
-.417
*
-.609
**
-.513
** .349 -.709
** -.225 .424
*
.445
*
TUG easy dt .657
**
-.756
**
.796
**
-.713
**
-.733
**
-.663
**
-.586
**
-.776
**
-.614
**
.455
*
-.643
** -.157 .653
**
.536
**
TUG hard dt .513
*
-.685
**
.753
**
-.578
*
-.655
**
-.561
* -.419 -.669
** -.418 .320 -.803
** -.566 .750
**
.556
*
LVF easy bl -.562
**
.428
* -.330 .384 .411
*
.601
**
.481
*
.518
**
.544
**
-.401
* .082 .036 -.184 -.074
LVF easy  dt -.630
**
.623
**
-.561
**
.617
**
.588
**
.612
**
.607
**
.718
**
.709
** -.276 .231 -.005 -.412
*
-.454
*
LVF hard  bl -.079 -.078 .098 .037 -.065 .131 .064 .144 .241 .052 .117 .259 .112 .341
LVF hard dt -.278 .355 -.384 .231 .213 .376 .286 .644
** .236 .000 .844
** .530 -.439 -.006
Step bl -.637
**
.690
**
-.667
**
.618
**
.631
**
.647
**
.655
**
.726
**
.666
**
-.566
**
.714
** .099 -.371
**
-.350
*
Step easy dt -.646
**
.680
**
-.652
**
.619
**
.622
**
.672
**
.663
**
.791
**
.729
**
-.538
**
.659
** .182 -.342
*
-.423
**
Step hard dt -.592
**
.670
**
-.677
**
.529
**
.518
**
.643
**
.617
**
.845
**
.686
**
-.445
**
.574
** .051 -.207 -.273
Stroop easy bl -.707
**
.755
**
-.707
**
.686
**
.736
**
.756
**
.710
**
.878
**
.831
**
-.497
**
.465
** .160 -.394
**
-.380
**
Stroop easy dt -.691
**
.749
**
-.746
**
.694
**
.694
**
.737
**
.679
**
.847
**
.795
**
-.552
**
.606
**
.372
*
-.397
**
-.497
**
Stroop hard bl -.695
**
.745
**
-.697
**
.640
**
.730
**
.785
**
.560
**
.810
**
.743
**
-.532
**
.415
* .071 -.346
* -.250
Stroop hard dt -.648
**
.759
**
-.744
**
.627
**
.635
**
.740
**
.638
**
.839
**
.733
**
-.487
**
.507
** .178 -.461
**
-.339
*
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*p<0.05 (light pink);**p<0.01 (dark pink). Unified Huntington’s disease rating scale (UHDRS); Total motor score (TMS); Total functional capacity (TFC); Functional 
assessment score (FAS); Letter verbal fluency (LVF); Short-form 12 (SF-12); Performance behaviour assessment (PBA); Clinch token transfer test (C3t); baseline 
(bl); dual task (dt); Timed Up and Go (TUG); Coefficient variation (CoV). 
.
UHDRS 
TMS
UHDRS 
TFC
UHDRS 
TFC stage
UHDRS 
FAS
UHDRS 
Independe
nce scale
UHDRS 
symbol 
digit 
correct
UHDRS 
LVF
UHDRS 
Stroop 
colour 
naming
UHDRS 
Stroop 
word 
reading
CAG score
SF-12 
physical 
summary
SF-12 
mental 
summary
PBA 
apathy
PBA 
executive 
function
Velocity bl -.569
**
.676
**
-.645
**
.627
**
.638
**
.679
**
.540
**
.664
**
.611
**
-.462
*
.677
** .290 -.513
**
-.459
**
Velocity easy dt -.621
**
.731
**
-.707
**
.608
**
.640
**
.674
**
.581
**
.736
**
.609
**
-.429
*
.752
** .334 -.557
**
-.518
**
Velocity hard dt -.335 .438 -.352 .348 .375 .576
** .232 .617
** .453 -.265 .356 -.061 -.311 -.120
Cadence bl -.109 .235 -.241 .146 .216 .278 .211 .087 .186 -.044 .246 -.141 -.224 -.205
Cadence easy dt -.020 .151 -.201 -.005 .035 .112 .188 .172 .097 .011 .433 -.052 -.250 -.300
Cadence hard dt -.327 .477
* -.417 .370 .394 .429 .267 .590
* .403 -.235 .435 -.212 -.141 -.072
Duration of double limb 
support bl
.279 -.241 .200 -.396
* -.343 -.288 -.186 -.266 -.302 .403
* -.383 -.185 .100 .095
Duration of double limb 
support easy dt
.352 -.301 .241 -.346 -.387 -.230 -.239 -.217 -.269 .270 -.549
* -.335 .031 .033
Duration of double limb 
support hard dt
.049 -.022 -.101 -.005 -.171 -.243 .171 -.132 -.035 -.024 .000 .371 -.120 -.056
Stride length CoV bl .528
**
-.517
**
.471
**
-.621
**
-.540
**
-.466
**
-.391
*
-.393
*
-.513
**
.576
**
-.506
* -.209 .217 .340
Stride length CoV easy 
dt
.485
**
-.510
**
.454
*
-.470
*
-.523
** -.366 -.295 -.409
* -.340 .347 -.409 -.212 .191 .196
Stride length CoV hard 
dt
.111 -.120 .010 -.089 -.098 -.340 .063 -.232 -.134 .075 .097 .305 .320 .095
Alphabet easy bl -.482
**
.567
**
-.566
**
.465
*
.530
**
.392
*
.570
**
.458
*
.398
*
-.545
** .427 -.146 -.371 -.320
Alphabet easy dt -.481
*
.590
**
-.621
**
.520
*
.524
* .406 .467
* .426 .451
* -.231 .570 .395 -.388 -.373
Alphabet hard bl -.514
*
.529
*
-.502
*
.464
*
.521
*
.538
*
.608
**
.648
**
.603
**
-.609
** .265 -.416 -.295 -.294
Alphabet hard dt -.404 .414 -.364 .238 .375 .538
* .264 .711
** .446 -.249 .188 -.406 -.105 -.018
W
al
k 
an
d
 t
al
k
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2.3.4 Discussion 
 
The C3t was developed to supply clinicians and researchers with a functional 
upper limb assessment specific to the symptoms that manifest in HD. The C3t assessment 
consisted of five primary items, where performance in three were of primary interest: the 
C3t Baseline simple, Baseline complex and the dual task. Together, the C3t was designed 
so it was quick to perform and easy to set up. It also used a quantitative rating method to 
score performance to improve reliability and test sensitivity. Performance was not only 
sensitive to disease stage but it also significantly correlated with all the UHDRS measures, 
equally to the Step and Stroop items and more than the TUG and LVF, and the Walk and 
talk dual tasks used in Part 1. 
 
The primary finding in this study was that people in the more advanced disease 
stages took significantly longer to perform the C3t, compared to stage 1 and stage 2 in 
the Baseline simple task. Importantly performance in the C3t dual task revealed that 
people in stage 1 performed significantly faster than stage 2. This was evident in the C3t 
Baseline complex and the dual task when differences between C3t total score were 
analysed, rather than just time taken alone. This suggests that the C3t could be a useful 
outcome measure for clinical trials, as developing therapeutics typically aim to target 
people in the early stages of HD (Kumar et al., 2015). One explanation for this 
performance deterioration is motor impairment due degeneration of basal ganglia 
circuitry. This has been shown to affect dextrous movements when grasping small food 
items in people with HD (Klein et al., 2011). Furthermore, the lateral striatum is implicated 
in such movements, as rats with unilateral quinolinic acid lesions to this region are 
impaired in a grasping and dexterity task when using their paw contralateral to the lesion, 
whilst maintaining performance on the ipsilateral side (Montoya et al., 1991; Döbrössy 
and Dunnett, 2003, 2004).  Importantly, previous studies have shown that performance 
in such grasping and dexterity tasks gradually improves following cell replacement 
therapy to the lesioned striatum (Döbrössy and Dunnett, 2003; M. D. Döbrössy and 
Dunnett, 2005). This suggests that the C3t could be a useful outcome measure to quantify 
changes following therapies that specifically target the striatum, such as cell replacement 
therapies. Additional explanations behind performance deterioration in the advancing 
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disease stages is acknowledged in Chapter 3, which describes the development and 
validation of a new standardised C3t. 
 
The results in this study also revealed that task complexity had an impact on C3t 
performance. For instance, people in stage 3,4 performed both the C3t Baseline complex 
and the dual task significantly slower than the Baseline simple. Whereas, people in stage 
2 performed the C3t significantly slower in just the dual task, and performance in stage 1 
did not significantly differ between any assessment item. This suggests that adding task 
complexity is a useful way to tease apart performance differences in different disease 
stages in HD (Vaportzis et al., 2014; Stout, Glikmann-Johnston and Andrews, 2016). The 
results also revealed that there was no significant difference in alphabet rate from 
baseline performance to the dual task, suggesting that people with HD might prioritise 
cognitive tasks when performing two tasks simultaneously. This could have negative 
implications when performing complex upper limb tasks at home. For example, using 
sharp utensils in the kitchen whilst talking, could lead to an increased risk of injury, if more 
attentional resources are allocated to the cognitive (talking) task.  A larger sample size is 
required to see if these findings are consistent.  
  
Findings from this study also revealed that performance in the C3t and the Step 
and Stroop dual tasks significantly correlated with HD specific measures including the 
UHDRS motor, cognitive, behavioural and functional questionnaires, as well as the SF-12 
and PBA measures, more than the TUG and LVF and the Walk and talk. Furthermore, C3t 
performance based on time and accuracy (C3t total) correlated better with all UHDRS 
measures and teased apart disease stage more so than time taken alone. In addition, the 
dual task assessment items in the Step and Stroop and C3t significantly correlated with 
the CAG disease burden score (Penney et al., 1997), suggesting that assessment items 
from both dual tasks were sensitive to disease progression in HD. 
 
Although the C3t could provide clinicians and researchers with a functional upper 
limb outcome measure for people with HD, there are a number of limitations that could 
restrict its use across other clinical sites. For example, the current C3t setup uses British 
coins. Although, the results in this study were sensitive to disease stage, the same result 
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might not apply to clinics where the British currency is less familiar. This could lead to 
longer performance times and less people ‘passing’ to the more complex C3t items. In 
addition, the current setup is not standardised and so the set up may vary in consistency, 
which could lead to more unreliable results.  
 
 
Assessing dual tasks in HD  Chapter 2: Part 2 
117 
 
2.4 Conclusions and future work 
 
The findings in this Chapter revealed that dual task interference and prioritisation 
strategies may differ in HD depending on the dual task carried out. Where some 
prioritised the motor task over the cognitive (Step and Stroop), whereas the opposite 
relationship was true for the TUG and LVF. Furthermore, mutual interference was more 
evident in the Walk and talk and the Clinch token transfer test (C3t).   
 
The dual tasks selected and developed in Part 1 revealed that the Step and Stroop 
best distinguished between disease stage, more so than the TUG and LVF and the Walk 
and Talk. As these were being developed, it became evident that current upper limb 
functional assessments for people with HD are limited. This led to a second study that ran 
in parallel, in which a new upper limb dual task assessment was developed (Part 2) and 
was called the Clinch token transfer test (C3t). This consists of three main assessment 
items which were designed to test bilateral dexterity with increasing task difficulty. 
Performance in this task revealed that people with HD were significantly slower 
performing the C3t as HD progressed, and with increasing task difficulty. Further analysis 
revealed that both the Step and Stroop and the C3t significantly correlated with HD 
specific measures and did so more than the TUG and LVF, and the Walk and Talk. 
 
This study is the first to examine differences in dual task performance across 
different stages of HD. This led to a limitation of the studies consisting of relatively small 
group sizes. Further validation will therefore require larger group sizes. Another limitation 
were potential practice effects. As the assessment items in each dual task were performed 
more than once, and in a short period of time, this may have led to results improving or 
stabilizing (Reeves et al., 2007). One way to truly assess dual task interference in the 
future would be to counterbalance the baseline and dual task assessment items, or leave 
a longer period between the baseline and the dual task. As a priority in this study was to 
ensure subjects could perform the baseline task before proceeding to the dual task, 
counterbalancing was not an option.  
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The findings in this study provide evidence that the C3t and the Step and Stroop are 
suitable upper limb and lower limb functional outcome measures for people with all 
stages of HD. In addition, performance in the C3t was able to tease apart people in early 
disease stages (stage 1 and stage 2). Distinguishing performance differences within the 
early stages of HD is of particular interest as this group is most likely to be amendable to 
neuroprotective treatment (Reetz, Werner and Schiefer, 2015). Therefore, the C3t may 
be suitable for inclusion in assessment batteries for novel interventions, such as cell 
transplantation. Prior to this, it is important that some of the design issues associated with 
the C3t are overcome, such as minimizing cultural bias associated with British coins, and 
standardising the C3t setup. Therefore, the study in Chapter 3 was developed to 
overcome some of these fundamental issues, as well as validating the new C3t design in 
a larger cohort of people with HD.  
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Chapter 3 
Validating a new functional dexterity assessment for 
people with Huntington’s disease 
 
 
 
Chapter Summary 
 
The findings in Chapter 2 revealed that the Clinch token transfer test (C3t) could be a useful 
functional, upper limb assessment for people with HD. However, given that the C3t setup 
was not standardised, this meant that using the C3t in other clinical sites would lack 
consistency and decrease the reliability of this assessment. Therefore, the aim of this 
Chapter was to standardise the new C3t design (C3t version 2; Part 1), evaluate and 
optimise the C3t v2 in people gene positive with HD (Part 2), and validate this a large group 
of people with HD and healthy controls (Part 3). 
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3.1 Introduction 
 
Selecting appropriate outcome measures plays an essential role to assess 
change in symptoms over time, assist with disease diagnosis or determine the 
effectiveness of a treatment (Williamson et al., 2012; Iansek and Morris, 2013). 
However, the usefulness of an outcome hinges on the population being tested and the 
question being asked. To establish this, selecting outcome measures that have known 
clinometric properties is desirable (Iansek and Morris, 2013) (See Chapter 1, Section 
1.3.1). These are used to assess the quality of an assessment, which includes important 
questions that should be considered, such as cost and length of time to perform, as 
well as important properties such as validity and reliability (Kimberlin and Winterstein, 
2008) (refer to Chapter 1,Table 1).  
 
Validity is the extent to which an assessment measures what it is intended to 
measure (Kimberlin and Winterstein, 2008). An assessment that is valid suggests that; 
when it  is used for a specific purpose, such as in a certain population, the outcomes 
are free from error. Different types of validity exist to measure the extent of these 
possible errors, and these can be divided into three categories: internal, external and 
test validity. Furthermore, each of these form subcategories and are described in 
Chapter 1 (Figure 6). Another important factor is to measure how reliable, or how 
consistent, the outcomes from an assessment are (Portney and Watkins, 2009). For 
example, when developing a new assessment it is important to ensure that the rater 
is not subject to bias and remains consistent scoring an assessment when there are no 
change in symptoms.  Reliability is also important to measure the chance of practice 
effects, which can be a problem if a patient repeatedly performs an assessment and 
becomes over familiar with the assessment procedure (Reeves et al., 2007). As a result, 
improvements are not reflective of a change in symptoms but instead a gradual 
improvement in the general test procedure. Therefore measuring test-retest reliability 
in a population where no treatment is being assessed to compare assessment 
outcomes when no symptoms are expected to have changed is important (Kimberlin 
and Winterstein, 2008).  
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In Chapter 2, a new upper limb, functional assessment was developed to 
overcome the lack of upper limb functional assessments available for people with HD. 
This was called the Clinch Token Transfer Test (C3t), and involved 3 primary 
assessment items, which involved; transferring British coins into a moneybox slot in 
order of size (baseline simple) and value, without and whilst reciting the alphabet 
(baseline complex and dual task). This was developed so each item performed was 
more complex than the last. This was used as a way to tease apart people with 
different levels of functional ability and therefore, different stages in HD. Furthermore, 
to reduce the chances of floor and ceiling effects, each assessment item consisted of 
set criteria that the participant had to meet before continuing to the next complex 
assessment item. To reduce observer bias, C3t performance was rated using a specially 
developed C3t total score, which was calculated by combining both time taken to 
perform the C3t and performance accuracy. The findings in Chapter 2, suggest that the 
C3t could have potential to distinguish between different disease stages in HD. 
Furthermore, C3t performance scores significantly correlated with the UHDRS 
assessments. To overcome some of the constraints associated with C3t in Chapter 2, 
the aim of the study in this Chapter was to develop and validate a new standardised 
version of the C3t (C3t v2) in a larger cohort of people with HD, and to assess how 
these scores differ, compared to a healthy control group.  
 
The data in this Chapter developed iteratively and formed three stages: 
i. Part 1: Standardising the C3t 
ii. Part 2: Testing and Optimising the C3t v2a 
iii. Part 3: Validating the C3t v2b 
 
Part 2 and Part 3 contain methods and results. These were conducted as part of 
one protocol. The methodology is therefore only described in detail in Part 2 and 
referred to where necessary in Part 3. A short summary is presented after Part 2 and 
a general discussion is presented at the end of this Chapter. 
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3.2 Part 1: Standardising the C3t  
 
The results in Chapter 2 revealed that C3t performance could distinguish between 
different stages of HD, and that results significantly correlated with scores from the 
UHDRS. Although the original C3t test setup provided proof of concept, it was limited 
due to its unstandardised setup, meaning as a clinical outcome measure, the setup was 
not easily reproducible if it was used across different clinical sites. For instance, the 
moneybox used in Chapter 2 consisted of a moneybox slot carved in the base of a tin 
can. Although this moneybox was not ideal, it was purposely chosen so, if the C3t was 
used across other clinical sites, a moneybox with the same dimensions could be easily 
accessed and purchased or easily made. Another limitation was the use of British coins. 
This meant the assessment was biased towards those that were largely familiar with 
this currency. Not only could this influence performance accuracy and the time to 
perform the C3t, but it also limited the number of countries the C3t could be used in.  
Following the achievement of Strategic Development Funding (Cardiff University), a 
standardised version of the C3t was developed (C3t version (v)2). From this the aim 
was to meet criteria according to the clinometric table presented in Chapter 1 (Table 
1). The key criteria included: 
 
i. The dimensions and general setup of the C3t v2 were the same as the original 
C3t 
ii. The setup was standardised 
iii. Compact when not in use 
iv. Robust and cost effective 
v. Easy to use 
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To achieve the criteria set, the following changes were made:  
 
i. The dimensions and general set up the same as the original C3t 
For the C3t v2, new tokens and a new moneybox were designed and manufactured 
(Figure 13). A primary aim was for the C3t v2 to closely resemble the old assessment. 
This was to ensure that the results achieved in Chapter 2 remained as sensitive (if not 
more so) than the old version. This meant that the height of the moneybox, the size of 
the moneybox slot, the size of the tokens and the distance between the position of the 
tokens and the moneybox slot, remained the same between the two assessment 
versions. In addition, the values printed on the new tokens were 200, 100, 50, 20, 10, 
5, 2, 1, which were the same as those presented in the Value baseline of the original 
C3t.   
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Figure 13: The C3t original set up (C3t v1) and the standardised set up (C3t v2). The dimensions of each test component remained the same between the 
unstandardised and standardised C3t.   
 
C3t v1 (before) C3t v2 (after) 
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ii. Standardised set up: 
To ensure the C3t set up remained consistent each time it was used, it was 
important that the test components were always positioned in a fixed location. This 
was achieved in a number of ways. To guarantee the distance between the tokens and 
the moneybox slot was fixed, shallow grooves were carved into a ‘money tray’ which 
was positioned within a tiled frame on the test board (Figure 14). The grooves in the 
money tray also meant that the tokens were less likely to slip out of position if they 
were knocked during testing. One important consideration was to ensure that the 
grooves on the money tray did not make it harder for the participant to retrieve the 
tokens, which may have affected the performance results. Therefore, different token 
groove depths were trialled to prevent this from being a problem. For the moneybox, 
a space within a platform was designed which ensured the moneybox was positioned 
in a fixed location (Figure 15). As the moneybox fitted inside the platform, rather than 
on top of it, this also provided stability, meaning if it was knocked during testing it did 
not fall over or out of place. Another important change in the C3t v2 was to 
manufacture tokens in place of British coins. This was to ensure the C3t could be used 
across sites outside of the UK to minimise bias.
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Tiled frames 
Figure 14: The money card without and with the tokens in position. Shallow grooves were carved 
into the money card meant that the position of each token was always fixed in the same 
location. In addition, tiled frames fixed the money card into position, meaning that the distance 
between the tokens and the moneybox always remained the same. 
Figure 15: The moneybox fitted in a set location within a moneybox platform. As the moneybox fitted 
inside the platform, this meant that the platform walls ensured the moneybox remained in position 
if it was knocked during the testing procedure. 
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iii. Compact when not in use 
The design of the C3t v2 specifically considered storage and transportation requirements, 
as all test components were housed within the C3t box to enhance the clinical utility (Figure 
16). 
 
 
 
iv. Robust and cost effective 
It was important that the materials used to make the test components were strong 
to minimise breakage with repeated use and therefore maximising its longevity.  
However, the number of materials that could be used were limited as it was also 
important that the C3t components were cost effective. As a result, the C3t v2 was 
made of a mix of dense cardboard and plastic.  
Figure 16: The C3t v2 is compact and could easily be folded away whilst storing all of the assessment 
components when it was not in use. 
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v. Easy to use: 
An important component of the C3t v2 was the design of the outer box. This 
needed to be large enough to house all of the assessment components, but also 
compact so it could be easily stored when it was not in use. As a result, it was important 
to minimise the number of assessment components so the outer box did not have to 
house numerous parts. For example, when the C3t v2 was folded away, the tokens 
were housed inside the moneybox. This was designed so the base of the moneybox 
opened to access the tokens (Figure 17). In addition, when the C3t v2 was in use, the 
outer box opened and formed part of the testing board. To ensure the walls of the 
outer test box did not obstruct the subject from picking up the tokens, the outer walls 
on the one side of the test box folded down, meaning the subject could easily access 
the tokens (Figure 18). 
 
To aid the efficiency of the C3t setup, a dot reference was printed on the side of 
each token which matched the number of dots printed in one of the grooves on the 
money card. This meant that the researcher could easily locate the placement of each 
token (Figure 14).  
 
The C3t v2 was also designed so it considered left and right handed people. 
Therefore, before performing the C3t, participants were asked whether they were left 
or right handed. For right handed people, the moneybox was positioned on the right 
side of the test box (Figure 18). If the subject was left handed, the test board was 
rotated 180 degrees. A different money card was also used to ensure the tokens were 
still positioned from largest to smallest and maintained the same distance from the 
moneybox as the right handed setup.  
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Figure 17: The moneybox was designed so the base could easily open to retrieve the tokens 
during testing, whilst also providing storage for the tokens when the C3t was not in use.   
Figure 18: C3t v2 complete setup: The C3t set up. The edges of the outer box folded down on the 
side of the tokens. This meant that the edges did not obstruct the participant from accessing 
the tokens when performing the C3t. These edges only folded down on the side of the tokens, 
but remained fixed upright on the side of the moneybox. This allowed the C3t to fold, forming a 
rigid box when it was not in use. 
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3.3 Part 2: Testing and optimising the C3t v2 
 
The aim of this section was to test the design of the new C3t v2 in people gene 
positive with HD. 
 
3.3.1 Methods 
3.3.1.1  Design 
 
This research was a cross sectional, observational study.  
 
3.3.1.2  Setting  
 
People with HD were recruited from the South Wales HD research and 
management clinic. Recruitment began in September 2015 and continued to February 
2016.  
 
Ethical approval was obtained from South East Wales Research Ethics 
Committee (REC reference: 14/WA/1195).  Many patients attending the HD clinic were 
already enrolled in the ENROLL-HD study (04//WSE05/89), and so their disease 
progression had been followed for a number of years. One of the optional components 
within the ENROLL-HD study was permission by participants to be contacted about 
other additional and affiliated HD research projects. In consenting to be enrolled in the 
ENROLL-HD study, participants also gave their permission for their unidentifiable data 
to be accessed by researchers conducting other HD related research.    
 
Potential participants were approached at the beginning of clinic and if 
interested were given an information sheet on the study. Participants were then given 
as much time as needed to decide if they wanted to take part and were later 
approached to discuss the study and asked if they would like to participate. If the 
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participant was happy to proceed, they were asked to sign a consent form prior to 
participation. Potential participants also had the option to take part in the study at a 
future clinic visit.   
 
3.3.1.3 Participants 
 
The aim of this study was to recruit was to recruit all people gene positive for HD.  
 
 Inclusion criteria for people with HD 
1) Confirmed to carry the HD gene through genetic testing 
2) Aged 18 years or above 
3) Enrolled in the ENROLL-HD study 
 
Exclusion criteria for all participants 
1) Inability to provide informed consent 
2) Any comorbid condition that had the potential to confound the results of the   
study 
 
3.3.1.4  Procedure 
 
The C3t procedure is presented in Table 21 (Figure 19). In each C3t item, there 
were set criteria developed that the participant had to meet before proceeding to the 
next, more complex item. The full assessment setup, procedure and instructions can 
be located in Appendix 13.  
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Table 21: C3t V2 assessment items and procedure 
 
The C3t assessment items were always performed in the order presented here.  C3t = Clinch 
token transfer test.  
 
 
3.3.1.5  Rating C3t performance 
 
All participants recruited were video recorded whilst performing the C3t. The 
rating procedure for the C3t remained the same as those described in Chapter 2 
(Section 2.3.1.3). Briefly, the time taken to complete the C3t baseline simple, complex 
and dual task was recorded. Participants were asked to start with their hands placed 
on their legs. As soon as they were instructed to “Go,” the stopwatch started, and 
Test 
order 
C3t item Procedure
1
C3t baseline 
simple
The subject was asked to transfer tokens in order of size as quickly as possible.
2 Value baseline
Whilst sitting the subject is presented with 8 values (50, 5, 10, 100, 200, 20, 2, 1) printed
on a laminated card placed in front of them. The subject is asked to say aloud the highest
value working their way in order to the lowest value.
3
Alphabet 
baseline
Whilst sitting the subject was asked to recite the alphabet as quickly as possible.
4
C3t baseline 
complex
The same procedure as (1) but tokens presented had values printed on them. The
subject was asked to transfer tokens in value order starting with the highest value token
to the lowest.
5 C3t dual task
The subject was asked to simultaneously and continuously recite the alphabet as quickly
as possible whilst performing the same C3t procedure as (4). Tokens were presented in a
different order to prevent practise effects.
 
Figure 19: C3t procedure. This involved picking up tokens of different size, transferring 
them between hands and putting them into a moneybox. 
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stopped as soon as the last token was released into the moneybox. If an error was 
committed (presented in Table 22) then this was recorded and contributed to the C3t 
total score calculation. The C3t total score took the time taken to perform the C3t, the 
number of errors committed and any dropped tokens into account, resulting in a unit-
less score which tend to fall in between 0-100 (refer to Chapter 2, Section 2.3.1.3, 
Equation 2: C3t total score). To measure the alphabet performance, the rate of correct 
letters said per second were calculated in the alphabet baseline and the C3t dual task.  
 
 
Any errors committed during the C3t performance were recorded and were recognised when 
calculated in the C3t total score (Section 2.3.1.3).  
 
 
3.3.1.6 Additional data collected 
 
As part of the ENROLL-HD assessment, participants had already supplied 
demographic data, current medications, and were assessed on the UHDRS 
assessments, including the UHDRS-TMS, UHDRS-TFC, UHDRS Cognitive score, UHDRS 
Functional Assessment scale, UHDRS independence scale, Short Form-12 (SF-12) and 
Problem Behaviour Assessment (PBA). This data was collected routinely as part of the 
participant’s Registry/ENROLL-HD assessment.  
 
3.3.1.7 Statistical Analysis 
 
SPSS version 20 (PASW) (IBM Corporation, USA) was used to evaluate the 
results of the study. 
 
Error Type Error meaning
Transfer error
The subject fails to transfer tokens between 
hands.
Value error
The subject transfers the tokens in an 
incorrect size or value order.
Dropping a 
token
The token falls or rolls outside the test box.
Table 22: C3t v2 error meanings 
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Demographic data, UHDRS scores and C3t performance (C3t time taken and 
C3t total) were evaluated using the mean and standard error of the mean (SEM).  
 
A two way repeated measures analysis of variance (ANOVA) was used to see if 
participant performance significantly differed with increasing task difficulty. Between 
subject factors included TFC stage (TFC scores: 11–13, stage 1 (earliest symptomatic 
stage); 7–10, stage 2; 3–6, stage 3; 1–2, stage 4; and score of 0 is stage 5 (most 
advanced stage).  Within-subject factors included C3t time (Time), C3t total score (C3t 
Total) and C3t item (C3t baseline simple, C3t baseline complex, C3t dual task).  If the 
sphericity assumption was not met (P<0.05), this was corrected using the Greenhouse-
Geisser test. 
 
A Bonferroni post hoc test was used for all tests if results were deemed 
statistically significant (p<0.05). 
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3.3.2 Results 
3.3.2.1 Participants 
 
Demographic information for the participants recruited in the C3t baseline are 
presented in Table 23. Twenty-one people consented to take part in the study from 
which fourteen people completed the C3t assessment. The number of people in each 
group that completed each item of the C3t are presented in Appendix 1. People in 
stage 3 and 4 were combined to form one group (stage 3,4) as only one stage 4 subject 
was recruited. There was no significant difference between CAG disease burden score, 
years of education or body mass index. Stage 1 were significantly younger than stage 
2 and stage 3.   
 
 
 
The table presents the mean demographics with the standard error of the means. Groups were 
categorised by pre-HD (TMS < 5 ) and manifest HD (TMS > 5). The HD groups were further 
categorised to form 3 groups which included stage 1, TFC =11-13; stage 2, TFC=7-10; stage 3,4 
TFC=1-6). A t-test was performed to identify group differences between pre-HD and manifest 
subjects. To identify group differences between controls and TFC disease stage, a one way 
ANOVA was performed with Group as a between subject factor and demographics as a within 
subject factor. If this met significance then a Bonferroni post-hoc was performed. Significance 
was met when p < 0.05. Where C3t = Clinch token transfer test; TMS = total motor score; TFC = 
total functional capacity; MBI = body mass index; n.s. = not significant. 
 
 
1 2 3,4
n (male:female) 3 (1:2) 18 (12:6) 9 (3:6) 7 (7:0) 5 (3:2)
Age 33.67 (0.88) 51.25 (3.48) t (21) = -1.917, p = n.s. 36.78 (4.22) 57.67 (4.22) 55.2 (5.66) F (2,20) = 6.91, p < 0.01 (s1 vs s2 and s3)
TMS 2.33 (0.33) 37.15 (5.48) t (21) = -2.414, p < 0.05 9.33 (5.96) 45.11 (5.96) 52 (8) F (2,20) = 12.77, p < 0.001 (s1 vs s2 and s3)
TFC 13 (0) 8.5 (0.77) t (21) = 2.211, p < 0.05 12.67 (0.41) 8.22 (0.41) 4 (0.55) F (2,20) = 83.28, p < 0.001 (All stages)
Functional scale 25 (0) 37.15 (5.48) t (21) = 1.869, p = n.s. 24.44 (0.98) 19.56 (0.98) 13.2 (1.32) F (2,20) = 23.70, p < 0.001 (All stages)
Independence 
scale
100 (0) 80.79 (3.51) t (20) = 2.13, p < 0.05 97.78 (2.94) 77.78 (2.94) 63.75 (4.41) F (2,19) = 23.69, p < 0.001 (All stages)
CAG disease 
burden score
219.5 (42.11) 369.03 (19.45) t (19) = -2.94, p < 0.01 300.94 (30.03) 394.63 (31.85) 358.88 (45.04) F (2,18) = 2.33, p = n.s.
Years of education 13.33 (2.33) 11.68 (0.68) t (20) = 0.855, p = n.s. 12.33 (1.07) 11.56 (1.07) 11.75 (1.61) F (2,19) = 0.137, p = n.s. 
BMI 31.9 (2.79) 29.31 (1.7) t (20) = 0.579, p = n.s. 30.44 (2.61) 29.73 (2.46) 28.32 (3.3) F (2,19) = 0.127, p = n.s. 
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Table 23: C3t v2b Participant demographics 
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3.3.2.2 Testing the C3t v2 
 
Half way through this study, C3t v2 test results were analysed to see if task 
complexity had an impact on C3t performance scores (See Table 24). This revealed 
people in stage 3,4 performed significantly slower in the Baseline complex relative to 
the Baseline Simple, but no difference in C3t total score. There was no difference in 
time or C3t total score between the Baseline Simple and Baseline complex for Stage 1 
or Stage 2. There was also no difference in time taken or C3t total score in the Dual 
task relative to Baseline complex for any disease stage.  
  
C3t = Clinch token transfer test. The C3t time was measured in seconds (light blue), where a 
lower score was indicative of better performance. The C3t total had no unit (dark blue), but a 
greater score was indicative of better performance.   
 
 
1 2 3,4
C3t Baseline Simple time 20.09 ± 4.35 28.7 ± 4.61 49.25 ± 5.83
C3t Baseline Complex time 20.6 ± 6.51 25.26 ± 7.3 57.77 ± 13.63
C3t Dual task time 21.43 ± 1.95 24.42 ± 2.39 44.68 ± 5.85
C3t Baseline Simple total 42.19 ± 3.5 31.12 ± 3.71 18.34 ± 4.69
C3t Baseline Complex total 41.45 ± 3.1 33.15 ± 3.51 13.46 ± 5.36
C3t Dual task total 39.97 ± 3.6 33.91 ± 4.4 17.91 ± 10.79
Baseline Simple vs Baseline Complex time 
Baseline Simple vs Dual task time
Baseline Simple vs Baseline Complex total
Baseline Simple vs Dual task time
C3t item
F(2,16) = 7.8, p<0.01; Stage 3 p<0.01
F(2,13) = 0.78, p = n.s.
F(2,16) = 0.641, p = n.s.
F(2,13) = 0.972, p = n.s.
TFC stage
Table 24: C3t v2 performance scores 
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3.3.2.3 Optimising the C3t v2 
 
As test difficulty did not have a significant effect on C3t performance for Stage 
1 and Stage 2, this suggests that participants were not finding the Baseline Complex or 
Dual task items any more difficult than the Baseline Simple. One explanation for this 
may be that participants became over familiar with the order that the tokens were 
presented in, and so instead of getting slower or less accurate with increasing task 
difficulty, they were stabilising. To reduce the chances of practice effects, different 
tokens were designed for the Baseline Simple and the Dual task. In this optimised 
version (C3t v2b), in the Baseline simple, no values were printed on the tokens (Figure 
20). In the Baseline Complex and the Dual task, the same values were used but they 
were presented in a different order on the money card.  
 
 
C3t Baseline Simple C3t Baseline Complex C3t Dual task 
Figure 20: C3t v2 money cards: The new token design for the C3t v2b. Tokens for the C3t Baseline 
Simple had no values printed on them. The C3t Baseline Complex and Dual task had the same 
values printed but were presented in a different order to each other. 
The C3t  Chapter 3: Part 3 
138 
 
3.4 Part 3: Validating the C3t v2b  
 
The aim of this study was to validate the C3t v2b in healthy controls and people 
gene positive with HD. 
 
3.4.1 Methods 
 
The methods followed in this study were part of the same protocol as those 
for Part 2 (Section 3.3.1). Sections that followed the same procedure as those 
described earlier are referred to where necessary.  
 
3.4.1.1 Design 
 
This research was a cross sectional, observational study. A subset of 
participants recruited were given the option to return 6 ± 2 weeks to redo the 
assessment.  
 
3.4.1.2 Setting  
 
People with HD were recruited from the Cardiff HD research and management 
clinic. Recruitment began in February 2016 and continued to January 2017. The 
remaining settings were the same as Part 2 (Section 3.3.1.2). 
 
3.4.1.3 Participants 
 
The aim of this study was to recruit was to recruit healthy controls and all 
people gene positive for HD. The inclusion and exclusion criteria for people with HD 
was the same as Part 2 (Section 3.3.1.3). 
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Inclusion criteria for healthy control participants 
1) Cannot be at risk for HD 
2) Aged 18 years or above 
 
Exclusion criteria for all participants 
1) Inability to provide informed consent 
2) Any comorbid condition that had the potential to confound the results of the   
study 
 
3.4.1.4 Dual task procedures 
 
The C3t procedure was the same as Part 2 (Section 3.3.1.4).  
 
3.4.1.5 Rating performance 
 
This was the same as Part 2 (Section 3.3.1.5). In addition, to calculate the change in 
performance in the Baseline Complex and the Dual task relative to baseline, the dual 
task cost (DTC) was calculated and expressed as percentage change. This was 
calculated in the same way as described in Chapter 2 (Section 2.2.2.5). This value could 
be positive or negative. For example, if the participant performed the C3t faster in the 
baseline simple relative to the dual task, then the DTC would be positive. If the 
participant performed the C3t faster in the dual task, compared to the baseline simple, 
then the DTC would be negative. DTC was calculated using the following equation: 
 
                   Dual task – Baseline task 
Baseline task 
 
x 100   = Dual task cost 
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3.4.1.6 Additional data collected 
 
This was the same as Part 2 (Section 3.3.1.6). The functional component of the 
Late-Life Functional Disability Instrument (LL-FDI) was used also collected in this study 
(Haley et al., 2002). This is a 32 item questionnaire that focuses on functional day to 
day activities such as using kitchen utensils to prepare meals, and getting into and out 
of a car and was used to see how the C3t correlated with self-reported performance 
in tasks related to daily living. This was rated on an ordinal scale ranging from no 
difficulty (=0) to cannot do (=5) (See Section 1.3.2.5 for more information on the LL-
FDI). A subset of participants also performed the Step and Stroop, described in Chapter 
2. A brief description of the Step and Stroop is presented in Table 25.  
 
  
The number of steps performed in 45 seconds were recorded for assessment items 1, 4 and 5. 
The number of correct answers given in 45 seconds was recorded for assessment items 2-5. 
 
3.4.1.7 Statistical Analysis 
 
SPSS version 20 (PASW) (IBM Corporation, USA) was used to evaluate the 
results of the study. 
 
Demographic data and UHDRS scores were evaluated using the mean and 
standard error of the mean (SEM).  
 
Test 
order
Dual task item Brief procedure
1 Step baseline Step onto and off an aerobic step 
2 Stroop baseline easy
Colour words are presented in their coloured ink. For example, pink is printed in the 
colour pink
3 Stroop baseline hard
Colour words are presented in a different coloured ink. For example, pink is printed in 
the colour grey
4 Step and Stroop easy Step whilst perfroming the Stroop easy
5 Step and Stroop hard Step whlst performing the Stroop hard
St
ep
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d
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p
Table 25: Step and Stroop procedure 
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The mean performance scores were plotted with the standard error of the 
means (SEM). Group comparisons were made using analysis of variance (ANOVA). 
Independent subject factors included Group (control, asymptomatic (pre-HD) or 
Manifest participants) or TFC stage (TFC scores = 13 and UHDRS-TMS < 5, pre-HD; 11–
13, stage 1 (earliest symptomatic stage); 7–10, stage 2; 3–6, stage 3; 1–2, stage 4; and 
score of 0 is stage 5 (most advanced stage), or healthy controls).  Dependent subject 
factors included C3t time (Time), and C3t total score (Total), Value time (Value time) 
and number of correct letters said per second (Alphabet rate).  
 
A two way repeated measures ANOVA was used to evaluate task difficulty in 
the C3t Baseline Complex and C3t Dual task compared relative to the C3t Baseline 
Simple performance, between TFC stage. The C3t item (baseline simple, complex or 
dual task) and TFC group were used as factors. If the sphericity assumption was not 
met (P<0.05), this was corrected using the Greenhouse-Geisser test. 
 
Receiver operating characteristic (ROC) curves used to evaluate the specificity 
and sensitivity of each C3t item between healthy controls and HD, and pre-HD and 
Manifest HD. The area under the curve (AUC) was used to interpret this result, where 
an outcome close to 1 was indicative of maximal specificity and sensitivity, whereas a 
result closer to 0.5 was no better than chance (Lalkhen and McCluskey, 2008). 
 
External validity: A Pearson’s correlation coefficient was used to reveal any 
associations between the C3t variables and the ENROLL-HD data collected.  
 
Test validity: Predictive validity was calculated using a multiple linear 
regression, where UHDRS TMS, TFC and functional scores were used as dependent 
variables and all C3t items as independent variables. Construct validity was tested 
using a multiple stepwise linear regression model, using the C3t time and total score 
as dependent variables and UHDRS-TMS sub-items as independent variables. A 
Pearson correlation was performed to identify the relationship between items from 
the Step and Stroop and the C3t.  
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Test-retest reliability: An intraclass correlation was performed using C3t 
performance scores from their first and second visit. 
 
A Bonferroni post hoc test was used for all tests if results were deemed 
statistically significant (p < 0.05). 
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3.4.2 Results 
 
The results in this section were presented in the following order: 
 
1. Participants 
2. Validating the C3t v2b 
a. External validity 
i. Is the C3t specific to people with HD? 
ii. Is the C3t sensitive to disease stage? 
b. Test validity 
i. Concurrent validity 
ii. Predictive validity 
iii. Construct validity 
c. How reliable is the C3t v2b? 
 
3.4.2.1 Participants 
 
Demographic information for the participants recruited in the C3t baseline is 
presented in Table 26. Eighty-four people consented to take part in the study from 
which twenty-one were healthy controls and sixty-two people were gene positive for 
HD. From these, twenty controls and fifty-four people gene positive with HD 
completed the C3t assessment. The number of people in each group that completed 
each item of the C3t are presented in Appendix 1. People in stage 4 and 5 were 
combined to form one group (stage 4,5) as only two stage 5 subjects were recruited. 
There was no significant difference between TFC groups for years of education. 
Subjects that were pre-HD were significantly younger than the stage 2 group. CAG 
disease burden score was significantly greater in stage 2 and stage 3 compared to pre-
HD. Stage 2 also had a significantly greater body mass index than stage 3.  
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The table presents the mean demographics with the standard error of the means. Groups were categorised by healthy controls, pre-HD (TMS < 5) and manifest 
(TMS > 5). The HD groups were further categorised to form 5 groups which included pre-HD (TMS > 5 and TFC = 13), stage 1, TFC =11-13 and TMS > 5; stage 2, 
TFC=7-10; stage 3, TFC=3-6; stage 4,5 =0-2). A t-test was performed to identify group differences between pre-HD and manifest subjects. To identify group 
differences between controls and TFC disease stage, a one way ANOVA was performed with Group as a between subject factor and demographics as a within 
subject factor. If this met significance a Bonferroni post-hoc was performed. Significance was met where p < 0.05.  
Where c3t v2b = Clinch token transfer test version 2b; TMS = total motor score; TFC = total functional capacity; MBI = body mass index; n.s. = not significant. 
 
 
pre-HD 1 2 3 4,5
n (male:female) 21 (9:12) 8 (6:2) 54 (32:22) / 8 (6:2) 23 (14:9) 17 (8:9) 11 (7:4) 3 (1:0) /
Age 45.52 (2.69) 37.75 (2.27) 51.21 (1.63) t (62) = -3.049, p < 0.01 37.75 (4.35) 48.44 (2.57) 56.83 (2.91) 50.55 (3.72)42.75.75 (6.17) F(5,79) = 3.285, p < 0.01; pre-hd vs s2
TMS / 0.38 (0.18) 35.35 (2.87) t (60) = -4.663, p <0.001 0.37 (4.72) 21.18 (2.85) 34.17 (3.15) 54.82 (4.03) 75 (7.72) F(4,57) = 30.53, p < 0.001; All stages except for s3 vs s4,5
TFC / 12.63 (0.18) 8.87 (0.5) t (60) = 2.889, p < 0.01 12.63 (0.368) 12.09 (0.22) 8.94 (0.25) 4.63 (0.31) 0.33 (0.6) F(4,57) = 171.034, p < 0.001; All stages except for pre-hd and s1
Functional scale / 24.88 (0.13) 20.04 (0.83) t (58) = 2.273, p < 0.05 24.88 (0.84) 24.5 (0.51) 20.39 (0.56) 13.44 (0.79) 5 (1.37) F(4,55) = 74.44, p < 0.001; All stages except for pre-hd and s1
Independence 
scale
/ 99.38 (0.63) 81.3 (1.95) t (56) = 3.681, p < 0.001 99.38 (2.72) 91.91 (1.68) 79.44 (1.82) 67.22 (2.57) 50 (5.45) F(4,53) = 35.465, p < 0.001; All stages except for pre-hd and s1, and s3 vs s4,5
CAG disease 
burden score
/ 260.71 (26.17) 400.29 (13.81) t (60) = -3.491, p < 0.001 260.71 (37.7) 373.39 (21.27) 411.78 (23.51) 424.73 (30.08)429.38 (30.08) F(4,57) = 3.749, p < 0.01; pre-hd vs s2 and s3
Years of 
education
/ 12 (0.71) 11.64 (0.38) t (59) = 0.352, p = n.s. 12 (0.97) 11.81 (0.6) 11.72 (0.65) 11.36 (0.83) 11 (1.59) F(4,56) = 0.122, p = n.s.
BMI / 27.49 (1.14) 27.37 (1.2) t (56) = 0.035, p = n.s. 27.49 (3.15) 29.27 (1.72) 29.78 (1.82) 20.62 (2.32) 24.95 (4.45) F (4,52) = 2.42, p < 0.05; s2 vs s3
Group differences
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Table 26: C3t v2b Participant demographics 
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3.4.2.2 Validating the C3t v2b 
 
3.4.2.2.1 External validity 
i. Is the C3t specific to people with HD? 
 
The purpose of this section was to see if C3t performance could distinguish between 
healthy controls and people with HD. Participants were grouped based on their 
UHDRS-TFC and UHDRS-TMS scores and formed either the Control, pre-HD or Manifest 
HD Group. 
 
The mean, minimum and maximum values for C3t performance (time and C3t 
total) scores for Group (Controls, Pre-HD, Manifest) is presented in Table 27. 
  
A univariate ANOVA was used where both time taken and C3t total score were 
used as factors. Manifest participants performed the C3t significantly slower and 
achieved a significantly lower C3t total score than Control and Pre-HD participants for 
the baseline simple, complex and dual task (Controls vs Manifest, All p<0.001; Pre-HD 
vs Manifest: Time, All p<0.05; Total, All p<0.001; Table 27, Figure 21). There was no 
between Controls vs Pre-HD participants for any C3t item, and no gender differences 
for any measure (p>0.05).  The results suggest that both time and C3t total score 
accurately measure performance differences between people with manifest HD 
compared to healthy controls and Pre-HD participants.  
 
For the value and alphabet baseline tests manifest participants performed the 
value baseline significantly slower and recited significantly less correct letters of the 
alphabet per second than controls (Table 27)  (Simple effects: Value and Alpha 
baseline: Control vs Manifest p<0.05). There was no performance difference between 
Pre-HD vs Manifest, or Pre-HD vs Control participants for the value and alphabet 
baseline tests (p>0.05).
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The mean C3t performance results with the standard error of the mean, minimum and maximum results in controls, pre-HD and manifest HD are presented. 
Time and Value time were measured in seconds (light blue), and the alphabet was measured using the number of letters recited per second (yellow). The total 
scores had no unit (dark blue). A low C3t time and value time, and a high total score and alphabet (correct/sec) score were indicative of better performance.   
C3t = Clinch token transfer test; SEM = standard error of the mean; Min = Minimum; Max = Maximum; Analysis of variance = ANOVA; Baseline = bl. 
 
Mean SEM Min Max Mean SEM Min Max Mean SEM Min Max F value (df, error) p value
Time Baseline Simple 14.09 2.92 8.04 43.48 14.22 4.72 9.6 21.7 27.85 1.82 10.54 87.48 9.95 (2, 80) p < 0.001 
Time Baseline Complex 13.73 3.12 10.92 17.64 15.43 4.93 12.26 19.8 33.59 1.97 12.07 81.51 17.4 (2, 75) p < 0.001
Time Baseline Dual task 14.08 3.27 11.93 18.16 15.37 5.16 11.02 22.77 33.45 2.15 14.38 99.04 14.75 (2, 71) p < 0.001
Total Baseline Simple 62.42 3.01 18.4 99.5 59.4 4.88 36.87 83.33 34.97 1.88 9.14 75.9 35.18 (2,80) p < 0.001
Total Baseline Complex 59.27 2.46 45.35 73.26 51.48 3.89 40.4 61.17 28.49 1.56 8.59 62.14 61.86 (2, 75) p < 0.001
Total Baseline Dual task 55.86 2.41 38.1 67.06 54.6 3.81 35.13 72.6 28.2 1.59 7.57 55.63 55.86 (2, 71) p < 0.001
Value time Baseline 5.48 1.34 4 8.16 5.41 1.89 3.08 9.81 9.99 0.73 3.28 45.36 5.96 (2, 74) p < 0.01
Alphabet correct/sec Baseline 4.41 0.33 2.4 8.36 3.39 0.55 2 4.92 2.36 0.21 0.49 9.52 14.29 (2, 83) p < 0.001
Alphabet correct/sec Dual task 3.05 0.26 1.19 5.11 2.09 0.39 0.5 4.36 1.46 0.12 0.31 3.21 24.53 (2, 71) p<0.001
C3t scores
Control Pre-HD Manifest ANOVA results
Table 27: C3t v2b performance scores in controls, asymptomatic and manifest HD 
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Figure 21: C3t v2b pre-HD vs manifest bar graphs: C3t performance in healthy controls, pre-
manifest and manifest HD. Time taken (Fig a) and C3t total score (Fig b) were used as primary 
measures where total score was more sensitive to differences between pre-manifest and 
manifest participants than time taken alone. Values show averages ± SEM. Where * p<0.05, ** 
p<0.01, *** p<0.001. 
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Receiver operating characteristic (ROC) curves were used to determine the 
sensitivity and specificity of C3t performance scores (time taken and C3t total score) 
between pre-HD vs Manifest participants, and HD vs Controls in the baseline simple, 
complex and dual tasks. An AUC outcome of 1 is indicative of 100% sensitivity and 
specificity.  
 
The AUC values from the ROC curve analysis are presented in Table 28. This 
revealed that all AUCs were greater than 0.85 indicating excellent specificity between 
Controls vs HD and sensitivity between Pre-HD and Manifest participants (Lalkhen and 
McCluskey, 2008).  
 
 
Table 28: AUC values based on C3t performance 
C3t Performance variable(s) 
Controls 
vs HD 
Pre-HD 
vs Man 
Time 
Baseline simple .868 .900 
Baseline complex .905 .914 
Dual task .889 .939 
Total 
Baseline simple .868 .868 
Baseline complex .923 .923 
Dual task .870 .870 
 
An AUC value equal to one defines a score with absolute specificity and sensitivity. AUC = Area 
under the curve, C3t = Clinch token transfer test, HD = Huntington’s disease, pre-HD = 
asymptomatic, Man = Manifest. 
 
 
ii. Is the C3t sensitive to disease stage in HD? 
 
The results thus far revealed the C3t was specific to people with HD. The purpose 
of this section was to see if C3t performance was sensitive to disease stage. Six disease 
stage groups were formed (Controls, pre-HD, Stage 1, Stage 2, Stage 3, Stage 4,5), 
which were based on their UHDRS-TFC and TMS scores. 
 
The mean, SEM and 95% confidence values for C3t performance (time and C3t 
total) are presented in Table 29. A univariate ANOVA revealed that Pre-HD participants 
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performed the C3t significantly faster (Figure 22) and achieved significantly greater C3t 
total scores (Figure 23) than those in the later stages of disease for the Baseline Simple, 
Complex and Dual task. Differences between disease stage were more obvious using 
the C3t total score as appose to time taken alone, indicating that people with more 
advanced HD were less accurate and performed the C3t slower than those in the 
earlier stages of disease. There were no significant Gender differences for any of the 
measures [Maximum: baseline simple, F(1,60)= 0.638, n.s; baseline complex, F(1,54)= 
0.391, n.s; dual task, F(1,51)= 0.839, n.s]. 
 
A univariate ANOVA was performed using Value baseline, the Alphabet 
accuracy (baseline and dual task) and TFC stage as factors. Healthy controls and people 
in the earliest stages of HD performed the value baseline and alphabet baseline 
significantly faster than people with more advanced stages of disease did [Value time: 
F(5,57)= 13.54, p< 0.001; Alphabet rate: F(5,60)= 5.24, p< 0.001]. Post hoc analysis revealed 
these differences were between all stages (p<0.05) except for Controls vs Pre-HD, 
Controls vs Stage 1, Pre-HD vs Stage 1 and Stage 2 vs Stage 3 (p>0.05). People in all TFC 
stages significantly differed from one another for the Alphabet test (All p<0.05), except 
between Pre-HD and Stage 4, 5. However, this Group consisted of just one subject.  
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The table presents the mean time taken and C3t total score ± SEM, and the 95% confidence 
difference range for each group across the Baseline Simple, Complex and Dual task. Data is 
presented to 2 decimal places. Groups were categorised by Controls and TFC disease stage (pre-
HD, TFC = 13 and TMS< 5; stage 1, TFC =11-13 and TMS > 5; stage 2, TFC=7-11; stage 3, TFC=3-
6; stage 4,5 =0-2). Time taken was measured in seconds and C3t total had no unit. A lower time 
and a greater C3t total score were indicative of better performance. Group comparisons are 
highlighted in yellow. pre-HD = asymptomatic; ANOVA = analysis of variance.   
Group
Time taken 
(seconds)
95% 
confidence 
differece 
(upper-lower 
bound)
C3t total (no 
unit)
95% 
confidence 
differece 
(upper-lower 
bound)
Control 14.34 ± 2.41 9.54 - 19.14 62 ± 2.73 56.55 - 67.45
pre-HD 13.33 ± 4.46 4.45 - 22.21 62.69 ± 5.06 52.61 - 72.78
Stage 1 20.59 ± 2.33 15.95 - 25.24 42.2 ± 2.65 36.92 - 47.47
Stage 2 23.8 ± 2.65 18.51 - 29.08 35.18 ± 3.01 29.18 - 41.19
Stage 3 46.62 ± 3.42 39.8 - 53.44 20.4 ± 3.89 12.65 - 28.14
Stage 4,5 37.85 ± 6.3 25.29 - 50.41 27.77 ± 7.16 13.5 - 42.04
ANOVA: F 
value and p 
value
Control 13.72 ± 2.39 8.95 - 18.49 59.32 ± 2.11 55.1 - 63.54
pre-HD 14.78  ± 4.34 6.12 - 23.44 52.88 ± 3.84 45.22 - 60.55
Stage 1 24.15 ± 2.39 19.38 - 28.91 36.51 ± 2.11 32.29 - 40.73
Stage 2 30.4 ± 2.68 25.05 - 35.74 22.51 ± 2.37 22.51 - 31.97
Stage 3 51.51 ± 3.67 44.19 - 58.83 17.05 ± 3.25 10.54 - 23.53
Stage 4,5 54.64 ± 6.14 42.39 - 66.88 16.37 ± 5.43 5.53 - 27.21
ANOVA: F 
value and p 
value
Control 14.14 ± 2.13 9.89 - 18.39 55.67 ± 2.12 51.44 - 59.9
pre-HD 14.89 ± 3.86 7.17 - 22.61 56.03 ± 3.84 48.35 - 63.71
Stage 1 25.01 ± 2.13 20.76 - 29.26 34.75 ± 2.12 30.53 - 38.98
Stage 2 28.97 ± 2.45 24.08 - 33.87 27.32 ± 6.66 22.45 - 32.19
Stage 3 65.58 ± 3.86 57.86 - 73.3 13.58 ± 3.84 5.9 - 21.26
Stage 4,5 32.44 ± 6.69 19.07 - 45.81 22.43 ± 6.66 9.12 - 35.73
ANOVA: F 
value and p 
value
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F(5,67)=20.78; p<0.001 F(5,67)=38.45; p<0.001
Table 29: C3t v2b performance scores grouped by TFC disease stage 
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   Figure 22: C3t v2b time bar graph across TFC disease stage. The mean time taken to perform the C3t ± SEM based on participants 
grouped by healthy controls and TFC stage of disease, where time was measured in seconds. Participants in the later stages of disease 
took on average significantly longer to perform each item of the C3t compared to those in the earlier stages. A shorter time was 
indicative of better performance. Less participants passed the Baseline Complex and Dual task in the more advanced disease stages 
leading to greater variability. See Figure 24 for the percentage of people that attempted but failed these assessment items. The data 
in the table presents significant differences between disease stage, where $ p<0.056; * p < 0.05; ** p < 0.01; *** p < 0.001. 
Baseline Simple Dual task Baseline Complex 
Baseline Simple Baseline Complex Dual task
pre-HD pre-HD pre-HD
Stage 1 Stage 1 *** Stage 1 **
Stage 2 Stage 2 *** Stage 2 ***
Stage 3 *** Stage 3 *** Stage 3 ***
Stage 4,5 * Stage 4,5 *** Stage 4,5
Controls Controls Controls
Stage 1 Stage 1 *** Stage 1 ***
Stage 2 Stage 2 *** Stage 2 *
Stage 3 *** Stage 3 *** Stage 3 ***
Stage 4,5 * Stage 4,5 ** Stage 4,5
Controls Controls *** Controls ***
pre-HD pre-HD *** pre-HD
Stage 2 Stage 2 Stage 2
Stage 3 *** Stage 3 *** Stage 3 ***
Stage 4,5 Stage 4,5 Stage 4,5
Controls Controls *** Controls ***
pre-HD pre-HD *** pre-HD *
Stage 1 Stage 1 Stage 1
Stage 3 *** Stage 3 $ Stage 3 ***
Stage 4,5 Stage 4,5 Stage 4,5
Controls *** Controls *** Controls ***
pre-HD *** pre-HD *** pre-HD ***
Stage 1 *** Stage 1 *** Stage 1 ***
Stage 2 *** Stage 2 $ Stage 2 ***
Stage 4,5 Stage 4,5 Stage 4,5 ***
Controls * Controls *** Controls 
pre-HD * pre-HD *** pre-HD 
Stage 1 Stage 1 Stage 1 
Stage 2 Stage 2 Stage 2 
Stage 3 Stage 3 Stage 3 ***
Stage 4,5
Control
pre-HD
Stage 1
Stage 2
Stage 3
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Figure 23 C3tv2b total score-bar graphs across TFC disease stage. The mean C3t total scores achieved ± SEM based on participants 
grouped by healthy controls and TFC stage of disease. Participants in the later stages of disease took significantly longer and were less 
accurate to perform each item of the C3t compared to those in the earlier stages indicated by a lower total score. This measure had no 
unit. A greater total score was indicative of better performance. Less participants passed the Baseline Complex and Dual task in the 
more advanced disease stages leading to greater variability. See Figure 24 for the percentage of people that attempted but failed these 
assessment items. The data in the table presents differences between disease stage, where $ p<0.056; * p < 0.05; ** p < 0.01; *** p < 
0.001. 
Baseline Simple Baseline Complex Dual task
pre-HD pre-HD pre-HD
Stage 1 ** Stage 1 *** Stage 1 ***
Stage 2 *** Stage 2 *** Stage 2 ***
Stage 3 *** Stage 3 *** Stage 3 ***
Stage 4,5 ** Stage 4,5 *** Stage 4,5 *
Controls Controls Controls
Stage 1 ** Stage 1 ** Stage 1 ***
Stage 2 *** Stage 2 *** Stage 2 ***
Stage 3 *** Stage 3 *** Stage 3 ***
Stage 4,5 ** Stage 4,5 *** Stage 4,5 ***
Controls *** Controls *** Controls ***
pre-HD *** pre-HD * pre-HD ***
Stage 2 Stage 2 Stage 2
Stage 3 *** Stage 3 *** Stage 3 ***
Stage 4,5 Stage 4,5 * Stage 4,5
Controls *** Controls *** Controls ***
pre-HD *** pre-HD *** pre-HD ***
Stage 1 Stage 1 Stage 1
Stage 3 $ Stage 3 Stage 3 $
Stage 4,5 Stage 4,5 Stage 4,5
Controls *** Controls *** Controls ***
pre-HD *** pre-HD *** pre-HD ***
Stage 1 *** Stage 1 *** Stage 1 ***
Stage 2 
$
Stage 2 Stage 2 
$
Stage 4,5 Stage 4,5 Stage 4,5
Controls *** Controls *** Controls ***
pre-HD ** pre-HD *** pre-HD ***
Stage 1 Stage 1 * Stage 1 
Stage 2 Stage 2 Stage 2 
Stage 3 Stage 3 Stage 3
Stage 4,5
Control
pre-HD
Stage 1
Stage 2
Stage 3
C3T total score
Baseline Dual task Triple task
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Premanifest 
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Baseline simple Baseline complex Dual task 
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3.4.2.2.2 C3t performance deteriorates with increased task difficulty in people with 
advanced HD 
 
As the C3t items increased in difficulty, more people in the later disease stages 
failed to meet the set criteria to continue to the complex and dual task items (subject 
drop-off). This resulted in smaller group sizes in the baseline complex and dual task, and 
reduced the Stage 4,5 group to a third in the dual task (Figure 24).  In comparison, 95% 
and 100% of the Control and Pre-HD participants completed the whole C3t assessment.   
 
Subject dropoff rate
Attempted Baseline Dual task Triple task
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%
)
20
40
60
80
100
120
Controls 
Pre-manifest 
Stage 1 
Stage 2 
Stage 3 
Stage 4,5 
Attempted
Baseline 
simple
Baseline 
complex
Dual task
Control 100 (n=21) 100 (n=21) 95 (n=20) 95 (n=20)
Pre-HD 100 (n=8) 100 (n=8) 100 (n=8) 100 (n=8)
Stage 1 100 (n=23) 100 (n=23) 89.47 (n=21) 89.47 (n=21)
Stage 2 100 (n=18) 100 (n=18) 86.67 (n=17) 86.67 (n=16)
Stage 3 100 (n=11) 100 (n=11) 87.5 (n=10) 62.5 (n=8)
Stage 4, 5 100 (n=3) 66.67 (n=2) 66.67 (n=2) 33.33 (n=1)
Participants that passed each C3t item (%)
Baseline 
complex 
Baseline 
simple 
Dual task 
Figure 24: C3t v2b subject drop off graph. The percentage of participants, grouped by TFC disease 
stage that passed the set criteria developed for the C3t Baseline Simple, Complex and dual task (See 
Appendix 1). The figure and the table presents the percentage of participants that were recruited 
and attempted the C3t (attempted). The plots in the Baseline Simple, Complex and Dual tasks 
presents the percentage of people that passed each of these items. Set criteria were developed for 
each C3t item (Appendix 2) and, if the participant met this criteria, they passed to the next, more 
complex, C3t item.   
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To see if C3t complexity had an impact on performance, a two way repeated 
measures ANOVA was performed using TFC stage as an independent subject factor, and 
C3t time and C3t total as between subject factors. This revealed that people in stage 1, 
stage 2, stage 3 and stage 4,5 took significantly longer to perform the C3t items with 
increased task complexity [TFC stage x C3t item: baseline simple vs baseline complex, 
F(5,72)= 4.65, p<0.001; baseline simple vs dual task, F(5,68)= 7.68, p<0.001; baseline complex 
vs dual task, F(5,68)= 14.27, p<0.001] (Table 30). Performance did not significantly differ in 
the control and pre-HD groups as items increased in difficulty.   
 
The data presented shows Bonferroni post-hoc outcomes to see if the complexity of the C3t item 
had an impact on performance. All groups except for pre-HD and controls performed significantly 
worse with increased task complexity (refer to Table 29 and for mean values, which are plotted in 
Figure 22 and Figure 23). Where * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
              There was no significant difference in C3t total score with increasing task 
complexity [TFC stage x C3t item: baseline simple vs baseline complex, F(5,72)= 0.63, p=n.s.; 
baseline simple vs dual task, F(5,68)= 0.26, p=n.s.; baseline complex vs dual task, F(5,68)= 0.42, 
p=n.s.]. There was also no significant difference in the alphabet performance between the 
baseline and dual task [baseline vs dual task, F(5,67)= 2, p=n.s.]. 
Group
C3t 
Baseline 
Complex
C3t Dual 
task
Control p = n.s. p = n.s.
pre-HD p = n.s. p = n.s.
Stage 1 * **
Stage 2 *** **
Stage 3 * ***
Stage 4,5 *** p = n.s.
Control / p = n.s.
pre-HD / p = n.s.
Stage 1 / p = n.s.
Stage 2 / p = n.s.
Stage 3 / ***
Stage 4,5 / **
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Table 30: C3t v2b Performance differences with task complexity. 
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3.4.2.3 Test validity 
 
3.4.2.3.1 Concurrent validity 
 
Concurrent validity is a form of criterion validity and is used to understand the 
extent a measure relates to other gold standard assessments.   
 
A Pearson correlation was used to evaluate if there was a relationship between 
C3t items and the UHDRS assessments (UHDRS-TMS, TFC, functional assessment score, 
independence scale and cognitive measures (verbal fluency, symbol digit and the Stroop 
task), CAG disease burden score, quality of life summaries from the SF-12, the apathy and 
executive function score from the Problem behaviour assessment and scores from the 
Late-Life Functional Disability Instrument).  
 
Correlation results are presented in Table 31. All C3t performance variables 
significantly correlated with UHDRS measures except between the alphabet in the C3t 
Dual task and the verbal fluency and Stroop colour naming. The C3t items significantly 
correlated with the current performance based functional measures used for ENROLL-HD 
(Timed up and go, and sit to stand), and the Late-Life Functional Disability Instrument. C3t 
items did not correlate with the SF-12 mental summary or the apathy and executive 
function scores from the Problem behaviour assessment.  
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*p<0.05 (light pink); **p<0.01 (dark pink). UHDRS = Unified Huntington’s disease rating scale; TMS = Total motor score; TFC = Total functional capacity; LVF 
= Letter verbal fluency; PBA = Performance behaviour assessment; SF-12 = Short-form 12; LL-FDI = Late life functional disability questionnaire. 
UHDRS 
TMS
TFC TFC stage FAS
Independance 
scale
UHDRS 
SD correct
UHDRS 
VF correct
UHDRS 
Stroop 
colour-
name 
correct
UHDRS 
Stroop 
word-
reading 
correct
CAG 
disease 
burden 
score
TUG
Sit to 
Stand
PBA 
apathy
PBA 
executive 
function
SF-12 
physical 
summary
SF-12 
mental 
summary
LL-FDI 
total
LLFDI- 
upper 
extremity
LLFDI- 
lower 
extremity
C3t Time Basline Simple .775
**
-.627
**
.621
**
-.673
**
-.580
**
-.565
**
-.466
**
-.591
**
-.589
**
.379
**
.953
**
-.653
** .100 -.070 -.396
* .112 -.423
**
-.460
**
-.437
**
C3t Time Basline Complex .812
**
-.718
**
.719
**
-.702
**
-.651
**
-.619
**
-.480
**
-.608
**
-.633
**
.411
**
.915
**
-.700
** .183 .093 -.351
* .039 -.439
**
-.448
**
-.471
**
C3t Time Dual task .732
**
-.678
**
.632
**
-.678
**
-.635
**
-.559
**
-.391
**
-.563
**
-.587
** .237 .940
**
-.702
** .174 .113 -.399
* -.284 -.517
**
-.537
**
-.537
**
C3t Total Basline Simple -.756
**
.633
**
-.618
**
.584
**
.574
**
.716
**
.468
**
.631
**
.609
**
-.489
**
-.667
**
.501
** -.183 -.041 .355
* .109 .507
**
.482
**
.468
**
C3t Total Basline Complex -.791
**
.682
**
-.678
**
.616
**
.639
**
.719
**
.432
**
.599
**
.582
**
-.487
**
-.649
**
.560
** -.242 -.147 .345
* .098 .475
**
.413
**
.441
**
C3t Total Dual task -.777
**
.655
**
-.604
**
.586
**
.674
**
.741
**
.428
**
.647
**
.633
**
-.377
**
-.637
**
.570
**
-.294
* -.155 .326 .257 .488
**
.438
**
.461
**
Value Baseline .674
**
-.631
**
.639
**
-.701
**
-.666
**
-.546
**
-.432
**
-.581
**
-.609
**
.302
*
.704
**
-.561
**
.392
** .156 -.447
** .081 -.433
**
-.513
**
-.456
**
Alphabet Baseline -.439
**
.475
**
-.367
**
.462
**
.421
**
.421
**
.348
**
.415
**
.400
** -.185 -.197 .535
** -.089 -.254
*
.393
* .266 .422
**
.453
**
.462
**
Alphabet Dual task -.405
**
.419
**
-.388
**
.312
*
.411
**
.428
** .113 .267 .316
* -.202 -.338 .418
*
-.365
** -.123 .356
* .280 .567
**
.444
**
.497
**
C3t Time Baseline simple 
vs Complex cost 
.107 -.182 .228 -.079 -.150 -.154 .004 -.052 -.085 .085 -.409
* .187 .100 .356
** -.023 -.070 .040 .100 .063
C3t Total Baseline simple 
vs Complex cost 
.043 -.157 .193 -.039 -.124 -.030 .086 .058 .014 .003 -.447
* .177 .131 .277
* -.045 -.027 .065 .132 .098
C3t Time Dual task cost .189 -.264 .243 -.192 -.307
* -.188 -.026 -.176 -.255 -.120 -.134 -.028 .320
*
.429
**
-.411
*
-.396
* .000 -.054 -.020
C3t Total Dual task cost .211 -.307
* .264 -.197 -.348
* -.220 -.043 -.181 -.255 -.089 .016 -.209 .350
*
.310
* -.319 -.288 -.006 -.060 -.034
Alphabet Dual task cost -.021 -.046 .014 -.069 -.109 -.132 .055 .069 -.030 .119 -.063 -.025 .278
* -.009 -.197 -.288 -.206 -.063 -.110
Table 31: The correlation between performance in each C3tv2b assessment item and UHDRS, PBA and SF-12 measures 
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3.4.2.3.2 Predictive validity 
 
Predictive validity is another form of criterion validity and is used to measure 
how well an instrument predicts the scores of another related assessment.  
 
A multiple linear regression revealed that all C3t items significantly predicted 
the UHDRS-TMS, UHDRS-TFC and UHDRS-functional score (Table 32). 
 
Table 32: C3t items significantly predict the UHDRS measures 
 
C3t time was measured in seconds (light blue) and the C3t total had no unit (dark blue). The 
UHDRS assessments were rated on an ordinal scale by a neurologist at South Wales HD clinic. 
The data in the table revealed all C3t items (C3t baseline simple, complex and dual task) 
significantly predict the UHDRS-TMS, TFC and functional score. Where UHDRS = Unified 
Huntington’s disease rating scale, TMS = total motor score, TFC = total functional capacity, C3t 
= Clinch token transfer test.  
 
R value F value p value R value F value F value R value F value p value
Baseline Simple 0.78 F(1,58)= 89.56 p<0.001 0.63 F(1,58)= 38.25 p<0.001 0.59 F(1,56)= 30.02 p<0.001
Baseline Complex 0.81 F(1,54)= 104.84 p<0.001 0.72 F(1,54)= 57.47 p<0.001 0.61 F(1,52)= 31.44 p<0.001
Dual task 0.73 F(1,50)= 58.28 p<0.001 0.68 F(1,50)= 42.7 p<0.001 0.58 F(1,48)= 24.57 p<0.001
Baseline Simple 0.76 F(1,58)= 79.01 p<0.001 0.64 F(1,58)= 39.23 p<0.001 0.68 F(1,56)= 48.7 p<0.001
Baseline Complex 0.79 F(1,54)= 89.84 p<0.001 0.68 F(1,54)= 47.05 p<0.001 0.7 F(1,52)= 51.13 p<0.001
Dual task 0.78 F(1,50)= 75.69 p<0.001 0.65 F(1,50)= 37.45 p<0.001 0.68 F(1,48)= 41.62 p<0.001
UHDRS-TMS UHDRS-TFC UHDRS Functional score
C
3t
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l
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To see which UHDRS-TMS sub items best predicated the C3t time and total, a 
stepwise, linear regression was performed. This revealed that dystonia, pronation and 
supination of the hand best predicted the C3t Time (Table 33). The UHDRS-TMS sub-
items that best predicted the C3t total score included pronation and supination of the 
hand, chorea and bradykinesia.   
 
  
C3t time was measured in seconds (light blue) and the C3t total had no unit (dark blue). UHDRS-
TMS items were rated on an ordinal scale by a neurologist at South Wales HD clinic. The data in 
the table presents the UHDRS-TMS items including total dystonia and total chorea score, which 
both consisted of the summed scores for the trunk, and left and right upper and lower 
extremities (all rated from 0 (normal) to 4 (marked/prolonged)). For the pronate/supinate item, 
patients had to repeatedly rotate their wrist so their hand faced upwards and downwards (rated 
from 0 (normal) to 4 cannot perform). Bradykinesia was measured ranging from 0 (normal) to 
4 (marked with long delays).  
 
3.4.2.3.3 Construct validity 
 
Construct validity is used to ensure the assessment used measures the 
constructs it intends to measure.  
 
As both the Step and Stroop and the C3t were designed to measure a similar 
construct (dual task performance), a Pearson correlation was performed to see how 
well the C3t items related to scores in the Step and Stroop (Table 34).  This revealed 
that all C3t and the Step and Stroop assessment items significantly correlated with 
each other (p<0.001). 
C3t item
UHDRS-TMS 
constructs
R R squared
Adjusted 
R squared
p
C3t Time Baseline Simple Dystonia total 0.817 0.667 0.655 <0.001
C3t Time Baseline Complex
Pronate, supinate/ 
dystonia
0.912 0.831 0.817 <0.001
C3t Time Dual task
Pronate, supinate/ 
dystonia
0.872 0.76 0.737 <0.001
C3t Total Baseline Simple
Pronate, supinate/ 
chorea total
0.846 0.716 0.695 <0.001
C3t Total Baseline Complex
Pronate, supinate, 
bradykinesia
0.884 0.782 0.765 <0.001
C3t Total Dual task
Pronate, supinate, 
bradykinesia
0.882 0.778 0.757 <0.001
Table 33: UHDRS-TMS sub items that significantly predict C3t v2b item scores 
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A subset of subjects performed both the C3t v2b and the Step and Stroop. All C3t and Step and 
Stroop items significantly correlated, where p<0.001 (pink).  The number of people that 
performed each item is presented below the correlation. C3t time was measured in seconds, C3t 
total had no unit, and the alphabet was measured using the number of correct letters of the 
alphabet recited per second. For the Stroop, the number of steps performed and the number of 
correct answers in the Stroop were recorded. C3t = Clinch token transfer test. 
Step 
Baseline
Step 
Simple 
Dual task
Step 
Complex 
Dual task
Stroop 
Baseline 
Simple
Stroop 
Dual task 
Simple
Stroop 
Baseline 
Complex
Stroop 
Dual task 
Complex
-.778
**
-.791
**
-.744
**
-.806
**
-.815
**
-.712
**
-.809
**
20 19 19 22 19 22 19
-.770
**
-.796
**
-.782
**
-.880
**
-.834
**
-.758
**
-.833
**
20 19 19 22 19 22 19
-.725
**
-.744
**
-.749
**
-.847
**
-.777
**
-.692
**
-.739
**
17 16 16 19 16 19 16
.911
**
.908
**
.872
**
.941
**
.919
**
.878
**
.923
**
20 19 19 22 19 22 19
.879
**
.860
**
.849
**
.927
**
.928
**
.885
**
.928
**
20 19 19 22 19 22 19
.841
**
.866
**
.883
**
.940
**
.862
**
.810
**
.883
**
17 16 16 19 16 19 16
.850
**
.848
**
.810
**
.796
**
.831
**
.752
**
.833
**
20 19 19 22 19 22 19
.795
**
.891
**
.856
**
.790
**
.835
**
.677
**
.806
**
17 16 16 19 16 19 16
C3t total Baseline 
Complex
C3t total Dual task
Alphabet Baseline
Alphabet Dual task
C3t time Baseline 
Simple
C3t time Baseline 
Complex
C3t time Dual task
C3t total Baseline 
Simple
Table 34: C3t v2b construct validity 
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3.4.2.4 How reliable is the C3t? 
 
One form of reliability is test-retest reliability. This is used to measure the 
stability of an assessment when no change in subject performance is expected and is 
usually carried out at two different time points to test the strength or association 
between the two scores. 
 
To evaluate C3t test-retest reliability, a subset of participants were asked to 
return to redo the C3t 6 ±2 weeks after their first visit. An intra-class correlation was 
used and the results are presented in Table 35. This revealed C3t time and C3t total 
scores for the C3t baseline simple test were most reliable producing an intra-class 
correlation of 0.973 (n=10). The total score takes number of errors into consideration 
and as a result produced scores with greater variability and overall lower intra-class 
correlations, ranging from 0.944 (C3t baseline: n=10) to 0.388 (C3t dual hard: n=7).  
  
An ICC of 1 is indicative of 100% reliability. Intraclass correlation coefficient (ICC); Clinch token 
transfer test (C3t); baseline (bl). 
C3t Time Baseline Simple 0.973 (0.898-0.993)
C3t Time Baseline Complex 0.625 (-0.921 - 0.934)
C3t Time Dual task 0.825 (0.106 - 0.969)
C3t Total Baseline Simple 0.944 (0.789 - 0.986)
C3t Total Baseline Complex 0.636 (-0.864 - 0.936)
C3t Total Dual task 0.388 (-2.132 - 0.893)
ICC (95% confidence)
Table 35: C3t v2b test-retest reliability 
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3.5 Discussion 
 
The aim of this study was to design a standardised version of the C3t and validate 
it in people gene positive with HD. To achieve these aims, this Chapter consisted of three 
Parts which developed iteratively. In Part 1, the C3t was designed with five main criteria 
in mind; i) to ensure, the original C3t and the C3t v2 were as similar as possible in terms 
of dimensions and set up; ii) the set up was standardised; iii) it was compact and could be 
easily stored when not in use; iv) the materials used were robust but also cost effective; 
v) it was easy to use. These criteria were made based on the clinometric table presented 
in Chapter 1 (Table 1). The results in Part 2 revealed that, although the C3t was sensitive 
to disease stage, the increasing C3t complexity levels did not impact the C3t performance 
scores. As this may have been due to the familiarity of the tokens, the C3t was optimised, 
to include different tokens for the C3t Baseline Simple, Baseline Complex and the Dual 
task. In Part 3 the optimised C3t (C3t v2b) was validated in people with all stages of HD 
and a healthy control group, and revealed that performance distinguished between 
people gene positive with HD and healthy controls, and was sensitive to disease stage. 
Performance significantly worsened with increasing task difficulty. It also significantly 
correlated with the UHDRS and quality of life and function measures (SF-12, Problem 
Behaviour assessment, Late life functional disability instrument), and was capable of 
predicting the UHDRS-TMS scores. All C3t dual task items significantly correlated with 
items from the Step and Stroop suggesting they measured similar baseline and dual task 
constructs. In addition, test-retest reliability revealed time taken to perform the C3t was 
a reliable measure.  
 
C3t performance can distinguish between healthy controls and people with HD 
 
The C3t v2b was tested in healthy controls and people with pre-HD and manifest 
HD. Manifest participants performed the C3t significantly slower and achieved a lower 
total score relative to the healthy control and pre-HD groups. ROC analysis revealed the 
C3t could distinguish between people gene positive with HD and healthy controls, as well 
as people with pre-HD and manifest HD. However, there was no difference in C3t 
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performance between healthy controls and pre-HD. As people with pre-HD will inevitably 
develop HD symptoms, it is more important that outcome measures for HD distinguish 
between different disease stages to track disease progression. On the other hand, as the 
pre-HD group was small (n=8), it may be that larger group sizes were required to reveal 
any performance differences between these groups.   
 
C3t performance can distinguish between stages of disease in HD  
 
As well as dividing participant’s scores into pre-HD and manifest groups, to 
identify different stages of HD, participants were also grouped based on their UHDRS TFC 
score (stage 1 (early) to stage 5 (advanced)). A limitation of this scoring is that stage 1 
typically consists of a mixed group of pre-HD and early manifest which could result in 
greater performance variability. Therefore, to dissect stage 1 further, people with a TFC 
score between 11 and 13, and a TMS score greater than 5 were classed as manifest stage 
1, and people with a TFC store equal to 13 and a TMS score less than 5 were classed as 
pre-HD. The mean total scores revealed the C3t was sensitive to all stages of disease, 
except Controls vs pre-HD participants. Importantly, performance in the C3t was sensitive 
enough to distinguish between people with pre-HD and stage 1. Overall, C3t performance 
speed and total score deteriorated in a stepwise manner, where controls and pre-HD 
performed the C3t quickest with a greater total score, and stage 4,5 performed the C3t 
slowest. People with more advanced stages of HD performed the C3t baseline simple, 
complex and dual tasks slower and produced a lower total score compared to those in the 
earlier disease stages. An explanation for this could be that, because the basal ganglia is 
involved in motor planning, motor initiation and motor accuracy) (Turner and Desmurget, 
2010; Dudman and Krakauer, 2016), as this circuitry degenerates in people with HD, this 
leads to progressively slower and less accurate performance (Despard et al., 2015).  
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The C3t assessment items increase in task complexity 
 
The C3t was designed to increase in task complexity so it was applicable to people 
with different functional ability. In Part 2, the C3t v2a was tested for the first time in 
twenty four people with HD. In this version, the C3t items were performed using the same 
tokens for the Baseline Simple, Complex and dual task. Although we expected 
performance to deteriorate as the items became more difficult, performance differences 
in stage 1 and stage 2 were marginal. One explanation for this was practice effects due to 
the familiarity of the token values. Therefore, token values were changed, and in the C3t 
v2b, all people in all TFC stages took significantly longer to perform the baseline complex 
and/or dual task relative to the baseline simple. Contrasting this, healthy controls and 
people with pre-HD maintained performance across the C3t Baseline Simple, Complex and 
dual task and did not perform any slower or produce a lower test score as the tests 
increased in complexity. These results are supported by a previous study that found 
healthy controls and people with pre-HD had the ability to gradually improve a motor skill 
when it was repeatedly performed, whereas people with manifest HD were impaired in 
motor skill learning (Shabbott et al., 2013). In this study, they tested motor skill learning 
and motor execution in a reaching based task (Shabbott et al., 2013), where participants 
used their finger to direct a cursor to a target. The target was reflected from a computer 
screen onto a mirror, where only the mirror was visible to the participant. The findings 
revealed that people with HD were slower and less accurate directing the cursor to the 
target and produced more variable trajectories over repeated sessions. In comparison, 
people with pre-HD and healthy controls improved, gradually becoming quicker whilst 
remaining accurate over sessions (Shabbott et al., 2013). One reason for this could be that 
people with pre-HD and controls have the ability to automate movement, allowing the 
allocation of more attentional resources on task accuracy compared to people with 
manifest HD that do not  (Thompson et al., 2010). As the basal ganglia is implicated in 
motor skill learning and automating responses (reviewed in: Turner and Desmurget, 2010; 
Dudman and Krakauer, 2016), this ability may gradually deteriorate as the circuitry 
progressively degenerates in HD.  
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C3t performance significantly differed between Stage 1 and pre-HD and controls. 
Stage 1 performed the C3t significantly slower and produced a lower C3t score. To our 
knowledge, there is no other functional upper limb assessment available that can 
distinguish the subtle differences between pre-HD and Stage 1. Furthermore, this was 
only evident in the more complex C3t items (Baseline Complex and Dual task), but not in 
the Baseline Simple, which supports that, different levels of complexity within 
assessments are important to capture all disease stages. The C3t was unable to distinguish 
differences between Stage 1 and Stage 2. Therefore, a more sensitive measure may be 
required to tease apart these disease stages. One option is to use accelerometers to 
quantify movement signatures, such as acceleration and deceleration, which cannot be 
captured using the current C3t rating method. Such methods have been applied in people 
with HD which found that accelerometers were a sensitive method to quantify gait and 
balance between people with pre-manifest and manifest HD (Dalton, Khalil, Busse, Rosser 
and Deursen, 2013). Furthermore, accelerometers have also been used in people with 
Parkinson’s disease to quantify tremor severity (Patel et al., 2012), and were recently 
worn by a small group of people with HD whilst performing the C3t (Bennasar et al., 2016). 
The latter study revealed accelerometers could distinguish between manifest and pre-
manifest HD groups. However, due to the small sample size, differences in movement 
parameters between disease stage were not tested, and as such, recruiting more people 
with HD is a current aim for future research. This is discussed in further detail in the 
General discussion (Chapter 5).  The findings in this study also revealed that performance 
in the Stage 4,5 group significantly differed consistently from controls and pre-HD, but no 
other stage. An explanation for this could be the small sample size in this group (maximum 
n=3) which reduced to n=1 in the dual task. Thus, more people from Stage 4 and 5 are 
required to better represent C3t performance in these disease stages.    
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Performance in the C3t significantly correlates with the UHDRS assessments, quality of life, 
and function related outcome measures 
 
Performance scores (time taken and C3t total) in the C3t items (Baseline simple, 
complex and dual task) significantly correlated with all UHDRS measures, evidencing 
strong concurrent validity. This was also true for the SF-12 physical summaries, the 
function component of the Late-Life Functional Disability Instrument, the Timed up and 
Go and the Sit to stand, which are all measures used to assess performance in daily 
functional tasks. Importantly, the C3t correlated with CAG disease burden score, which 
again suggests that the C3t performance is capable of tracking disease stage in HD. This 
score is especially useful for people with pre-HD, given that these groups can be 
heterogeneous, with some people closer to disease onset than others (Klöppel et al., 
2015). However, a larger pre-HD group is required to identify if C3t performance is 
sensitive enough to tracking this, given the pre-HD group size in this study was n=8. The 
C3t did not correlate with the apathy score from the Problem behaviour assessment. As 
there is no gold standard apathy outcome measure, other apathy assessments, such as 
the Apathy Evaluation scale (Clarke et al., 2011), could be used to prove or disprove these 
findings. In addition, the C3t did not correlate with the executive function summary from 
the Problem behaviour assessment. However, as the C3t items significantly correlated 
with the Symbol digit test, the Stroop tasks and the Letter verbal fluency, which are both 
measures of executive function (Craufurd and Snowden, 2002), this suggests that the 
ordinal scale used to rate patient responses in the Problem behaviour assessment, may 
not be an accurate executive function measure.  
 
Predictive Validity 
 
The C3t items (C3t Baseline simple, complex and dual task) significantly predicted 
the UHDRS-TMS, TFC and functional score, suggesting C3t performance accurately 
predicts motor and functional symptoms associated with HD.   
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Further analysis revealed the UHDRS-TMS sub-items that predicted C3t 
performance included: dystonia, chorea, bradykinesia and pronate/supinate hand. 
Dystonia and chorea are involuntary movements common in people during the early to 
mid-stages of HD, which manifest due to degeneration of the indirect pathway (Cepeda 
et al., 2007). Theoretically, involuntary movements, such as chorea and dystonia could 
push the hand away from its intended trajectory during performance, increasing the time 
to complete the C3t. This study also revealed that the bradykinesia sub-item predicted 
C3t performance. Bradykinesia is a symptom that tends to manifest in the advanced 
stages of HD, and results from degeneration of the direct pathway (Drago et al., 1998). 
This is required to initiate movement and is sometimes referred as the ‘Go’ pathway 
(Braunlich and Seger, 2013; Nelson and Kreitzer, 2014). Thus, increased bradykinesia will 
ultimately make synchronous upper limb movements required for the C3t more physically 
demanding and inefficient. This could result in an increased time to perform the C3t 
compared to people with pre-HD and those in the early stages. Furthermore, pronation 
and supination sub item scores also significantly predicated C3t performance. Pronation 
and supination are particularly important for grasping and release based tasks (Klein et 
al., 2011, 2012). Typically, when someone grasps an item, the hand will pronate above 
the target and prepare the first and second digits as the hand draws closer to the target, 
followed by a grasp and supination (Klein et al., 2011, 2012). A previous study revealed 
that people with HD had abnormal pronation and supination as well as mistiming when 
preparing to grasp an object (Klein et al., 2011). This could affect the speed and accuracy 
of picking up tokens and manipulating the token within the hand during the C3t. 
Surprisingly, the oculomotor TMS sub-item was not a predictor of C3t performance. 
Previous studies suggests oculomotor function is required during reaching and grasping 
tasks (Whishaw et al., 2002; Klein et al., 2011, 2012). An explanation for this could be that 
the UHDRS-TMS sub-item is not sensitive enough to identify subtle changes in oculomotor 
function. Such changes have however been identified in people with pre-HD using 
computerized oculomotor assessments (Tabrizi et al., 2009). Therefore, objective tools 
that can quantify subtle changes in oculomotor function are required to confirm the 
findings reported in this study.  
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Construct Validity 
 
Measuring construct validity is challenging. This is because an assessment such as 
the C3t is multidimensional, meaning it consists of multiple potential constructs 
(Kimberlin and Winterstein, 2008). Given that the C3t significantly correlated with UHDRS 
and functional measures, this suggests that the C3t assessment captures, motor, cognitive 
and function (using the LL-FDI and the UHDRS functional assessment score) constructs 
(Westen and Rosenthal, 2003).  Furthermore, given the C3t and the Step and Stroop items 
significantly correlate, this suggests they to measure similar constructs, and could relate 
to the motor, cognitive and functional constructs they both possess. 
 
C3t reliability 
 
Time taken to perform the C3t resulted in high test-retest reliability for the 
Baseline Simple, Complex and Dual task, but was lower for the C3t total score. An 
explanation for this could be that participants that committed an error one week, may 
have remembered the C3t instructions on their return visit. As a result, less, or no errors 
were committed, leading to a change in C3t total score, but not in the C3t time. Another 
consideration is that it may not be surprising that performance differs in functional 
outcome measures, such as the C3t, from one week to the next. People with HD are 
known to have ‘good and bad days’ in terms of symptom severity and general function 
(Sparbel et al., 2008). As a result, performance in a multi-dimensional outcome measure, 
such as the C3t, could differ from one week to the next, resulting in greater performance 
variability. As test-retest reliability was assessed in a small sample size (n=10), retesting 
reliability in a larger group of people with HD is required to confirm these hypotheses.  
 
Study limitations 
 
One of the main caveats in this study were the small TFC group sizes, particularly 
pre-HD and Stage 4,5. In addition, as the C3t increased in difficulty, more people with 
advanced HD, mainly Stages 3 and Stage 4,5 were unable to meet the set criteria to pass 
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the complex C3t items. This resulted in more people in these groups ‘failing,’ meaning 
they could not proceed to the next (more complex) assessment item. Therefore group 
sizes got smaller for the more complex assessment items, and reduced the Stage 4,5 group 
to one person in the dual task (Figure 24). As previously mentioned, the small sample size 
used to assess C3t test-retest reliability may have also increased the amount of variability 
in the results test-retest results. Therefore, a greater sample size is required to truly 
identify differences between TFC disease stage and to calculate test-retest reliability with 
greater experimental power.    
 
Another study constraint was that no other upper limb outcome measure, such 
as the pegboard test was used to compare performance with the C3t. Therefore, there is 
no way of knowing if the C3t is more sensitive than current upper limb assessments on 
the market. However, although it is important to test this in the future, as all C3t items 
significantly correlated with the upper limb score of the Late-Life Functional Disability 
Instrument (described in Chapter 1, Section 1.3.2.5), this suggests that C3t performance 
is related to daily tasks that require upper limb function. Furthermore, all C3t scores also 
correlated with lower limb score of the Late-Life Functional Disability Instrument, 
suggesting that the C3t could be used as an assessment that relates to overall body 
function in people with HD.  
 
The C3t takes between 5-10 minutes to perform. Although this means that 
assessment results can be obtained quickly, and the patient burden is reduced, a 
limitation is that this may have led to practice effects in the Baseline complex and dual 
task, leading to faster, more accurate (indicated by the C3t total) performance. For 
instance, the dual task requires the participant to transfer tokens in value order, whilst 
simultaneously reciting the alphabet. However, the same values are presented here as in 
the value baseline and the C3t baseline complex. Thus, due to the familiarity of the values, 
this could mean less cognitive effort is required in the dual task. To overcome this, a study 
is underway to redesign the C3t. This includes developing new tokens with different 
values for the baseline complex and dual task (Appendix 4) and is discussed in more detail 
in the General discussion (Chapter 5).  
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Conclusions: The C3t as a functional outcome measure 
 
The C3t is a novel dual-task assessment that has potential to provide sensitive 
feedback regarding upper limb function in HD. Importantly, performance differences 
were evident in early disease stages (pre-HD vs Stage 1), which are the stages commonly 
targeted for clinical trials to test the effectiveness of new treatments (Glorioso et al., 
2015; Kumar et al., 2015). Furthermore, for treatments where a specific brain region is 
targeted, such as cell replacement therapy in HD; it is important that outcome measures 
which involve basal ganglia function (i.e. the circuitry being ‘fixed’), and that are sensitive 
to HD symptoms, are available to assess . In addition, sensitive, objective scoring methods 
that are used in the C3t, as appose to ordinal rating scales, are crucial for interventions 
such as cell transplantation, where symptom changes are gradual and can be subtle 
(Wijeyekoon and Barker, 2011).  
 
As an assessment, the C3t requires minimal researcher training and is inexpensive 
to produce. It is also small and compact, and can easily be stored, which avoids the 
common problem of restricted space in clinical settings. Furthermore as the C3t is 
independent of both language and culture barriers, this makes it an attractive outcome 
measure for clinical trials globally.
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Chapter 4 
Identification of the neural correlates underlying 
successful performance of a rodent analogue of the 
Stroop task 
 
 
Chapter Summary 
 
The Stroop task is a widely used task measuring attention and conflict resolution, which 
shows sensitivity across a range of diseases, including Huntington’s disease (HD). A rodent 
analogue of the Stroop task, the ‘Response-Conflict task’, allows for systematic 
investigation of the neural systems underlying performance in this test.   
 
The aim of this study was to determine whether neural regions relevant to HD are utilised 
during conflict resolution.  To achieve this, the expression patterns of the immediate early 
genes (IEG) Zif268 and C-fos were analysed throughout cortical and basal ganglia 
subregions of the rodent brain. 
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4.1 Introduction 
In Chapters 2 and 3, the rationale for developing dual task assessments 
developed was because previous studies suggest that people with HD are impaired 
when required to perform multiple tasks simultaneously (see Chapter 1, Table 2). 
Furthermore, one explanation for this could be because of striatal dysfunction (see 
Chapter 1, Section 1.4.3.1, page 41). In people, neuroimaging techniques such as fMRI, 
can be used to quantify the neural regions activated in behavioural tasks. However, 
this becomes increasingly difficult in people with HD due to increased involuntary 
movement, which can cause artefacts in the image (Andersson et al., 2017). 
Furthermore, fMRI cannot be used pre-clinically. Understanding the neural correlates 
that underlie preclinical outcome measures is crucial to assess the effectiveness of 
phase I clinical trials. Therefore, in this study, it was of interest to take the Stroop task 
utilized in Chapter 2, and which is currently used in people with HD, to identify which 
neural regions were employed in a rodent analogue.  
 
The Stroop task  is a bi-conditional discrimination task which requires a subject 
to select task relevant information whilst ignoring task irrelevant stimuli (Bullard et al., 
2012). This task is commonly used to test executive functions such as attention and 
conflict resolution. In the classic Stroop task, subjects are required to either read 
colour-words, written in their coloured ink (e.g. PINK in the colour pink), or say the 
coloured ink of the word which do not correspond (e.g. PINK in the colour yellow) 
(Bullard et al., 2012). This is one of the few cognitive assessments reported to measure 
cognitive decline in HD, where performance gradually deteriorates as the disease 
progresses (Barker et al., 2013) and directly correlates with striatal degeneration 
(Sanchez-Pernaute et al., 2000). Neuroimaging studies have highlighted several 
regions of the brain activated for successful performance of the Stroop task, including 
the striatum (caudate and the putamen), dorsolateral prefrontal cortex  (DLPFC) and 
anterior cingulate cortex (ACC) (Egner and Hirsch, 2005; Harrison et al., 2005; Ali et al., 
2010).  
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A rodent response conflict task (rRCT) was previously developed to target the 
same neural processes as those underlying performance in the human Stroop task 
(Haddon and Killcross, 2005). This operant based task tests a rodent’s ability to follow 
task-specific rules by suppressing task irrelevant stimuli. This involves the presentation 
of two audio (A1 or A2) and two visual stimuli (V1 or V2), which are each associated 
with either a left or right lever. The type of stimuli presented (audio or visual) is 
dependent upon the one of two contexts the animal is placed in (C1 or C2). After 
intensive training, animals are tested under a congruent or incongruent condition. In 
the congruent scenario, both the auditory and visual stimuli correspond to the same 
lever press. In the incongruent condition, the audio-visual stimuli presented are 
associated with different levers. The animal is required to disambiguate the audio-
visual stimuli by attending to the context it is placed in (the ‘rule’), thereby suppressing 
the tendency to respond to the opposing lever. 
  
Previous lesion based studies suggest that involvement of the medial 
prefrontal cortex (mPFC) is required for successful performance in the rRCT. This is 
understood to be most analogous to primate DLPFC, and can be sub divided into three 
sections; the ACC, prelimbic cortex (PrL), infralimbic cortex (IL) and precentral cortices. 
Specifically, rats with PrL, IL and ACC lesions all performed worse in a rodent response 
conflict task either through ablation of goal directed behaviour, lack of inhibitory 
control or lack of cognitive control (Haddon and Killcross, 2005, 2011; Marquis, 
Killcross and Haddon, 2007; Dwyer et al., 2010; Oualian and Gisquet-Verrier, 2010). 
Additional lesion based studies revealed that lesions to the retrosplenial cortex (RSC), 
impaired performance in the incongruent trials of the rRCT (Nelson et al., 2014), 
whereas no performance differences were seen in animals with hippocampal lesions 
(Haddon and Killcross, 2007). Surprisingly, no study has yet investigated if subregions 
of the striatum are involved in rRCTs, which given its involvement in the human Stroop 
task (Ali et al., 2010) is of particular relevance seeing as the focal disease in this thesis 
is  HD.  
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Understanding which regions of the brain are activated during specific tasks 
can be assessed using fMRI in humans. As this is not possible in rodents, an alternative 
strategy is the use of immediate early gene (IEG) markers. These are a class of response 
genes that are rapidly transcribed upon learning and memory, and encode for a variety 
of different transcription factors (reviewed in: Minatohara, Akiyoshi and Okuno, 2015). 
In turn IEGs regulate the expression of “late” genes responsible for producing long-
term cellular modifications (Sheng and Greenberg, 1990). Given stimulation does not 
require an initial round of protein synthesis this facilitates a rapid cellular response 
lasting from seconds to minutes (Pérez-Cadahía, Drobic and Davie, 2011). As a result, 
IEGs can be used as an effective molecular marker of primary cellular responses, which 
can be quantified in brain regions of interest to measure neural activity implicated in 
learning and memory (Herdegen and Leah, 1998). 
 
The main aim of this study was to identify neural regions activated by or 
recruited during the performance of the rRCT using IEG expression. Although the 
striatum is understood to be involved in the human Stroop task (Ali et al., 2010), no 
previous studies have researched the involvement of the striatum in the rRCT. 
Therefore, as well as analysing IEG expression in a variety of cortical and temporal lobe 
structures, a particular interest was to see if subregions of the striatum were 
implicated in successful performance in the rRCT.  
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4.2 Methods 
4.2.1 Experimental design 
 
In this study, the aim was to compare IEG activity in selected areas of the brain 
between two groups of rats that underwent behavioural rRCT operant training (rRCT 
control (congruent) and rRCT incongruent) and Cage Controls. The behavioural 
procedure for the rRCT controls and rRCT incongruent groups are described below. 
Cage Controls received no training and were perfused at the end of the study. The 
recipes used for the immunohistochemistry can be located in Appendix 5. 
  
4.2.2 Subjects 
 
Twenty-four female Lister-hooded rats (Harlan Olac, UK) were included in this 
experiment, 16 of which underwent operant testing and 8 remained as cage controls. 
Rats were housed in groups of 4 and maintained on a rat chow diet at 85-90% of their 
original ab libitum weights, each fed 12g per day. Cage controls were handled regularly 
and given food ad libitum for a total of 6 weeks before being perfused. Holding rooms 
were maintained in a temperature (21+/-2˚) and humidity (55+/-10%) controlled room 
at a 14:10-h light/dark cycle. 
 
4.2.3 Apparatus 
 
Behavioural training took place in a bank of 12 skinner operant boxes 
(Campden Instruments, Loughborough, UK), controlled by the Cambridge Cognition 
Control BNC software (Campden instruments, Version 1.23), as described (Dunnett 
and White, 2006). Each operant box was fixed with two retractable levers fitted either 
side of a magazine where rats retrieved 45mg of sucrose pellet rewards dispensed 
following a correct response. Lights were fitted above each lever, the magazine and a 
3W house light on the ceiling of the operant chamber. Six operant boxes were fitted 
with a laminated checked context with the smell of cumin, which was mixed with the 
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sawdust in the tray below the floor, and 6 were fitted with a laminated stripy context 
with the smell of cinnamon.  
 
4.2.4 Behavioural testing 
 
Behavioural training took place between 9am and 17.00 from Monday to 
Friday with one training session taking place in the morning in one context and a 
training session in the other context in the afternoon. 
 
4.2.4.1 Pre-training 
 
Each animal received one magazine training session and two lever press-
training sessions in each context.  
 
4.2.4.2 Context/stimuli training 
 
Operant training was based on the study by (Haddon and Killcross, 2005) with 
minor modifications. Each training session lasted for 48 minutes. The context, for 
example context 1 (C1; checked context and cumin) was always associated with audio 
stimuli (A1 or A2), whereas context 2 (C2; stripy context and cinnamon) was always 
associated with visual stimuli (V1 or V2; Figure 25). Auditory stimuli consisted of either 
white noise (A1) or tone (A2), and visual stimuli consisted of flashing (V1) or a steady 
light (V2). Animals were trained to associate each stimulus with either the left or the 
right lever. Following a correct response, a sucrose pellet reward was dispensed via a 
lit magazine. Stimulus-response associations were fully counterbalanced across all 
rats. An example of the stimuli presented during a training session is presented in 
Figure 25.  Each training session (in either context 1 or 2) consisted of 24 
pseudorandom stimulus presentations, 12 of each (either A1 and A2 or V1 and V2). 
Stimulus presentations lasted for 60 seconds with 60 seconds inter-stimulus interval. 
Rats were trained to learn stimulus-response associations for 23 days until they 
performed to 80% accuracy.
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Figure 25: Operant setup of the rRCT. This figure presents a schematic of the operant set up for the 
rRCT during training. This illustrates the two different contexts rats were placed in, which were either 
associated with two different types of auditory (A1 and A2) or two different types of visual stimuli (V1 
and V2), and each corresponded with a correct left or right lever press response. Briefly, the rRCT 
control task consisted of pressing the lever associated with the ‘congruent’ audio-visual stimuli. The 
rRCT incongruent was where audio-visual stimuli were incongruent. Therefore, rats had to attend to 
the context or the ‘rule’ to decipher the correct lever press response. 
Where: rRCT = rodent response conflict task; LP1 and LP2 = Left and right lever press; LP2 = Lever 
press right; A1 and A2 = auditory stimuli 1 and 2; V1 and V2 = visual stimuli 1 and 2.  
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4.2.4.3 Extinction tests 
 
All animals received 8 testing sessions (x4 rRCT control tests and x4 rRCT 
incongruent tests), each test lasting for 25 minutes and was run in extinction (i.e. in 
the absence of sucrose rewards). The extinction tests were used to ensure that the 
reinforcement of a reward was not guiding the rat to the correct response. The 
extinction test is used to probe an ‘extinction burst’; an short increased response in an 
attempt to achieve the desired reward (Lattal and Lattal, 2012). Animals then received 
two days of training (as described in Section 4.2.4.2, context/stimuli pre-training) 
before the next extinction test day.  
 
For the control test, animals were placed in one of the two contexts and 
presented with simultaneous audio-visual stimuli followed by the exposure of the left 
and right levers. In this condition, both stimuli corresponded to the same lever. In the 
incongruent test, animals were exposed to audio-visual stimuli, which corresponded 
to opposing levers. To respond correctly, the rat had to utilize the context (‘rule’) and 
determine which context-stimulus association had been previously learnt. Responding 
according to the previously learnt context-stimulus association meant that a ‘correct’ 
lever press was one that was associated with the stimulus that had previously been 
paired with the context.  
 
To ensure that IEG expression was only activated based on the rRCT, rats were 
put into a darkened room for 90 minutes before and after each training session. 
 
4.2.4.4 Final extinction test 
 
Based on performance scores from the previous testing sessions, groups were 
biased so those with highest performance accuracy were put into the rRCT incongruent 
group and those remaining were put into the rRCT control group. This allowed us to 
study IEG expression in animals that could perform the incongruent rRCT to a high level 
of accuracy. Tissue was harvested 90 minutes after the central point in the testing 
A rodent analogue of the Stroop task  Chapter 4 
178 
 
session, which coincided with peak C-fos activation.  All rats were placed into a 
darkened room before and after the test to minimize any environmental stimuli that 
could have activated IEG expression.  
 
4.2.5 Perfusion (performed by Dr M.J. Lelos) 
 
Rats were terminally anaesthetized with sodium pentobarbital (Euthatal, 
Merial, Woking, UK) and sacrificed by transcardial perfusion with 0.01M phosphate 
buffered saline (PBS). Each rat received 250ml of 4% paraformaldehyde (PFA) over 5 
minutes. Rats were decapitated and brains removed and stored in 4% PFA for 4 hours 
before transferred into a 25% sucrose solution in PBS at room temperature.  
 
4.2.6 Sectioning 
 
Brain tissue was cut coronally into 40µm thick sections on a freeze microtome. 
Sections were stored in a 1 in 12 series at -20°C in 48 well plates in ethylene-glycol-
based cryoprotectant.  
 
4.2.7 Immunohistochemistry 
 
A 1:12 series of free floating sections were used for each 
immunohistochemical assay. Zif268 staining was performed by Jessica Griffiths, an 
undergraduate student. Endogenous peroxidases were quenched by incubating 
sections in 10% methanol, 10% hydrogen peroxide and 80% distilled water. Sections 
were blocked with 3% normal serum and then incubated in the primary antibody 
Zif268 (1: 1000; Egr-1 (C-19) Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 1% 
normal serum in room temperature overnight. The same procedure was performed 
using the C-fos rabbit polyclonal antibody (1:5000; Ab-5, Synaptic Systems GmBH, 
Germany, cat. 226003/4), except for no blocking stage was implemented prior to 
primary antibody incubation. The following day sections were incubated with a 
biotinylated secondary antibody with 1% normal serum for 3 hours. The sections were 
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immersed in avidin-biotinylated enzyme complex (Vector Laboratories, Peterborough, 
UK) with 1% normal serum for 2 hours and stained with  3,3′-Diaminobenzidine (DAB) 
until light brown. Sections were mounted onto gelatinized glass slides and left to air 
dry overnight. The sections were dehydrated in ascending concentration of 70%, 95% 
and 100% of alcohols and then immersed in xylene. Slides were cover slipped using di-
n-butyl phthalate in xylene (DPX) mounting medium and air-dried. 
 
Sections were visualized using a brightfield Leica DMRB microscope at x5 
objective and captured using an Olympus DP70 camera on Leica Application Suite 
Imaging software. Some images were captured and stitched together using Windows 
Live Photo Gallery. 
 
4.2.8 Image J analysis 
 
All images were analysed blind. IEG expression was quantified using Image J 
software (Version 1.51, National Institutes of Health, USA). To quantify the number of 
immunoreactive nuclei, an individual threshold was set for each region of interest and 
remained consistent for all animals. A watershed was applied and the number of 
immunoreactive positive nuclei were counted in set area and averaged across both 
hemispheres. The number of immunoreactive positive (IR) nuclei per 10µm2 were 
calculated using the equation: 
 
100* (Average number of IR positive nuclei)   = Average IR nuclei / 10µm2 
                                      Average area  
  
4.2.9 Regions of interest 
 
Cytoarchitectonic subfields of the prefrontal cortex (prelimbic cortex, 
infralimbic cortex and anterior cingulate cortex), striatum (dorsolateral, dorsomedial 
and ventral), hippocampus (CA1, CA2, CA3 and dentate gyrus), retrosplenial cortex 
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(dysgranular (RSCa) and granular (RSCb)) and the auditory cortex were identified in all 
sections using nomenclature based on (Paxinos and Watson, 2007) (Figure 26). 
immunoreactive positive counts were also made in the auditory cortex which was used 
as an internal control for IEG staining specifically between rRCT groups (rRCT 
incongruent and rRCT control) and Cage controls. 
 
The neuroanatomical coordinates used when counting were between 4.7mm 
to 2.70mm from bregma for all prefrontal cortical regions; 1.60mm to -1.40mm from 
bregma for all striatal regions; -2.30mm to -4.30mm from bregma for all hippocampal 
subregions; -1.60mm to -4.52mm from bregma for the retrosplenial cortex; -3.14mm 
to -4.42mm from bregma for the auditory cortex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bregma 2.2mm Bregma 0.48mm Bregma 3.14mm 
Figure 26: IEG brain regions of interest: Coronal sections representing brain regions of interest taken 
from Paxinos and Watson 1997: ACC, anterior cingulate cortex, ACC; AUD, auditory cortex; DG, dentate 
gyrus; DLS, dorsolateral striatum; DMS, dorsomedial striatum; IL, infralimbic cortex; PrL, prelimbic 
cortex; RSC, retrosplenial cortex; VS, ventral striatum. 
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4.2.10 Statistical Analysis 
 
SPSS version 20 (PASW) (IBM Corporation, USA) was used to analyse the data. 
For all  behavioural training data, performance during the first 10 seconds of stimuli 
presentation was used (Haddon and Killcross, 2006). In the final extinction test, this 
was taken only from the first 12 minutes of the final test, coinciding with peak C-fos 
activation (Chaudhuri, Matsubara and Cynader, 1995; Kaminska, Kaczmarek and 
Chaudhuri, 1996). The percentage accuracy and the average number of correct vs 
incorrect lever presses were presented in graphs with the standard error of the mean 
(SEM). Differences between the numbers of correct vs incorrect responses during the 
final test were calculated using a paired t-test.  
 
For the IEG counts, the mean number of immunoreactive positive nuclei per 
µm2 were presented in graphs with the SEM. A one way ANOVA was used with a 
between-subjects variable of ‘Group’ (Cage Control, rRCT control or rRCT incongruent) 
and using the brain region of interest as the dependent variable.  
 
A Pearson correlation was used to correlate IEG expression with performance 
accuracy during the first 10 to 60 seconds of stimuli presentation in the first half of the 
final task. 
 
All ANOVAs and t-tests performed used p< 0.05 to reject the null hypothesis.  
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4.3 Results 
4.3.1 Subjects 
 
Due to illness, one rat was perfused before the end of the experiment. An 
additional two rats were removed from analysis due to an inability to learn the 
behavioural task and inconsistent staining. All remaining rats in the Cage Control (n=8), 
rRCT control (n=7) and rRCT incongruent group (n=6) completed the experiment. 
 
4.3.2 Behavioural results 
4.3.2.1 Previous training and testing 
 
All rats performed the training sessions to a high level of accuracy, successfully 
responding to the correct lever following stimulus presentation, performing greater 
than 85 ± 2% accuracy.  
 
The final rRCT control and incongruent groups were biased, based on 
performance from the eight previous extinction tests (x4 control and x4 incongruent).  
The best performers formed the rRCT incongruent group and achieved on average 
59.08 ± 2.35% correct responses in the previous rRCT incongruent extinction tests. Rats 
that formed the final rRCT control group achieved on average 51.03 ± 3.34% correct 
responses in the previous rRCT control extinction tests. 
 
4.3.2.2 Final test 
 
The first six minutes of the final test were used for analysis. Rats in the rRCT 
incongruent group achieved significantly more correct than incorrect lever responses, 
achieving on average 71.96 ± 4.8% accuracy [t(5)=4.39, p<0.01; Figure 27]. The rRCT 
control group achieved on average 51.34 ± 4.85% correct responses [t(6)=0.121, p= n.s]. 
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4.3.3 IEG results 
4.3.3.1 Zif268 results 
 
Representative images of Zif268 staining are presented in Figure 28. 
 
Striatum.  Immunoreactive staining in the DLS and DMS were no different between 
any of the groups [Group: DLS, F2,18 = 2.27, p = n.s.; DMS, F2,18 = 3.201, p = n.s.; Figure 
29a and 29b]. However, a trend was seen in the VS which was driven by a 
downregulation of Zif268 in the rRCT control groups relative to Cage Controls [Group: 
F2,18 = 3.463, P = 0.053; rRCT control vs Cage Controls p = 0.086; Figure 29c]. 
 
Prefrontal cortex. Group differences in Zif268 counts were identified in subregions of 
the PFC. In the ACC, there was a significant upregulation of Zif268 between Cage 
Controls and rRCT controls [Group: F2,17 = 4.569, p < 0.05;  Cage Controls vs rRCT 
controls <0.05; d]. In the IL cortex, there was an upregulation of Zif268  in the rRCT 
incongruent group compared to Cage Controls, and a trend towards greater Zif268  
expression between rRCT incongruent and rRCT controls [Group: F2,13 = 6.195, p < 0.05; 
Figure 27 The Mean number of correct and incorrect lever presses in the final rRCT. Bars showing 
the SEM. Where * p<0.05. 
** 
A rodent analogue of the Stroop task  Chapter 4 
184 
 
rRCT incongruent vs Cage Controls p<0.05; rRCT incongruent vs rRCT controls p = 
0.051; Figure 29f]. No difference in IEG expression was seen between groups in the PrL 
[Group: F2,14 = 0.094, n.s.; Figure 29e].  
 
Hippocampus. In the CA1 there was a significant upregulation of Zif268 in the rRCT 
controls compared to Cage Controls [Group: CA1, F2,18 = 4.335, p< 0.05; rRCT controls 
vs Cage controls p<0.05; Figure 29g]. In the CA3 there was also a significant 
upregulation between both rRCT groups and Cage controls [Group: F2,18 = 5.109, p< 
0.05; rRCT incongruent and rRCT controls vs Cage Controls p<0.05, Figure 29h]. There 
was a trend toward significance in the DG driven by an upregulation in the rRCT 
incongruent group compared to Cage Controls [Group: F2,18 = 3.487, p = 0.052; rRCT 
incongruent vs Cage Controls p=0.095;Figure 29j], No differences were seen between 
Groups in the CA2 [Group: F2,18 = 1.393, n.s. Figure 29k]. 
 
Retrosplenial cortex. IR positive counts in the RSCb revealed a significant upregulation 
of Zif268 expression in rRCT incongruent group relative to Cage Controls [Group: F2,18 
= 4.734, p<0.05; rRCT incongruent vs Cage Controls p<0.05;Figure 29 l]. There was a 
main effect of Group in the RSCa, however no individual comparisons met significance 
Figure 29k). Initial differences seemed to be driven by an upregulation in Zif268 in the 
rRCT incongruent group relative to Cage controls [Group: RSCa, F2,18 = 3.667, P<0.05; 
rRCT incongruent vs Cage Control p = 0.071].  
 
Auditory cortex. There was a significant upregulation in Zif268 expression in the rRCT 
incongruent and rRCT contols relative to Cage Controls, but no significant difference 
between rRCT controls and rRCT incongruent [Group: F2,17 = 6.453, P<0.01; rRCT 
incongruent and rRCT congruent vs Cage controls p<0.05; Figure 29m]. 
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Figure 28: Representative images of Zif268 staining in subregions of the prefrontal cortex (a), 
striatum (b), auditory cortex (c), Retrosplenial cortex (d) and hippocampus (e). Where 
ACC=anterior cingulate cortex, PrL=prelimbic cortex, IL=infralimbic cortex, MS =medial striatum, 
LS=lateral striatum, RSC = Retrosplenial cortex, VS=ventral striatum, DG=dentate gyrus. Images 
presented here were captured by Jessica Griffiths. Images were taken at x1.25 magnification.  
Zif268 staining 
RSCa 
RSCa 
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d) 
 
d) 
Figure 29 continues on the next 
page. 
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Figure 29: The average number of 
immunoreactive positive Zif268 cells in 
subregions of the striatum (Fig.a-c), 
prefrontal cortex (Fig d-f).  hippocampus (Fig. 
g-j), retrosplenial cortex (Fig. k, l) and 
auditory cortex (Fig m). PrL, prelimbic cortex; 
IL, infralimbic cortex; ACC, anterior cingulate 
cortex; DLS, dorsolateral striatum; DMS, 
dorsomedial striatum; VS, ventral striatum. 
DG, dentate gyrus; RSC, retrosplenial cortex; 
Aud, auditory cortex. Error bars show ± 
standard error of the mean. *P<0.05, 
**P<0.01. 
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4.3.3.2 C-fos results 
 
Representative images of C-fos staining in the Retrosplenial cortex and the auditory 
cortex are presented in Figure 30. 
 
The RSCb was the only region where C-fos expression differed across group, revealing 
a significant upregulation in the rRCT incongruent group relative to Cage Controls. 
[Group: F2, 18 =4.826, P< 0.05; rRCT incongruent vs Cage Controls, p<0.05;Figure 31a]. 
 
There was a trend toward significance in the PrL, driven by an upregulation in the rRCT 
controls relative to Cage Controls, but a downregulation in the rRCT incongruent group 
relative to the Cage Control group [Group: PrL, F2,14 =3.511, p= 0.058].  
 
There were no significant differences in C-fos expression in any of the following regions 
of interest: PFC [Group: IL, F2,14 =1.108, p = n.s.; ACC, F2,18 =1.218, p= n.s.], striatum 
[Group: DLS, F2,18 =2.451, p = n.s.; DMS, F2,18 =2.005, p = n.s.; VS, F2,18 =1.228, p = n.s.], 
hippocampus [Group: CA1, F2,17 =1.553, p= n.s.; CA2, F2,17 =1.066, p= n.s.; CA3, F2,16 
=0.26, p= n.s.; DG, F2,17 =0.129, p = n.s.) and RSCa [Group: F2,18 =1.063, p=n.s.].  
 
In the Auditory cortex, there were no significant differences in C-fos expression 
between any Group [Group: F2,16 = 0.76, p = n.s.; Figure 31b]. As IEG counts were taken 
from the Auditory cortex as a control region (refer to Section 4.2.9), given that there 
were no differences in C-fos expression between cage controls and rRCT groups that 
undertook operant training, this made us question the C-fos staining patterns for the 
brain regions recorded.  
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RSCa 
RSCa 
a) b) 
Figure 31: The average number of immunoreactive C-fos positive nuclei counted in the Retrosplenial cortex b (a) 
auditory cortex (b) in the Cage Control, rRCT control and rRCT incongruent groups. This revealed no significant 
differences between any of the groups (P>0.05). Bars show standard error of the mean. 
Figure 30: Representative C-fos images in the retrosplenial cortex and the auditory cortex of a rat 
that undertook operant training. Figure a) was taken at x5 magnification and figure b) was was 
taken at x1.25 magnification, and the magnified image was taken at x5.  Where RSC = retrosplenial 
cortex (agranular (a) or granular (b)). 
A rodent analogue of the Stroop task  Chapter 4 
190 
 
4.3.3.3 The relationship between behavioural performance and IEG 
expression  
 
Correlation results between Zif268 expression and performance accuracy 
throughout the entire stimuli presentation are presented in Table 37. 
 
The C-fos counts significantly, positively correlated with performance accuracy 
from the rRCT incongruent group in both the RSCa [r=0.879, n=6, p<0.05] and RSCb 
[r=0.8596, n=6, p<0.05], but for no other region for any Group (p>0.05).  
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 DLS = dorsolateral striatum;  DMS = dorsomedial striatum; VS= ventral striatum; ACC=anterior cingulate cortex; PrL=prelimbic cortex; IL=infralimbic cortex;  RSC=Retrosplenial 
cortex. Where * p<0.05, ** p<0.01 (hall significant values highlighted in beige). 
Table 37: The correlation between performance accuracy and Zif268 expression sub-regions of the brain 
 
Figure 32Table 38: The correlation between performance accuracy and Zif268 expression sub-regions of the brain 
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4.4 Discussion 
 
The aim of the study described in this Chapter was to identify the neural 
regions recruited during response conflict processing, using the operant rRCT. More 
specifically, given that people with HD are impaired in RCTs such as the Stroop task, a 
particular interest was to identify whether the striatum was activated during 
performance in the rRCT. Immediate early genes, C-fos and Zif268 were used to 
measure neural recruitment in numerous cortical and midbrain structures. The results 
revealed significant changes in Zif268 activity in the prefrontal cortex (IL and ACC), 
hippocampus (CA1, CA3, DG), retrosplenial cortex (RSCa and RSCb) and the auditory 
cortex between Cage Controls, rRCT controls and/or rRCT incongruent groups. Zif268 
expression in the dorsomedial striatum consistently correlated with performance 
accuracy throughout the duration of stimulus presentation in both the rRCT control 
and rRCT incongruent groups. C-fos expression significantly differed between groups 
in the RSCb. However, there were no changes in C-fos expression in any other brain 
region, including auditory cortex, which was used as an internal control. This is 
explained in further detail in the discussion below.   
 
Behavioural performance in the rRCT extinction test 
 
During the final extinction test, rats in the rRCT incongruent group were 
required to disambiguate audio-visual stimuli based on the context in which they were 
placed in. Rats in the rRCT incongruent group achieved significantly more correct than 
incorrect responses, supporting previous studies that rats can successfully identify and 
respond to conflicting information (Haddon and Killcross, 2005, 2011; J. Haddon and 
Killcross, 2006; Marquis, Killcross and Haddon, 2007). Groups formed for this final test 
were sorted in such a way as to ensure optimal performance in the incongruent tests, 
since this was the neural process that we were interested in investigating. As a result, 
the RCT control group contained rats that had learnt the associations less well and 
therefore only achieved 51% accuracy. However, as these rats were exposed to 
auditory stimuli, visual stimuli, odours, handling, contexts and produced motor 
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movements - they formed a critical control group to account for the effect of these 
external and internal stimuli on IEG expression.  
 
IEG expression 
 
The neuronal IEGs C-fos and Zif268 both increase and decrease downstream 
gene expression and are used regularly as markers for general neural activity and 
neuronal activation during learning or memory retrieval (Martinez, Calvo-Torrent and 
Herbert, 2002; Rygh et al., 2006). This study utilised changes in IEG expression as a 
means of identifying which brain regions were recruited during performance in the 
rRCT. The IEGs used in this study peak at different time points, with C-fos peaking 
between 90-120 minutes after stimulus onset contrasting with Zif268 which peaks 
between 30-60 minutes and reduces to basal levels within 24 hours (Chaudhuri, 
Matsubara and Cynader, 1995; Kaminska, Kaczmarek and Chaudhuri, 1996; Davis, 
Bozon and Laroche, 2003). In our study, cage control animals were not exposed to any 
sound stimuli. As a result, it was expected a significant difference in Zif268 expression 
in the auditory cortex of cage controls, relative to the auditory cortex in animals that 
underwent operant testing. This region was therefore used as an IEG internal control 
and, when using Zif268 this confirmed a significant upregulation in the rRCT groups 
compared to cage controls. However, no differences were observed between Cage 
Controls and rRCT groups when C-fos were analysed. In addition, C-fos staining 
appeared patchy and inconsistent, which may have been due to notorious sensitivity 
of the C-fos antibody and perhaps subtle differences in tissue perfusion and fixation. 
Therefore, it is acknowledged that there is a fundamental caveat associated with the 
data derived from the C-fos staining in this study.   
 
Zif268 expression in the PFC, hippocampus and retrosplenial cortex 
 
In this study, changes in IEG expression in subregions of the PFC in rRCT groups 
were observed. There was a significant upregulation of Zif268 positive nuclei in the IL 
cortex in the rRCT incongruent group relative to Cage Controls, but no difference 
between rRCT controls and Cage Controls. This suggests that the upregulation in the 
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rRCT incongruent group may have been required for conflict resolution. This contrasts 
with findings from a previous finding that used the rRCT and revealed that temporary 
inactivation of the IL did not affect the accuracy of performance in the incongruent 
test  (Marquis, Killcross and Haddon, 2007). Other studies had revealed different roles 
for the IL cortex including behavioural flexibility (Oualian and Gisquet-Verrier, 2010) 
and extinction learning (Barker, Taylor and Chandler, 2014), whilst others have shown 
it is fundamental for fixed behaviour such as habits (Marquis, Killcross and Haddon, 
2007). In our study, as rats had experienced the extinction test numerous times, the IL 
may have been recruited for extinction learning or perhaps the transition from goal 
directed to a more habitual response, leading to an increase in Zif268 expression.  
 
The results in this study also showed an upregulation of Zif268 in the ACC in 
both rRCT groups relative to Cage Controls, suggesting that this may have been 
recruited due to the exposure of stimuli and/or motor responses rather than conflict 
resolution per se. This finding is somewhat surprising as numerous studies suggest that 
the ACC is involved when evaluating conflict scenarios (Pardo et al., 1990; Braver et 
al., 2001; De Pisapia and Braver, 2006; Haddon and Killcross, 2006). However, this 
region has also been implicated in the evaluation of action-outcomes and may serve 
an explanation to the Zif268 upregulation in both rRCT groups (Botvinick, Cohen and 
Carter, 2004).  
 
Counts recorded from the hippocampus revealed significant changes in Zif268 
activation in the CA1 and CA3 subregions between Cage Controls and the rRCT groups. 
This supports previous findings that suggest the CA1 and CA3 subregions of the 
hippocampus are involved in associative learning, specifically pairing a stimulus to a 
context (Izuma, Saito and Sadato, 2010), but not necessarily for conflict resolution 
(Haddon and Killcross, 2007).  
 
Changes in Zif268 expression in the RSC were identified between Cage 
Controls and the rRCT groups. Interestingly, there was a Zif268 upregulation in the 
rRCT incongruent group relative to Cage Controls, but no difference in the rRCT control 
group. This supports a previous finding that suggest the RSC is involved in conflict 
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resolution (Nelson et al., 2014). They found rats had no problem learning context-
dependent rules but did have difficulty in selecting task relevant stimuli (Nelson et al., 
2014). However, they did not look at differences between the RSCa and RSCb 
subregions. The RSCb is more extensively connected with cortical and subcortical 
regions than RSCa (Hindley et al., 2014), suggesting this region may be more involved 
in resolving conflict and why a general upregulation was seen in the RSCa but not 
specific to the rRCT incongruent group.  
 
Is the striatum necessary for conflict resolution? 
 
Huntington’s disease provides a unique model for studying striatal 
involvement in the Stroop task, where a previous study revealed striatal degeneration 
correlated with performance accuracy in the incongruent Stroop task (Sanchez-
Pernaute et al., 2000; Ali et al., 2010). As striatal involvement has not yet been tested 
in the rRCT, analysing the potential involvement of this region during a conflicting 
scenario was of particular interest in this study. The results revealed a significant 
positive correlation between Zif268 expression in all subregions of the striatum at 
various time points during stimulus presentation of the final test. Conversely, no 
changes were observed in general Zif268 expression counts between any of the 
Groups. 
 
 Zif268 expression in the DMS correlated with performance accuracy more 
than any other subregion in both the rRCT control and rRCT incongruent group in the 
first 20-40 seconds of stimuli presentation. The DMS is analogous to the human 
caudate and anterior putamen, and has previously been implicated in decision making 
and in particular goal directed behaviour (Yin et al., 2005; MacDonald et al., 2014). As 
decision making behaviours are more likely to occur at the beginning of stimuli 
presentation, this may explain why the final 20 seconds of stimulus presentation did 
not significantly correlate with performance accuracy. With regards to goal directed 
learning, in this particular task the animal learns to respond to a stimulus, which is 
reinforced with a sucrose. During extinction tests, no reward is given (Haddon and 
Killcross, 2005; Haddon and Killcross, 2006; Marquis, Killcross and Haddon, 2007). This 
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is carried out in an attempt to achieve an ‘extinction burst’, which is where the rat’s 
behaviour temporarily increases in an attempt to achieve the desired food reward 
(reviewed in: Lattal, 2012). However, over time, as no food reward is given, this leads 
to extinction learning, and a decrease in the goal-directed response as the rat learns 
no reward is given (reviewed in: Todd, Vurbic and Bouton, 2014). In this study, as there 
was no significant relationship between Zif268 expression and performance accuracy 
during the final 20 seconds of stimulus presentation, this may have been a result of 
initial goal-directed behaviour, which gradually decreased with increased extinction 
learning. 
  
The DLS and VS of the rRCT incongruent group also significantly correlated with 
performance accuracy during the first 10 seconds of stimulus presentation. As the DLS 
is implicated in stimulus response associations (Stalnaker et al., 2010), which form the 
basis of habit formation after excessive goal-directed learning (Yin, Knowlton and 
Balleine, 2004; Balleine, Liljeholm and Ostlund, 2009), this suggests initial responses to 
stimuli presentation may have been driven by repeated exposure to the incongruent 
stimuli during previous extinction tasks. Interestingly, a significant correlation between 
Zif268 expression and performance accuracy was also seen in the VS in the first 10 
seconds of stimulus presentation. As the VS is activated under rewarding experiences 
(Burton, Nakamura and Roesch, 2015), this suggests responses may have been driven 
by the expectation of a food reward.  
 
In HD as the disease progresses the greatest changes appear to be in the less 
cognitively demanding tasks,  specifically in the time taken to recite colour names and 
words read, i.e. the congruent task (Snowden et al., 2001; Ho et al., 2003). An 
explanation for this could be that information processing speed and recitation of 
automatic over-learned sequences deteriorates as the disease progresses, which is 
thought to involve a striatal contribution (reviewed in: Saling and Phillips, 2007).  
Therefore, in this study, the striatum may be more important for the rRCT control task 
than the incongruent rRCT and could explain why no changes in Zif268 expression were 
observed in the rRCT incongruent group using the immunoreactive counts alone. 
Furthermore, as the rRCT control group consisted of animals that had learned the rRCT 
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tasks less well, this would also explain why no Zif268 changes were observed in this 
group either.   
 
Experimental caveats 
 
A main limitation to this study was the small sample size used. Larger group 
sizes in this study would have increased the experimental power.   
 
In this study, there was reason to believe extinction learning may have driven 
some of the Zif268 expression changes in the rRCT groups. Certain methodological 
differences between this study and the existing literature might explain this 
discrepancy. In this study, rats were exposed to nine extinction tests (compared to 2 
in the original rRCT study (Haddon and Killcross, 2005), interspersed with behaviour 
training. This experimental procedure was designed as previous attempts to carry out 
this study resulted in rats unable to perform the rRCT incongruent tests. To reduce this 
risk, the rRCT was optimised by utilizing contexts that were more obvious, and 
repeated extinction tests to ensure rats were able to perform the incongruent rRCT 
and therefore obtain the optimal rRCT incongruent group.  
 
In this study, IEGs were used to understand the neural processes that may 
have been activated during response conflict. However, using this method does not 
definitively determine the precise role of that brain region. As a result, this study 
should be treated as the first of a series of studies, which would include lesion and 
inactivation experiments to fully determine what each brain region does in this task. 
As previously mentioned, a limitation to this study was the poor C-fos staining resulting 
in inconclusive results for this IEG. Although the C-fos immuno-histological staining 
was optimised prior to this study, C-fos is a notoriously temperamental antibody and 
may therefore explain the inconsistent staining observed.  
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Future work and Conclusions 
 
To conclude, this study revealed that rats could successfully respond to 
conflicting stimuli in the incongruent rRCT. This allowed comparison of Zif268 
differences between Cage Controls, rRCT controls and rRCT incongruent groups in 
numerous brain regions, including sub-regions of the PFC, striatum, hippocampus and 
RSC. Interestingly, Zif268 expression correlated with performance accuracy in all sub-
regions of the striatum. However, whether this was due to genuine recruitment 
required either for conflict resolution or for the rRCT control task, or if this was a result 
of extinction learning is inconclusive. Therefore, additional studies are required to 
determine the precise role striatal involvement in the rRCT. 
 
As mentioned previously, future work could include using larger sample sizes 
in a similar study for greater experimental power and sensitivity to smaller effects. 
Furthermore, additional optimisation of the C-fos antibody is of interest given the 
inconclusive results using this IEG. It should be noted, other IEGs such as Arc are also 
activated and important for learning and memory (reviewed in: Minatohara, Akiyoshi 
and Okuno, 2015) and could therefore be used as an additional IEG marker in a 
repeated study. 
 
Future work could also include further analysis of IEG results through 
structural equation modelling. This statistical technique allows the analysis and testing 
of observed IEG activity using a computational model of anatomically connected brain 
regions. This would allow us to test and compare interdependences between and 
within networks of neural activity as shown by other groups (Lelos and Good, 2012; 
Kinnavane, Albasser and Aggleton, 2015). In our case, this  would allow a more in depth 
analysis of the neural networks recruited for successful performance of the rRCT, 
whilst informing us of other interconnected brain regions that have been implicated in 
the human Stroop task, such as the parietal cortex, cerebellum and the thalamus 
(Coulthard, Nachev and Husain, 2008; Ide and Li, 2011; Becerril and Barch, 2013). 
.
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Chapter 5 
General Discussion 
 
 
 
Discussion Summary 
 
In this thesis I have described the development and evaluation of novel assessments 
that could be used to sensitively track neurodegeneration in people with HD and in the 
future, potentially a preclinical model of HD. In Chapters 2 and 3, dual task assessments 
were developed to specifically recruit the basal ganglia circuity. In Chapter 2, this 
revealed that the Step and Stroop and the Clinch token transfer test (C3t) significantly 
distinguished between disease stage in HD, more so than other dual task assessments 
that were tested.  To take the C3t findings further, in Chapter 3, the C3t design was 
standardised and validated in people gene positive for HD and in healthy controls. This 
revealed that the C3t had high external and test validity, and most importantly that it 
distinguished between the earliest stages of HD, suggesting that this could be an 
informative functional outcome measure for future HD clinical trials. As the Stroop task 
is a common cognitive assessment used in people with HD, in Chapter 4, the aim was 
to understand the neurobiology associated with a rodent analogue of the Stroop task. 
This revealed that striatal activation significantly correlated with the Stroop 
performance from rats in the incongruent group, and the control (congruent) group. 
Therefore, this could be the first in a series of studies to understand if the striatum is 
involved during response conflict. 
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5.1 Thesis summary 
 
The aim of the work in this thesis was to develop functional outcome measures 
that are sensitive to the deficits seen in HD. This is crucial to accurately track disease 
progression, and to assess the efficacy of developing therapeutics, such as cell 
transplantation. If we are going to develop any new treatments, we need to show a 
benefit from the cellular level (graft integration) to the clinic and importantly, if this 
improves the standards of daily living. In addition, with regards to cell transplantation, we 
also need to start thinking about what functions we might expect to improve if we are 
reconnecting the cortico-basal ganglia-thalamo circuitry. However, current outcome 
measures with high ecological validity and that are sensitive to HD are limited and do not 
allow such sensitive assessment.  
 
One improvement that we might expect to see is the ability to perform two or 
more tasks simultaneously. Dual tasking is one example of a function consistently 
performed in daily life, and therefore may be a useful outcome measure to assess 
functional performance in people with HD. In addition, previous studies suggest that 
dividing attention between two or more tasks may involve the fronto-striatal circuitry for 
optimal performance (Yogev-Seligmann, Hausdorff and Giladi, 2012; Yildiz and Beste, 
2015). As this is a primary site of degeneration in people with HD, it is not surprising that 
HD patients have difficulty performing two tasks simultaneously (See Chapter 1, Table 2). 
Furthermore, in some cases, this may require prioritising attention when two potential 
outcomes are presented. An important aspect of decision making is to select an 
appropriate action in the face of conflicting information (response conflict), and this is 
required to successfully perform the Stroop task.  
 
The findings in this thesis support that people with HD are deficient when 
performing two tasks simultaneously, although the extent to which performance 
deteriorates is not consistent, where in some tasks the motor task is prioritised and in 
other tasks the cognitive task is prioritised. Therefore attention does not seem to be 
General Discussion  Chapter 5 
201 
 
allocated definitively toward the motor or the cognitive element of the dual task and 
instead it depends on the motor-cognitive tasks combined. The C3t involved automating 
aspects of behaviour for optimal performance and, from all of the dual tasks tested, this 
was the most sensitive to disease stage. This suggests that the basal ganglia circuitry may 
be recruited during this assessment due to the clear stepwise deterioration of 
performance with increasing disease stage. Furthermore, the findings in Chapter 4 
suggest that the striatum could be implicated during response conflict in a rodent 
analogue of the Stroop task suggesting that the striatum may be involved in selecting and 
prioritising one task over another when two outcomes are presented. Understanding the 
neural correlates that are required for such tasks could help explain why people with HD 
have difficulty performing some common daily tasks, such as allocating attention when 
two outcomes are presented.  
 
In Chapter 2, Part 1, three lower limb dual tasks were selected and developed for 
testing in HD. This included, the Walk and talk, which had been used in a previous HD 
study (Fritz et al., 2016); the TUG and LVF, which are two single tasks that are commonly 
used in HD, and were previously used as a dual task in the elderly (van Iersel, 2007), but 
never in HD; and the Step and Stroop which was newly designed for this study. Whilst 
planning Part 1, it become evident that the dual tasks selected thus far all focussed on 
lower limb function. As no current upper limb tasks could be adapted for dual task testing, 
a new upper limb dual task assessment was designed and developed for this study. This 
novel assessment was originally named the Moneybox test, but was later changed and 
referred to throughout this thesis as the Clinch token transfer test (C3t). As part of the 
assessment development, it was important to include functions that tapped into the 
degenerating neurocircuitry in HD. Furthermore, to ensure that these dual tasks were 
sensitive to people with different levels of functional ability, it was important that they 
included different levels of complexity.  
 
The results in Chapter 2 revealed that different motor-cognitive dual tasks elicit 
different levels of interference in people with HD. The Step and Stroop and the C3t best 
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distinguished between disease stage in HD and significantly correlated with UHDRS scores 
and quality of life measures, more than the Walk and talk, and the TUG and LVF.  
 
In Chapter 2, it became evident that there was a need to standardise the C3t. 
Thus, the aim of this chapter was to design and develop the C3t version 2 and then 
validate this in a large cohort of people gene positive with HD. When the new design was 
tested in people with HD (Chapter 3, Part 2), it was clear that performance was not 
changing with increased task complexity, suggesting that there were practice effects. 
Therefore, the C3t was optimised, which involved re-positioning the tokens in the Baseline 
complex and dual task. In Part 3, this was validated in people with all stages of HD and in 
healthy controls, and revealed that C3t performance was significantly slower and less 
accurate in people with manifest HD compared to healthy controls. In addition, 
performance declined in a stepwise pattern between each disease stage, where people 
with pre-HD performed the C3t fastest and achieved the best C3t total score, whereas 
people in stage 4,5 performed the C3t most slowly and achieved the lowest C3t total 
score. The design changes made in Part 2 also meant that participants performed less well 
with increasing task difficulty, although this performance decline was significant only for 
the mid to advanced disease stages (stage 3 and stage 4,5). Overall, the results in Chapter 
3 revealed that the C3t had both external and test validity. Time taken to perform the C3t 
was also reliable in the few people recruited to redo the assessment. Whilst there was 
more variability in the Baseline complex and dual task using the C3t total score, this may 
have mimicked the fluctuating disease symptoms experienced by HD patients, which may 
become more apparent with increased task difficulty. A greater sample size is required to 
confirm this hypothesis.  
 
As well as developing sensitive outcome measures for people with HD, it is just as 
important that such assessments are available in pre-clinical models of HD. As the Stroop 
task is regularly used in clinic, in Chapter 4, a rodent analogue of the Stroop task was 
tested in a group of healthy rats. To understand the neural correlates associated with this 
task, immediate early gene expression was used as a marker in the striatal and cortical 
brain regions. The findings revealed that Zif268 expression in the striatum significantly 
General Discussion  Chapter 5 
203 
 
correlated with performance in both the Stroop control (congruent) and Stroop 
incongruent task. Therefore, this could provide the first of a series of experiments to 
understand the extent the striatum is involved for optimal performance in this task.   
5.2 Methodological considerations 
 
Symptoms associated with HD can significantly vary from one individual to the 
next (Ross et al., 2014), where some people experience greater motor abnormalities 
whilst maintaining cognitive function, whereas others show the reverse. This makes 
categorising people into disease stage challenging. Two common methods to categorise 
disease stage is to divide people into pre-manifest and manifest groups, or categorising 
people based on their UHDRS-TFC score.  However, there are well known limitations using 
both of these methods (see Chapter 1, Section 1.1.7). In Chapters 2 and 3, HD 
performance was compared using both methods. This resulted in small group sizes 
particularly when subjects were grouped by TFC disease stage. In addition, group sizes got 
smaller in the more advanced disease stages as they failed to meet the criteria set to 
proceed to the complex dual task items, which reduced the experimental power. 
However, as the CAG disease burden score significantly correlated with the Step and 
Stroop, and the C3t total score this suggests that these assessments accurately tracked 
disease progression in HD.  
 
It is important to acknowledge that the participants in the dual task studies may 
not have reflected the whole HD population. It is well known that people with HD are 
apathetic and less motivated than healthy controls (van Duijn et al., 2014). Therefore, it 
is possible that results generated from certain studies are biased towards people who are 
more motivated and perhaps less affected by behavioural changes, resulting in the 
neuropathological profile for this group not being accurately captured. As people with all 
disease profiles attend South Wales HD clinic, I attempted to overcome this problem by 
approaching people whilst they were at clinic to ask if they were interested in taking part 
in the study. As the study did not take an excessive amount of time (between 15-45 
minutes), all participants approached in Chapters 2 and 3 agreed to take part in the study 
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whilst they were at clinic. This meant that no additional journey for the study was 
required, thus reducing the impact of apathy on recruitment.  
 
In Chapters 2 and 3, as part of the study design, it was important that participants 
were able to pass the baseline criteria before proceeding to the dual task. This meant that 
the test order remained consistent across all participants, and it ensured participants 
could perform the baseline task before continuing to the more complex dual task. 
However, this may have resulted in practice effects, leading to less dual task interference.  
This was more apparent in certain tasks, such as the LVF, but not in the C3t v2b. In the 
LVF, subjects performed better in the dual task condition than at baseline, whereas in the 
C3t v2b, practice effects that were evident in previous C3t versions were eliminated 
following optimisation of the assessment setup and procedure. Therefore, future studies 
that are interested only in calculating dual task interference should consider 
counterbalancing dual task items.  
 
5.3 Future directions 
5.3.1  Potential techniques to measure neural activity during dual task performance 
 
The rationale for selecting and developing the dual tasks in Chapters 2 and 3 was 
because they were understood to target the brain regions affected in HD. One way to 
clarify this would be to use neuroimaging, which would be a feasible future study. 
Functional neuroimaging techniques, such as fMRI, are sensitive to motion artefact 
meaning that involuntary movements that increase in HD could result in distorted images 
(Zhang et al., 2014). Although some techniques are now available to reduce the impact of 
movements on image quality, it would nevertheless reduce the range of disease stage 
assessed. Furthermore, assessing the direct neural correlates implicated during the Step 
and Stroop, and the C3t cannot be performed in a scanner. One option is to use nuclear 
neuroimaging techniques such as near-infrared spectroscopy (NIRS) and transcranial 
magnetic stimulation (Bakker et al., 2007). Functional NIRS (fNIRS) is in some ways 
General Discussion  Chapter 5 
205 
 
comparable to fMRI in that it can recognise changes in oxygenated and deoxygenated 
haemoglobin (Gramigna et al., 2017). Thus, when a brain region is required for a 
particular function, oxygenated blood is directed to that region to support those 
functional processes  (Cutini and Brigadoi, 2014; Gramigna et al., 2017). However, this 
technique is limited because it is unable to measure activity more than a few 
centimetres  from the surface of the skull (Figure 33) (Gramigna et al., 2017), meaning 
that basal ganglia activity is not accessible using this measure. Another option is to use 
transcranial magnetic stimulation. Similar to fNIRS, this also detects cortical activity 
(Deng, Lisanby and Peterchev, 2014). However, this measure differs from fNIRS in that, 
computational models can be used to identify the ongoing subcortical circuitry involved 
in various tasks and can provide a link between behaviour and cortical regions activated  
(Geeter, Dupré and Crevecoeur, 2016). Such techniques could be used during 
performance in the Step and Stroop and the C3t to further understand the 
neurocircuitry activated during these assessments.  
 
 
 
Figure 33: A brain reconstruction adapted from (Gramigna et al., 2017) of the penetration depth 
achieved using fNIRS. This reaches just a few centimetres below the surface of the skull. Although 
the caudate and putamen is not clear in this image, the green arrow and purple line give an 
indication of the estimated depth required to measure functional activity in the basal ganglia and 
more specifically the caudate-putamen.    
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5.3.2  The C3t: What next? 
 
As well as using the techniques previously described to understand the regions activated 
and the circuitry involved when performing the C3t, there are a number of avenues being 
actively investigated to optimise the C3t development further. It is the intention that the 
C3t will, in the future, be considered a standard outcome measure for use in clinical 
settings and in clinical trials to measure upper limb function in people with HD. The 
standardisation of the C3t was fundamental to optimise the assessment sensitivity and 
setup (see Chapter 3, Part 1). Whilst this could not have been achieved without funding 
from a School of Healthcare Sciences Research Development award (Cardiff University), 
the limited funding allocated for the C3t development minimised the materials that could 
be used to develop the C3t v2. As a result, the C3t v2 is prone to breakage with repeated 
usage. To overcome this, funding from the MRC Confidence in Concept, as well as funding 
from Wales Brain Repair and Intracranial Neurotherapeutics (BRAIN) unit, and the REPAIR-
HD FP7 European consortium, has allowed the development of a new, robust C3t design 
(Figure 34). The aim was to design and develop the new C3t using strong materials that 
could be cleaned easily, whilst also ensuring that it was compact. The design of this new 
C3t is described further in Appendix 4. As some of the test procedures have changed 
compared to those described in Chapters 2 and 3, the next step involves recruiting people 
with HD to validate the new design. 
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The neurological basis behind successful performance of the C3t is intact basal 
ganglia circuitry relaying to the motor cortex for the grasping and dexterity component 
(Kim and Hikosaka, 2015) and also the frontal cortical regions to plan (Glover, Wall and 
Smith, 2012), coordinate (Serrien, Burgunder and Wiesendanger, 2001) and attend to the 
cognitive components (Vaportzis, Georgiou-Karistianis, Churchyard and Stout, 2015). 
Therefore, the C3t could also be sensitive to other populations that have basal ganglia 
dysfunction, such as Parkinson’s disease (Rochester et al., 2014; Rolinski et al., 2015; 
Weingarten et al., 2015) and subtypes of epilepsy (Panayiotopoulos, Obeid and Tahan, 
1994; Vollmar et al., 2011; Wandschneider et al., 2014). Funding from an MRC Confidence 
in Concept application, means that the new C3t design (mentioned in the paragraph 
above; Appendix 4) will soon be evaluated in people with Parkinson’s and juvenile 
myoclonic epilepsy to evaluate its sensitivity in populations other than HD.  
 
C3t performance is currently rated using time and number of errors committed. 
Although this method sensitively distinguished subtle differences between people with 
Pre-HD and Stage 1, it was not able to detect differences between healthy controls and 
Pre-HD (Chapter 2, Part 3). Explanations for this include (i) the small sample size in the 
pre-HD group, reducing the experimental power; and (ii) it may have been that the 
Figure 34: C3t v3 new design. A prototype of the new C3t. The new design is described in detail in 
Appendix 4. This work was funded by REPAIR-HD, Wales Brain Repair and Intracranial 
Neurotherapeutics (BRAIN) and the MRC Confidence in Concept. 
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majority of pre-HD people recruited were far away from disease onset (Klöppel et al., 
2015). As this latter group was heterogeneous some people might have been closer to 
disease onset than others, leading to greater variability in performance.  
 
One method that could increase the sensitivity of the C3t is to use objective 
instruments, such as accelerometers. These can be worn on the body to quantify 
movement parameters, and were recently tested using the C3t (Bennasar et al., 2016). In 
this study, triaxial accelerometers were worn on each wrist and the chest whilst people 
with HD and healthy controls performed the C3t. Signal processing and pattern 
recognition methods were applied and identified specific movement signatures 
associated with the HD group compared to controls. In a separate study, motion analysis 
techniques were used to validate the accelerometers (Jones et al., 2016: Unpublished 
data). This technique involved light reflective sensors positioned on certain joints of each 
arm, to capture a number of movement parameters, and revealed that the 
accelerometers accurately quantified movement parameters during C3t performance 
(Figure 36).  Additional work in collaboration with Cardiff School of Engineering also 
includes validating the accelerometers worn during the C3t in a larger cohort of people 
with HD. A previous study revealed that different levels of variance could be identified in 
the movement paths taken by people with manifest HD, relative to pre-HD and controls 
(Bennasar et al., 2017. Unpublished data). Thus, future work involves i) the continued 
recruitment of people with HD to perform the C3t whilst wearing accelerometers ii) to 
identify if involuntary movement is affected with increased cognitive load, and iii) to 
optimise the algorithms developed for the C3t to interpret these into clinically relevant 
and understandable outcomes.  
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C3t 
Figure 36: C3t accelerometers: Outcomes using objective instruments to quantify C3t 
performance. The graphs presented were produced in collaboration with Jones et al, 2017 
(unpublished data) (a) and Bennasar et al, 2017 (unpublished data) (b, c). Figure a, shows an 
image captured using motion analysis. The reflective markers (red dots) were positioned on the 
accelerometers on the wrist, the elbow and upper arm and quantified movement parameters to 
validate the accelerometer outputs. Figures b and c shows the amount of chaos quantified when 
performing the C3t. Each cycle (picking up the token > transferring the token > token in the 
moneybox) is identified as the periods in between the red dots on the graph. In Figure c, the cycles 
are distinct, whereas the cycles in the participant with manifest HD are variable and unclear. The 
y axis presents all negative values in b) due to the direction the axis with respect to gravity. This 
work was funded by REPAIR-HD and MRC Confidence in Concept funding. 
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As previously suggested, accelerometers worn during the C3t and the new C3t design 
could provide an informative measure of functional dexterity for clinicians and 
researchers to assess C3t performance in people with HD. However, a caveat of the 
accelerometers currently used is the amount of raw data produced, meaning that data 
output cannot be easily interpreted. To overcome this, funding from the Wellcome Trust 
Institutional Strategic Support Fund was awarded to develop a C3t Android App in 
collaboration with Cardiff University, School of Engineering (Figure 37). This is currently 
under construction, but, upon completion, the aim is to incorporate the specific 
algorithms developed for the accelerometers (described in the paragraph above) with the 
App. The App will also be made available to rate the C3t without the accelerometers, 
which will be used to calculate the time taken and the C3t total score. A future 
consideration is to integrate radio-frequency identification tags into the tokens to 
generate a more sensitive breakdown of C3t performance, which does not require the 
cost of accelerometers. This will reduce the labour intensive recording of C3t performance 
by the rater. Ultimately, the App will provide instantaneous, informative feedback to the 
clinician or researcher, which in the future can be adapted for using accelerometers and 
develop it so it is specific for other disease populations. 
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Figure 37: C3t App; Screenshot examples of the C3t App, developed by Woodgate et al., 2017 (Unpublished data). To begin the clinician/researcher is given 4 
options: create a subject; browse subjects that have previously performed the C3t; manage subjects from previous studies; take the test (Figure a). In Figure 
b, the subjects information is added, and saved in a research folder (Figure c). The researcher selects which C3t item they would like the subject to perform 
(Figure d) and presented with a rating page specific to that C3t item (Figure e). Once the subject has completed the assessment they are instantly presented 
with C3t outputs. The completed App will also provide the accelerometer outputs. This work was funded by REPAIR-HD and ISSF Wellcome trust funding. 
 
Figure 38: C3t App; Screenshot examples of the C3t App, developed by Woodgate et al., 2017 (Unpublished data). To begin the clinician/researcher is given 4 
options: create a subject; browse subjects that have previously performed the C3t; manage subjects from previous studies; take the test (Figure a). In Figure 
b, the subjects information is added, and saved in a research folder (Figure c). The researcher selects which C3t item they would like the subject to perform 
(Figure d) and presented with a rating page specific to that C3t item (Figure e). Once the subject has completed the assessment they are instantly presented 
with C3t outputs. The completed App will also provide the accelerometer outputs. This work was funded by REPAIR-HD and ISSF Wellcome trust funding. 
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5.3.3 Can dual task training be used as a rehabilitation strategy post 
transplantation? 
 
A primary outcome in Chapters 2 and 3 were the development and evaluation of 
dual task performance in people with HD. Although the idea was that these could be 
useful outcome measures, there is evidence to suggest that dual task training could be 
used for rehabilitation purposes for people for neurological conditions such as stroke 
(Yang et al., 2007; Plummer et al., 2014), dementia (Schwenk et al., 2010) and Parkinson’s 
disease (Fernandes et al., 2015; Sahu and Sri Vastava, 2015). Although specific dual task 
training has not yet been tested in HD, this may be a promising avenue to investigate in 
terms of rehabilitative training post transplantation. As discussed in Chapter 1 (Section 
1.2.2), there is a wealth of preclinical evidence to suggest that striatal specific training 
post transplantation is required for optimal graft integration and graft function. However, 
this has been has been largely neglected in clinic. Therefore, future studies could be used 
to investigate the effects of dual task training as a potential rehabilitation strategy post 
transplantation. Alternatively, dual task outcome measures could be used to validate 
alternative and newly developed rehabilitation strategies for use post transplantation. 
Alongside learning to use the transplant, additional factors such as the dosage (amount 
of rehabilitative training), type of training, and importantly when to begin training the 
graft must also be considered (Clinch et al., 2017).  
 
Can cell transplantation improve automated behaviour? 
 
One explanation of why people with HD are impaired when performing during 
dual tasks is an inability to automate performance in one or both behaviours (Ashby, 
Turner and Horvitz, 2010; Thompson et al., 2010). It is well understood that habitual 
(automatic) behaviour involves the dorsolateral striatum (Yin, Knowlton and Balleine, 
2004; Ashby, Turner and Horvitz, 2010; Manuscript, 2013). Therefore, automating 
behaviour that is required for performance in some dual tasks could be an outcome that 
improves following cell transplantation. However, this has not yet been tested in clinic or 
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in previous pre-clinical studies.  Thus, future studies could investigate whether habitual 
learning could be affected by transplants.   
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5.3.4 Final conclusions 
 
The work presented in this thesis evidences new and previously developed 
outcome measures that could be used to assess disease symptoms in clinic and in pre-
clinical models of HD. It is crucial that the effectiveness of clinical trials in HD are 
accurately assessed. In clinic, one way of doing this is to use outcome measures that 
tap into basal ganglia circuitry to sensitively track disease progression and have high 
ecological validity. Another important consideration is, where possible, to translate 
pre-clinical and clinical outcome measures. This is important to optimise and develop 
new treatments and translate findings from the bench to bedside. 
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Appendix 1 
 
In Chapters 2 and 3, dual task assessments were developed assessed, which 
each consisted of five assessment items. Furthermore, set criteria was developed for 
each assessment item, which the participant had to meet before proceeding to the 
next, more complex task. This meant that a different number of people performed 
each assessment item, for each dual task. The data presented in Table A-1 shows the 
number of people that completed each assessment item of the Walk and talk, TUG 
and LVF, and the C3t v1 (performed in Chapter 2). The number of people that 
performed each assessment item in the Step and Stroop is presented in Table A-2 
(performed in Chapter 2). The number of people that performed each assessment item 
in the C3t v2a is presented in Table A-3 (See Chapter 2, Part 2), and the number of 
people that performed the assessment items in the C3t v2b is presented in Table A-4 
(See Chapter 2, Part 3). All groups were categorised as pre-HD (total functional capacity 
(TFC) = 13 and Unified Huntington’s Disease total motor score < 5) and manifest (all 
symptomatic stages). The manifest group was further delineated by TFC disease stage 
(stage 1, TFC =11-13; stage 2, TFC=7-10; stage 3, TFC=3-6; stage 4, TFC=1-2; stage 5, 
TFC=0.
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Table A-1: The sample sizes in the Walk and talk, TUG and LVF and C3t 
 
Performance in the Walk and talk, TUG and LVF and C3t v1 were presented in Chapter 2. Due to 
the small sample size recruited in stage 4, people in stage 3 and stage 4 were combined to form 
stage 3,4. The column in orange presents the total number of people with HD recruited for the 
assessment items. Where Pre-HD = pre-manifest HD; TUG = Timed up and go; LVF = Letter verbal 
fluency; C3t = Clinch token transfer test. 
 
Table A-2: The sample sizes in the Step and Stroop 
 
Performance in the Step and Stroop was presented in Chapter 2. Due to the small sample size 
recruited in stage 5, people in stage 4 and stage 5 were combined to form stage 4,5. The column 
in orange presents the total number of people with HD recruited for the assessment items. 
Where Pre-HD = pre-manifest HD. 
 
 
1 2 3,4
Walk baseline 4 28 13 5 14 32
Alphabet Simple 3 23 11 4 11 26
Alphabet Complex 3 23 12 4 10 26
Walk and talk Simple 3 16 10 3 6 19
Walk and talk Complex 3 15 10 3 5 18
TUG baseline 4 28 12 6 14 32
LVF Simple 4 23 12 6 9 27
TUG and LVF Simple 4 21 11 5 9 25
LVF Complex 4 17 9 4 8 21
TUG and LVF Complex 3 15 7 4 7 18
C3t baseline v1 3 26 9 5 15 29
Value baseline v1 3 20 8 5 10 23
Alphabet baseline v1 3 21 8 5 11 24
C3t Simple v1 3 20 9 5 9 23
C3t Complex v1 3 17 9 5 6 20
W
al
k 
an
d 
ta
lk
TU
G
 a
nd
 L
V
F
C
3t
 v
1
ManifestPre-HDAssessment item
TFC disease stage
Total
1 2 3 4,5
Step baseline 8 50 23 14 18 3 58
Stroop Simple 8 57 23 16 19 3 61
Step and Stroop Simple 8 46 23 14 16 1 54
Stroop Complex 8 46 23 12 16 1 52
Step and Stroop Complex 8 37 22 10 13 0 45
St
ep
 a
nd
 
St
ro
op
Assessment item Pre-HD TotalManifest
TFC disease stage
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Table A-3: The sample sizes in the C3t v2a 
 
Performance in the C3t v2a was presented in Chapter 3, Part 2. Due to the small sample size 
recruited in stage 4, people in stage 3 and stage 4 were combined to form stage 3,4. The column 
in orange presents the total number of people with HD recruited for the assessment items. 
Where Pre-HD = pre-manifest HD; C3t = Clinch token transfer test. 
 
 
Table A-4: The sample sizes in the C3t v2b 
 
Performance in the C3t v2b was presented in Chapter 3, Part 3. Due to the small sample size 
recruited in stage 5, people in stage 4 and stage 5 were combined to form stage 4,5. The column 
in orange presents the total number of healthy controls recruited for the study, and in the 
second column, the total number of people with HD. Where Pre-HD = pre-manifest HD; C3t = 
Clinch token transfer test. 
 
1 2 3,4
C3t baseline v2a 3 18 9 7 5 21
Value baseline v2a 3 15 9 6 3 18
Alphabet baseline v2a 3 13 9 6 1 16
C3t Simple v2a 3 15 9 6 3 18
C3t Complex v2a 3 13 9 6 1 16
C
3t
 v
2a
Assessment item Pre-HD Manifest
TFC disease stage
Total
pre-HD 1 2 3 4,5 Controls HD
C3t baseline v2b 21 8 54 8 23 17 11 3 21 83
Value baseline v2b 16 8 53 8 22 17 11 3 16 77
Alphabet baseline v2b 20 8 49 8 21 16 9 3 20 77
C3t Simple v2b 20 8 50 8 21 16 10 3 20 78
C3t Complex v2b 20 8 46 8 21 15 8 2 20 74
C
3
t 
v
2
b
TFC disease stage Total 
Assessment item Pre-HDControls Manifest
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Appendix 2 
 
This following dual task procedures, instructions and task rules developed are 
presented for the Walk and talk, TUG and LVF and the Step and Stroop. These were 
performed in Chapter 2. The task rules were developed based on clinical observations 
alongside Professor Monica Busse that were made before the study in Chapter 2 had 
begun. 
 
Walk and Talk 
Walk baseline 
 
Task: 
The participant was asked to walk at their steady pace to the end of the GaitRite, turn 
around a cone positioned 1m past the end of the GaitRite and walk back. The 
participant repeated this process for 30 seconds. 
 
Instructions: 
“When I say “Go” I want you to walk at your normal steady pace to the end of the mat, 
around the cone and back, like this (example). I will tell you to stop after 30 seconds of 
walking. Do you have any questions? Ready? Go”  
 
Rules: 
o The subject had to walk to the end of the GaitRite mat to proceed to the dual 
task.  
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Baseline: Alphabet simple 
 
Task: 
Whilst sitting the participant was asked to recite the alphabet beginning with the letter 
A. This was timed and the participant was asked to stop when they finished the 
alphabet. 
 
Instructions:  
“I would like you to recite the alphabet beginning with the letter A, pronouncing each 
letter, as quickly as possible, like this (example). Do you have any questions? Ready? 
Go” 
 
Rules 
o The alphabet must complete the alphabet within 60 seconds 
o The subject must achieve 75% answers correct to proceed to the walking while 
taking dual task. 
o If a wrong answer was given then an error was recorded and the number of 
correct answers from then on was counted.  
 
Baseline: Alphabet complex 
 
Task: 
Whilst sitting the participant was asked to recite every other letter of the alphabet 
beginning with the letter A. This was timed and the participant was asked to stop when 
they finish the alphabet. 
 
Instructions:  
“I would like you to recite every other letter of the alphabet beginning with the letter 
A, pronouncing each letter, and doing this as quickly as possible, like this (example). Do 
you have any questions? Ready? Go” 
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Rules 
The same rules applied as the alphabet simple task but subjects were given 90 seconds 
to complete the test. 
 
Walking whilst talking dual simple 
 
Task: 
Whilst walking along the GaitRite, the participant was asked to recite the alphabet, 
beginning with the letter A. This was timed and the participant was asked to stop after 
30 seconds. 
 
Instructions:  
“When I say “Go” I want you to recite the alphabet as quickly as you can beginning with 
the letter A. As you do this walk along the mat, at your normal walking speed. When 
you reach the end of the mat, walk around the cone and back. If you reach the end of 
the alphabet before I stop you, begin again with the letter A. I will stop you after 30 
seconds. Do you have any questions? Ready? Go”. 
 
Rules: 
o The subject had to walk one length of the GaitRite to proceed to the more 
difficult dual task. 
o The subject was encouraged to walk if they stopped for longer than 5 seconds. 
They were reminded to keep walking once. 
o If a wrong answer was given then an error was noted and the number of 
correct answers from then on was counted.  
 
Walking whilst talking dual complex 
 
Task: 
Whilst walking along the GaitRite, the participant was asked to recite every other letter 
of the alphabet beginning with the letter A. This was timed and the participant was 
asked to stop after 30 seconds. 
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Instructions:  
“When I say “Go” I want you to recite every other letter of the alphabet as quickly as 
you can beginning with the letter A.  As you do this walk along the mat, at your normal 
walking speed. When you reach the end of the mat, walk around the cone and back. If 
you reach the end of the alphabet, begin again pronouncing every other letter of the 
alphabet beginning with the letter A. I will stop you after 30 seconds. Do you have any 
questions? Ready? Go” 
 
Rules: 
o The same rules as the walking and talking dual simple task.  
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TUG and LVF dual task 
TUG  baseline: 
 
Task: 
Participants were asked to stand from a hard chair, walk 3m, around a cone and back, 
finishing by sitting in the chair.  
 
Instruction: 
“When I say, I want you to start with your back against the chair and your hands on 
your lap, stand from the sitting position, walk to and around the cone and back, 
finishing by sitting in the chair, like this (example). Do you have any questions? Ready? 
Go” 
 
Rules:  
o The subject started by sitting with their backs against the chair and hands on 
their legs 
o The time is stopped as soon as the subject completes the sitting descend and 
their back is straight. 
o If the subject has a walker the subject could do the test but it must be noted. 
o If the participant took longer than 45 seconds to complete the test they did 
not proceed to the TUG and LVF dual task. 
 
Letter verbal fluency baseline simple 
 
Task: 
Whilst sitting, the participant was asked to say as many different words they could 
think of beginning with the letter ‘R’. The participant was asked not to repeat 
themselves and not to include the names of people or places. Each correct word given 
was recorded as well as any repeated words or names of people or places (errors). The 
test lasted for 30 seconds. 
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Instructions: 
“I am going to give you a letter of the alphabet and I would like you to tell me as many 
different words you can think of that start with that letter as quickly as you can. For 
example if I say S you might say snake, slide or stir. Try to avoid any repetition and do 
not include the names of people or places. During the test try to sit as still as possible. 
I will tell you when the test is over. Do you have any questions? Now please give me 
as many different words beginning with the letter R. Go.” 
 
Rules:  
o Errors were given if the subject repeated a word already stated or if they 
named people or places. 
o A minimum of 3 answers had to be given to pass 
 
Letter verbal fluency baseline complex 
 
Task: 
The same procedure as the Simple version but a more challenging letter was given. 
 
Instructions: 
“I am going to give you a letter of the alphabet and I would like you to tell me as many 
different words you can think of that start with that letter as quickly as you can. For 
example if I say S you might say snake, slide or stir. Try to avoid any repetition and do 
not include the names of people or places. During the test try to sit as still as possible. 
I will tell you when the test is over. Do you have any questions? Now please give me 
as many different words beginning with the letter N. Go.” 
 
Rules:  
o The same rules as the LVF simple applied 
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TUG and LVF dual simple 
 
Task: 
The participant was asked to perform the timed up and go whilst performing a letter 
verbal fluency task 
 
Instructions:  
“When I say, I want you to start with your back against the chair and your hands on 
your lap, stand from the sitting position, walk to and around the cone and back, 
finishing by sitting in the chair. Whilst doing this I want you to give me as many different 
words you can think of beginning with a letter. Try not to repeat yourself and do not 
say the names of any people or places. Do you have any questions?  
Please give me as many different words beginning with the letter R. Go” 
 
Rules: 
o The subject had to complete the TUG in 1 minute to proceed to the more 
difficult dual task 
o The subject was reminded to continue walking if they stopped for longer than 
5 seconds. This could be done once. 
o The same rules as the baseline TUG and LVF applied to proceed to the TUG 
and LVF dual complex. 
 
TUG and LVF dual complex 
 
Task: 
The same as the TUG and LVF simple dual task but a harder letter was given for the 
LVF. 
 
Instructions:  
“When I say, I want you to start with your back against the chair and your hands on 
your lap, stand from the sitting position, walk to and around the cone and back, 
finishing by sitting in the chair. Whilst doing this I want you to give me as many different 
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words you can think of beginning with a letter. Try not to repeat yourself and do not 
say the names of any people or places. Do you have any questions?  
Please give me as many different words beginning with the letter N. Go” 
 
Rules: 
o The same rules as the TUG and LVF simple applied.  
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Step and Stroop 
Stepping baseline 
 
Task: 
The participant was instructed to face forwards with the step in front of them. They 
were asked to step onto the step, one foot at a time, and then back down, whilst 
staring straight ahead for 45 seconds.  
 
Instructions: 
“When I say “Go” I would like you to step onto the box one foot at a time and then step 
down as quickly but as safely as you can, ensuring that your whole foot is on the step 
and staring straight ahead when doing this like this (example). If you look down or if 
you don’t put your whole foot on the step I will remind you during the test. I will stop 
you after 45 seconds.  Do you have any questions? Ready? Go” 
 
Rules 
o The subject was asked to look straight ahead when stepping  
o The subject was asked to put their whole foot on the step and to avoid running 
(half a foot placed on the edge of the step to maximise speed). If the subject 
did this during the test they were instructed to stop running. 
o One step was counted when two feet were either on top of the step or on the 
floor. 
o The subject had to complete 4 steps to proceed to the Step and Stroop dual 
task. 
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Stroop reading and colour baseline 
 
Task: 
Whilst sitting, the participant was asked to name colours (either pink, grey or yellow) 
from a total of x8 blocks presented on a PowerPoint presentation. They were then 
asked to read the words of colours (either pink, grey or yellow) from a total of x8 
blocks. Subjects were not timed to do this but had to achieve 12 out of 16 correct 
answers to continue to the next stage of the test. 
 
Instructions 
“When I say “Go” I would like you to name the colours you see in the boxes on the 
screen, naming them from left to right. You will then see words reading the names of 
colours, and again I would like you to read the colours from left to right. You will see 
either yellow, pink or grey for all options shown. Do you have any questions? Ready? 
Go” 
 
Rules: 
o The subject had to achieve 6 out of 8 in both of the tests to proceed to the 
Stroop tasks. 
 
Stroop Simple baseline 
 
Task: 
Whilst sitting, the participant was asked to read the colour names displayed (written 
in either yellow, pink or grey). The colour words were written in their coloured ink, for 
example pink was in the colour pink. The participant was given 45 seconds to give as 
many answers as possible. Subjects were shown 4 words at a time via a PowerPoint 
presentation and the slides were changed using a USB pen. 
 
Instructions 
“When I say “Go” I would like you to name the words you see in the boxes on the screen, 
naming them from top to bottom, as quickly as you can, like this (example). A new 
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colour sequence will appear on the screen when you reach the bottom.  You will see 
either yellow, pink or grey for all options shown. I will stop you after 45 seconds. Do 
you have any questions? Ready? Go” 
 
Rules: 
o The subject had to achieve 75% pass rate to proceed to the Stroop complex 
and the Step and Stroop simple dual task.  
o The number of correct answers and errors were recorded 
 
Stroop complex baseline 
 
Task: 
Whilst sitting, the participant was asked to say the coloured ink of the colour-words 
shown. The ink of the words were incongruent to the colour-names. The participant 
was given 45 seconds to give as many answers as possible. Subjects were shown 4 
words at a time via a PowerPoint presentation and the slides are changed using a USB 
pen. 
 
Instructions 
“When I say “Go” I am going to show you words on the screen and I would like you to 
say the coloured ink of the words shown.  For example, the correct answer here would 
be pink *point to example on screen*.  I will stop timing you after 45 seconds and I 
want you to work as quickly as you can. You will see either yellow, pink or grey for all 
options shown. Do you have any questions? Ready? Go” 
 
Rules: 
o The same rules as the Stroop simple applied. 
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Step and Stroop dual task: simple 
Task: 
Whilst stepping the participant was asked to read the colour words displayed (written 
in either yellow, pink or grey). This test was the same as the Stroop congruent baseline 
test. The participant was given 45 seconds to give as many answers as possible.  
 
Instructions 
“When I say “Go” I would like you to read the words you see in the boxes on the screen, 
naming them from top to bottom, as quickly as you can, like this (example). A new 
colour sequence will appear on the screen when you reach the bottom.  You will see 
either yellow, pink or grey for all options shown. Whilst doing this I want you to step as 
quickly but as safely as you can, as you did before. I will stop you after 45 seconds. Do 
you have any questions? Ready? Go” 
 
Rules: 
o The subject had to perform 2 steps to proceed to the more difficult dual task 
o The subject was encouraged to continue stepping if they stopped for longer 
than 10 seconds. This was only done once. 
o The same rules applied as the Stroop baseline tasks.  
 
Step and Stroop dual task complex:  
 
Task: 
Whilst stepping, the participant was asked to say the coloured ink of the colour-words 
shown. The ink of the words are incongruent to the words. The participant is given 45 
seconds to give as many answers as possible. Subjects are shown 4 words at a time via 
a PowerPoint presentation and the slides are changed using a USB pen. 
 
Instructions 
“When I say “Go” I am going to show you words on the screen and I would like you to 
say the coloured ink of the words shown.  For example, the correct answer here would 
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be pink *point at the onscreen example*.  I will stop timing you after 45 seconds and I 
want you to work as quickly as you can. You will see either yellow, pink or grey for all 
options shown. Whilst doing this I want you to step as quickly but as safely as you can, 
as you did before. Do you have any questions? Ready? Go” 
 
Rules: 
o The same rules applied as the Stroop Simple dual task 
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Appendix 3 
 
The Clinch token transfer test manual 
 
In Chapters 2 and 3 a new upper limb dual task assessment was developed and 
was called the Clinch token transfer test (C3t).  This was originally called the Moneybox 
test. To ensure the testing procedure remained consistent when the C3t was carried 
out, a manual was developed (Figure A-5). 
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Figure A-1: The Moneybox test manual developed and used for Chapter 2, Part 2. 
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Appendix 4 
 
The development of the C3t v3 
 
The standardised C3t v2 was manufactured by MinuteMan Press, Cardiff, and was 
funded by a Strategic development fund application, from the School of Healthcare, 
Cardiff University. The development of the C3t v2 was an integral part of the C3t 
development process as this meant the C3t setup was more reliable. Furthermore, as the 
British coins were changed to tokens this meant that it was no longer biased to people 
very familiar with this currency and therefore could be used in other countries. As a result 
the C3t v2 has been tested in clinical sites in Cardiff, Manchester, Germany and France as 
part of REPAIR-HD (an FP7 European consortium grant). However, a limitation of the C3t 
v2 is that the materials it is constructed from cannot be cleaned easily and they are prone 
to breakage. Therefore, through the achievement of an MRC Confidence in Concept grant, 
I have worked closely with Thread design, Cardiff, to improve the construction of the C3t 
and setup. This development process is described below. 
 
To begin, it was important that the designers understood the assessment concept 
and therefore, the key properties of the C3t that needed developing or redesigning.  From 
this, key features were developed to optimise the assessment procedure for both the 
participant and for the researcher. For the participant, it was important that the C3t had 
an approachable design and interface. For the researcher it was important that the 
following criteria were met: 
a. Smooth transition throughout from one C3t item to the next 
b. A quick setup and transition between assessment items 
c. Easy to set up 
d. Consistent (standardised) testing  
e. Compartments to ensure components do not go missing 
f. Compact  
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Whilst meeting these criteria was important, a primary aim was that the test 
procedure did not change from the C3t v2. This was to maintain the promising results 
developed in Chapter 3 using this test. Therefore the overall dimensions of the 
assessment remained the same (Figure A-2).  
 
  
Figure A-2: Dimensions of the C3t v2 were taken. This was done to maintain the consistency of 
sensitive results achieved using the C3t v2 with the new C3t test design. 
 
 
An important factor that drove the decision making process for the new C3t 
development was that it needed to be affordable. Therefore, a target price of £100 per 
unit was chosen. Using this budget as a benchmark, a list of the physical parts of the C3t 
that needed to be incorporated and designed was made, and the materials and tools that 
could be used to construct the new C3t were brain stormed (Figure A-3).   
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Figure A-3: The test components and possible materials and tools that were suggested to construct 
these. 
 
Design 
It was important that the C3t were made of materials that did not ware easily 
over time and could also be cleaned. The overall aims regarding the design of the C3t 
were: 
 Colour – off white 
 Clinical appearance – clean look 
 Friendly feel – not intimidating 
 Sense of quality and robustness 
 Easy maintenance 
 Integrated 
 
Design ideas for the C3t  
 
A number of promising designs for the C3t were brainstormed with Thread 
design. This generated the options presented in Figure A-4. Although these were compact 
Test components 
 Moneybox 
 Test platform that could be folded – the C3t would be set up on this 
 Tokens – 3 sets (for the Baseline simple, complex and dual task) 
 Token trays (x3 so the C3t test setup can be prepared before the participant takes 
the test 
 Value baseline card 
 An overall case, which would contain compartments to house the C3t test 
platform, accelerometers and a tablet (for the C3t App) 
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and integrative, the main limitation with each of these was the way the moneybox was 
constructed and positioned. The concern with these designs was that people with a 
movement disorder, such as HD, would use the length or platform of the moneybox to 
stabilise their wrist when performing the C3t. This could lead to a faster performance 
time, and reduce the sensitivity of this assessment.   The final C3t design is presented in 
Figure A-5.  This design is compact and avoids the moneybox limitation associated with 
the designs in Figure A-4. The idea is that this design will fit into a larger case that will also 
support the tablet for the C3t App and accelerometers.
  Appendix 4 
290 
 
 
Figure A-4: C3t design ideas. The designs presented were put together by Thread design. These were abandoned because of the construction of the moneybox, 
which could have provided a platform to stabilize the wrist and essentially make the assessment easier and less sensitive for people with a movement disorder.  
Design 1 
 
Design 2 
 
Design 3 
 
Design 4 
 
  Appendix 4 
291 
 
 
  
 
Figure A-5: The figures present different orientations of the final C3t design, both open (a), closed 
(b) and positioned within the outer assessment box (c) which will also house the accelerometers 
and tablet for the C3t App. 
 
 
a) Open 
b)   Closed 
c)   Housed inside the outer assessment box 
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Tokens  
 
Given that the C3t assessment can be performed in 5 minutes, there is a risk of 
practice effects as the token values become more familiar to the subject. The tokens used 
in the C3t v2 present same values for the Baseline complex and the dual task. To prevent 
potential practice effects, in Chapter 3 (Part 2), the C3t v2 was optimised by keeping the 
values the same, but changing the order the tokens were presented in for the Baseline 
complex and the dual task. One of the biggest changes that has been made to the new 
C3t design is that different token values are used for the Baseline complex and the dual 
task. As this could mean that the dual task is more difficult, the new C3t will need to be 
re-validated in people with HD. However, in making this change, it is anticipated that it 
will improve the sensitivity of the C3t and lead to greater dual task interference between 
disease stages in HD. 
 
One risk using the C3t in people with a motor deficits is that there is an increased 
risk that the tokens are accidently knocked during the testing procedure. This was 
considered in the C3t v2, and to prevent this from happening shallow grooves were made 
on the money card (token trays), which the tokens were positioned in. In the new C3t, 
different design ideas were suggested to ensure the tokens were even more secure when 
positioned in the grooves of the token trays (see Figure A-6). The final design of the new 
C3t tokens houses a magnet, which is sandwiched inside the token. As the token trays also 
contain a magnet and shallow grooves (see Figure A-7), this means that the tokens are 
less likely to knock out of position during testing.  
 
Figure A-6: Different token design ideas to ensure the tokens remained in position during the C3t 
testing procedure 
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Token trays 
 
To ensure the new C3t is easy to use, three trays were designed so they stacked 
on top of one another, meaning that the C3t setup can be prepared before the subject 
arrives (Figure A-7).  In addition, each tray contains grooves which contain markings. The 
markings match the token required for that location and assessment item. 
 
 
  
 
 
 
 
 
Figure A-7: Token trays are stacked to allow for quick and easy setup for the researcher. In addition, 
the markings on the tokens match the markings in the groves of the token tray so each token is 
positioned in the right location for each assessment item. 
 
Moneybox 
 
Another change to the C3t is the moneybox (Figure A-8). Although the original 
idea was to keep the design the same as the C3t v2, a new, compact moneybox has been 
designed for the C3t. Importantly, the moneybox slot and the height of the moneybox 
have remained the same as the C3t v2. 
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Figure A-8: The moneybox design for the new C3t.The height and moneybox slot have remained the 
same as the C3t v2.  
 
Logo 
 
The logo designed for the C3t v2 was printed onto a sticker and attached to the 
outer assessment box. However, a concern was that, over time, a sticker could begin to 
ware and start peeling off. An alternative option was to imprint the logo onto the outer 
box. However, due to the tooling restrictions involved in this process, this meant designing 
a much simpler logo with less detail.  
 
A lot of thought went into the logo design, as I wanted the logo to relate to the 
C3t procedure or concept in some way. The final C3t orientation was designed so it 
represented an abstract shape of the caudate and putamen, the brain regions affected in 
people with HD could be required for successful performance in the C3t. One option was 
to put the C3t into a brain shaped template, or into a disc shape to represent the token. 
It was decided that the simplest design was the clearest and so the logo in Figure A-9a 
was selected. Other logo options that were designed are presented in Figure A-9b. 
  Appendix 4 
295 
 
  
Figure A-9: C3t logo designs. The logo in Figure a) presents the final logo design selected for the 
new C3t. Figure b) shows the alternative logo options that were eliminated.
 
 
 
 
 
 
 
 
 
 
a) 
b) 
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Appendix 5 
Recipes 
 
 
The following recipes were used for the histological procedures performed in Chapter 4. 
 
 
Perfusion and tissue storage 
 
Paraformaldehyde (PFA) solution - stored at 4 degrees Celsius 
40g PFA (4%) 
1 L Prewash buffer (recipe below) 
Heat to dissolve 
pH 7.3 (orthophosphoric acid) 
 
Prewash buffer (PBS) – stored at 4 degrees Celsius  
18g di-sodium hydrogen phosphate 
9g sodium chloride 
1L distilled water 
pH 7.3 (orthophosphoric acid) 
 
Sucrose (25%) 
250g sucrose 
1L PBS 
pH 7.3 
 
Antifreeze (800ml) 
4.36g Di-sodium hydrogen orthophosphate (A)  
1.256g Sodium di-hydrogen orthophosphate (B)  
Dissolve in 320 ml distilled water (C) 
A, B and C dissolved fully and pH 7.3-7.4 then add:  
240ml Ethylene Glycol  
240ml Glycerol  
 
Histology and Immunohistochemistry 
 
4x Tris buffered saline 
96g Trizma base 
72g sodium chloride 
2L distilled water 
pH 7.3-7.4 
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0.2% Triton X-100 in TBS (TXTBS) 
0.5ml Triton X-100 
250ml TBS 
 
Tris non-saline (TNS) 
6g Trizma base 
1L distilled water 
pH 7.3-7.4 
 
Endogenous Peroxidase Quench 
10ml methanol 
10ml hydrogen peroxide (30%) 
40ml distilled water 
 
ABC solution  
5ul A (DAKO)  
5 ul B (DAKO)  
1ml 1 % serum in 1 x TBS  
 
Dehydration 
70% alcohol (5 minutes) 
95% alcohol (5 minutes) 
100% alcohol (5 minutes) 
Xylene (10 minutes) 
Coverslip using DPX 
 
 
 
 
 
